
<html lang="en"     class="pb-page"  data-request-id="8e5911ed-b126-4f95-a5d5-fb911ddc6bcf"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2017.60.issue-10;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.7b00345;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)" /></meta><meta name="dc.Creator" content="Martin W.  Rowbottom" /></meta><meta name="dc.Creator" content="Gretchen  Bain" /></meta><meta name="dc.Creator" content="Imelda  Calderon" /></meta><meta name="dc.Creator" content="Taylor  Lasof" /></meta><meta name="dc.Creator" content="David  Lonergan" /></meta><meta name="dc.Creator" content="Andiliy  Lai" /></meta><meta name="dc.Creator" content="Fei  Huang" /></meta><meta name="dc.Creator" content="Janice  Darlington" /></meta><meta name="dc.Creator" content="Patricia  Prodanovich" /></meta><meta name="dc.Creator" content="Angelina M.  Santini" /></meta><meta name="dc.Creator" content="Christopher D.  King" /></meta><meta name="dc.Creator" content="Lance  Goulet" /></meta><meta name="dc.Creator" content="Kristen E.  Shannon" /></meta><meta name="dc.Creator" content="Gina L.  Ma" /></meta><meta name="dc.Creator" content="Katherine  Nguyen" /></meta><meta name="dc.Creator" content="Deidre A.  MacKenna" /></meta><meta name="dc.Creator" content="Jilly F.  Evans" /></meta><meta name="dc.Creator" content="John H.  Hutchinson" /></meta><meta name="dc.Description" content="LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine). Condensation with other allysines o..." /></meta><meta name="Description" content="LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine). Condensation with other allysines o..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 15, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00345" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00345" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00345" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00345" /></link>
        
    
    

<title>Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00345" /></meta><meta property="og:title" content="Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0015.jpeg" /></meta><meta property="og:description" content="LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages, a process critical for the remodeling of the ECM. Dysregulation of this process can lead to fibrosis, and LOXL2 is known to be upregulated in fibrotic tissue. Small-molecules that directly inhibit LOXL2 catalytic activity represent a useful option for the treatment of fibrosis. Herein, we describe optimization of an initial hit 2, resulting in identification of racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone 28, a potent irreversible inhibitor of LOXL2 that is highly selective over LOX and other amine oxidases. Oral administration of 28 significantly reduced fibrosis in a 14-day mouse lung bleomycin model. The (R,R)-enantiomer 43 (PAT-1251) was selected as the clinical compound which has progressed into healthy volunteer Phase 1 trials, making it the “first-in-class” small-molecule LOXL2 inhibitor to enter clinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00345"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00345">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00345&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00345&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00345&amp;href=/doi/10.1021/acs.jmedchem.7b00345" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4403-4423</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00359" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00332" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+W.++Rowbottom">Martin W. Rowbottom</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-3934-1948" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gretchen++Bain">Gretchen Bain</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Imelda++Calderon">Imelda Calderon</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Taylor++Lasof">Taylor Lasof</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Lonergan">David Lonergan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andiliy++Lai">Andiliy Lai</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fei++Huang">Fei Huang</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Janice++Darlington">Janice Darlington</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++Prodanovich">Patricia Prodanovich</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angelina+M.++Santini">Angelina M. Santini</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+D.++King">Christopher D. King</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lance++Goulet">Lance Goulet</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kristen+E.++Shannon">Kristen E. Shannon</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gina+L.++Ma">Gina L. Ma</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine++Nguyen">Katherine Nguyen</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deidre+A.++MacKenna">Deidre A. MacKenna</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jilly+F.++Evans">Jilly F. Evans</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+H.++Hutchinson">John H. Hutchinson</a></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-0462-1405" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker Hill Street, Suite 300, San Diego, California 92109, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 1-858-764-8045. Fax: 1-858-225-6042. E-mail: <a href="/cdn-cgi/l/email-protection#abc6d9c4dcc9c4dfdfc4c6ebdbc3cad9c6cac0ceca85c8c4c6"><span class="__cf_email__" data-cfemail="214c534e56434e55554e4c61514940534c404a44400f424e4c">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00345&amp;href=/doi/10.1021%2Facs.jmedchem.7b00345" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4403–4423</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 4, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 March 2017</li><li><span class="item_label"><b>Published</b> online</span>15 May 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 May 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00345</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4403%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMartin%2BW.%2BRowbottom%252C%2BGretchen%2BBain%252C%2BImelda%2BCalderon%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D10%26contentID%3Dacs.jmedchem.7b00345%26title%3DIdentification%2Bof%2B4-%2528Aminomethyl%2529-6-%2528trifluoromethyl%2529-2-%2528phenoxy%2529pyridine%2BDerivatives%2Bas%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BEfficacious%2BInhibitors%2Bof%2Bthe%2BCopper-Dependent%2BAmine%2BOxidase%252C%2BLysyl%2BOxidase-Like%2B2%2B%2528LOXL2%2529%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4423%26publicationDate%3DMay%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00345"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2538</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">27</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00345" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;W. Rowbottom&quot;},{&quot;first_name&quot;:&quot;Gretchen&quot;,&quot;last_name&quot;:&quot;Bain&quot;},{&quot;first_name&quot;:&quot;Imelda&quot;,&quot;last_name&quot;:&quot;Calderon&quot;},{&quot;first_name&quot;:&quot;Taylor&quot;,&quot;last_name&quot;:&quot;Lasof&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Lonergan&quot;},{&quot;first_name&quot;:&quot;Andiliy&quot;,&quot;last_name&quot;:&quot;Lai&quot;},{&quot;first_name&quot;:&quot;Fei&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Janice&quot;,&quot;last_name&quot;:&quot;Darlington&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;Prodanovich&quot;},{&quot;first_name&quot;:&quot;Angelina&quot;,&quot;last_name&quot;:&quot;M. Santini&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;D. King&quot;},{&quot;first_name&quot;:&quot;Lance&quot;,&quot;last_name&quot;:&quot;Goulet&quot;},{&quot;first_name&quot;:&quot;Kristen&quot;,&quot;last_name&quot;:&quot;E. Shannon&quot;},{&quot;first_name&quot;:&quot;Gina&quot;,&quot;last_name&quot;:&quot;L. Ma&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;Nguyen&quot;},{&quot;first_name&quot;:&quot;Deidre&quot;,&quot;last_name&quot;:&quot;A. MacKenna&quot;},{&quot;first_name&quot;:&quot;Jilly&quot;,&quot;last_name&quot;:&quot;F. Evans&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;H. Hutchinson&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;4403-4423&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00345&quot;},&quot;abstract&quot;:&quot;LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages, a process critical for the remodeling of the ECM. Dysregulation of this process can lead to fibrosis, and LOXL2 is known to be upregulated in fibrotic tissue. Small-molecules that directly inhibit LOXL2 catalytic activity represent a useful option for the treatment of fibrosis. Herein, we describe optimization of an initial hit 2, resulting in identification of racemic-trans-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone 28, a potent irreversible inhibitor of LOXL2 that is highly selective over LOX and other amine oxidases. Oral administration of 28 significantly reduced fibrosis in a 14-day mouse lung bleomycin model. The (R,R)-enantiomer 43 (PAT-1251) was selected as the clinica&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00345&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00345" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00345&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00345" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00345&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00345" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00345&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00345&amp;href=/doi/10.1021/acs.jmedchem.7b00345" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00345" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00345" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00345%26sid%3Dliteratum%253Aachs%26pmid%3D28471663%26genre%3Darticle%26aulast%3DRowbottom%26date%3D2017%26atitle%3DIdentification%2Bof%2B4-%2528Aminomethyl%2529-6-%2528trifluoromethyl%2529-2-%2528phenoxy%2529pyridine%2BDerivatives%2Bas%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BEfficacious%2BInhibitors%2Bof%2Bthe%2BCopper-Dependent%2BAmine%2BOxidase%252C%2BLysyl%2BOxidase-Like%2B2%2B%2528LOXL2%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D10%26spage%3D4403%26epage%3D4423%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/jmcmar.2017.60.issue-10/20170525/jmcmar.2017.60.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine). Condensation with other allysines or lysines drives the formation of inter- and intramolecular cross-linkages, a process critical for the remodeling of the ECM. Dysregulation of this process can lead to fibrosis, and LOXL2 is known to be upregulated in fibrotic tissue. Small-molecules that directly inhibit LOXL2 catalytic activity represent a useful option for the treatment of fibrosis. Herein, we describe optimization of an initial hit <b>2</b>, resulting in identification of racemic-<i>trans</i>-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone <b>28</b>, a potent irreversible inhibitor of LOXL2 that is highly selective over LOX and other amine oxidases. Oral administration of <b>28</b> significantly reduced fibrosis in a 14-day mouse lung bleomycin model. The (<i>R</i>,<i>R</i>)-enantiomer <b>43</b> (PAT-1251) was selected as the clinical compound which has progressed into healthy volunteer Phase 1 trials, making it the “first-in-class” small-molecule LOXL2 inhibitor to enter clinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64707" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64707" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The lysyl oxidase (LOX) family of enzymes are copper-dependent amine oxidases consisting of five distinct isoforms, namely, lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) 1 through 4.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The LOX family is divided into two subgroups based on structural differences in the N-terminal domain. Both LOX and LOXL1 contain a highly basic propeptide that requires cleavage in order to generate active enzyme, whereas LOXL2, 3, and 4 contain four scavenger receptor cysteine-rich (SRCR) domains which are thought to mediate protein–protein interactions and cell adhesion.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> All LOX family members possess a conserved carboxy-terminal catalytic domain containing both a His-X-His-X-His copper binding motif and a post-translationally modified lysine tyrosylquinone (LTQ) cofactor. These enzymes localize to the extracellular matrix (ECM) where they catalyze the oxidative deamination of the terminal ε-amine of lysine and hydroxylysine residues in both collagen and elastin. This results in the generation of highly reactive aldehydes (allysine) that can further condense with other allysines or intact lysines to form inter- and intramolecular cross-linkages, a process critical for normal remodeling of the ECM.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a> Dysregulation of this process can lead to increased cross-linking, resulting in abnormal and uncontrolled ECM deposition in tissues. If left unchecked, this can lead to pathological fibrosis characterized by excessive scarring, impairment of organ function, and ultimately organ failure. Examples include fibrosis of the lung<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> (such as idiopathic pulmonary fibrosis or IPF), liver,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> kidneys,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and skin<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (systemic sclerosis). Unfortunately, current treatment options for patients diagnosed with fibrosis are extremely limited. Only for IPF have new antifibrotic medications been recently approved, these being nintedanib and pirfenidone.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> However, these agents offer only modest benefit to patients,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> so there is a need for additional therapies for both IPF and other types of fibrotic diseases. Given that aberrant ECM deposition is a driver in the progression of fibrotic disease and that LOX family enzymes are key mediators of this process, inhibition of one or more LOX proteins may delay or even halt disease progression. One family member in particular, LOXL2, has been extensively studied and shown to be upregulated in both fibrotic tissue and certain cancers.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition to its role in the ECM, an intracellular role has been proposed, and LOXL2 has been reported to be involved in the induction of epithelial to mesenchymal transition (EMT), a process central to tumor cell invasion and metastasis. LOXL2 can mediate EMT via either stabilization of the transcription factor Snail1 or catalytic oxidative-deamination of the trimethylated lysine 4 of histone H3 (H3K4me3).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Although deamination of H3K4me3 to give the corresponding allysine requires catalytically competent LOXL2, the mechanism is not well understood but has been suggested to involve release of trimethylamine, followed by oxidation to give the aldehyde (allysine).<a onclick="showRef(event, 'cit11b'); return false;" href="javascript:void(0);" class="ref cit11b">(11b)</a> As such, an inhibitor of LOXL2 capable of cell and nuclear penetration could be effective in modulating EMT, and both extracellular and intracellular inhibition of LOXL2 may be more efficacious in the treatment of both fibrosis and metastatic cancers. Simtuzumab is a LOXL2-specific monoclonal antibody that only partially inhibits catalytic activity via binding to a distal allosteric site located in the fourth SRCR domain.<a onclick="showRef(event, 'cit10b'); return false;" href="javascript:void(0);" class="ref cit10b">(10b)</a> Although the corresponding mouse antibody (AB0023) demonstrated efficacy in several preclinical models of fibrosis and cancer,<a onclick="showRef(event, 'cit10b cit10d'); return false;" href="javascript:void(0);" class="ref cit10b cit10d">(10b, 10d)</a> subsequent Phase 2 trials with simtuzumab in patients with pancreatic cancer, IPF, and liver fibrosis failed to demonstrate efficacy, and development was recently discontinued.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> We envision that a small-molecule approach toward selective inhibition of LOXL2 will have significant advantages over an antibody, for instance, (i) complete inhibition of catalytic activity via direct binding to the catalytic active site, (ii) greater penetration into the fibrotic matrix, and (iii) access to both extra- and intracellular compartments, allowing for inhibition of LOXL2 activity in the ECM and within cells. There are currently no published structures of selective inhibitors of LOXL2, and the only published small-molecule inhibitor is the pan-LOX(L) inhibitor β-aminopropionitrile (BAPN) <b>1</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, LOX is a ubiquitous enzyme, and mice deficient in LOX show severe cardiovascular and pulmonary defects.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Therefore, our goal was to identify inhibitors of LOXL2 that are selective over LOX. Given the paucity of selective small-molecule leads and the lack of NMR or X-ray structures for any of the LOX(L) enzymes, our approach started with the examination of the proposed mechanism by which LOX(L) proteins enzymatically convert lysines to allysines. A simplified proposed mechanism is shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b.<a onclick="showRef(event, 'cit10a'); return false;" href="javascript:void(0);" class="ref cit10a">(10a)</a> Briefly, the ε-amine (of lysine residues) reversibly binds one of the carbonyl groups of the LTQ cofactor (of <b>I</b>) to yield the substrate Schiff base intermediate (<b>II</b>). Subsequent irreversible conversion of the substrate Schiff base to the product Schiff base intermediate (<b>III</b>) occurs via proton abstraction (postulated to be mediated by a nearby active site basic residue) and concomitant reduction/aromatization of the quinonoid ring (of <b>II</b>). Hydrolysis of <b>III</b> yields the aldehyde (allysine) and the intermediate aminophenol (<b>IV</b>), which is then recycled, via a number of steps involving O<sub>2</sub> and Cu, to regenerate the catalytically active species (<b>I</b>) with release of both hydrogen peroxide and ammonia.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Upon the basis of the proposed mechanism, we hypothesized that a substrate-like aminomethyl-containing small molecule should be able to compete with lysine in binding directly to the LTQ carbonyl, thus forming a small molecule-containing substrate Schiff base (<b>II</b>) which is presumably converted to the product Schiff base (<b>III</b>). Furthermore, whereas the lysine-containing Schiff base (<b>III</b>) readily undergoes hydrolysis releasing allysine, the small molecule-containing Schiff base may be able to form a tightly bound Schiff base complex which could be more resistant to hydrolytic cleavage.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In addition, LOXL2 is glycosylated at the active site, while LOX is not, and this structural difference may provide an opportunity to design inhibitors selective for LOXL2 versus LOX.<a onclick="showRef(event, 'ref2 cit10a'); return false;" href="javascript:void(0);" class="ref ref2 cit10a">(2, 10a)</a> With this in mind, we executed a focused screening campaign and rapidly identified a series of 2-substituted pyridine-4-ylmethanamines as moderately selective LOXL2 inhibitors. The best compound, 4-(aminomethyl)-2-chloropyridine <b>2</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a) was shown to have ∼30-fold selectivity over LOX and was also selective against a panel of amine oxidases.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Herein we describe the SAR and lead optimization campaign around <b>2</b> which led to the identification of racemic-<i>trans</i>-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone <b>28</b>, a highly potent LOXL2 inhibitor with significantly improved selectivity over LOX. Compound <b>28</b> is an orally bioavailable, irreversible inhibitor of LOXL2 that exhibits efficacy in a mouse bleomycin lung fibrosis model with once-daily oral dosing. Subsequent profiling of the individual enantiomers of <b>28</b> ultimately led to the selection of the (<i>R</i>,<i>R</i>)-enantiomer <b>43</b> (PAT-1251)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> as the lead compound.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Structures of the known pan-LOX(L) inhibitor BAPN <b>1</b>, and the LOXL2 inhibitor <b>2</b>. (b) Proposed mechanism for the oxidation of lysine amines by LTQ-containing lysyl oxidase enzymes. (c) Proposed complex between LOXL2 and either lysine residues or pyridine-derived inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All compounds described herein were prepared as illustrated in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a>–<a class="ref internalNav" href="#sch4" aria-label="4">4</a>. Compounds <b>6</b>, <b>9</b>, and <b>10</b> were obtained in the following manner (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Reaction of 2-chloro-4-pyridinecarbonitrile <b>4</b> with phenol in the presence of Cs<sub>2</sub>CO<sub>3</sub> gave 2-phenoxypyridine derivative <b>5</b>. Subsequent nitrile reduction followed by treatment with HCl afforded compound <b>6</b>. Treatment of <b>4</b> with methyl 4-hydroxybenzoate in the presence of Cs<sub>2</sub>CO<sub>3</sub> gave para-substituted 2-phenoxypyridine derivative <b>7</b>. Reduction of the nitrile followed by <i>N</i>-Boc protection of the resulting amine, then base-mediated hydrolysis of the ester, afforded carboxylic acid derivative <b>8</b>. Subsequent HATU-mediated coupling of <b>8</b> with the appropriate amine followed by <i>N</i>-Boc deprotection gave final compounds <b>9</b> and <b>10</b> as HCl salts. Final compounds <b>13</b>–<b>20</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) were obtained in analogous fashion via reaction of 2-chloro-4-pyridinecarbonitrile <b>4</b> with methyl 3-hydroxybenzoate to afford the meta-substituted 2-phenoxypyridine derivative <b>11</b>. Subsequent nitrile reduction, <i>N</i>-Boc protection, and then ester hydrolysis gave acid-derivative <b>12</b>, which was readily converted to compounds <b>13</b>–<b>20</b>. Coupling of acid-derivative <b>12</b> with methyl 4-aminobenzoate, followed by ester hydrolysis and <i>N</i>-Boc deprotection, gave final compound <b>21</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). 4-(Methylamino)-6-(trifluoromethyl)pyridine derivatives <b>25</b>–<b>33</b> were prepared as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Treatment of 2-chloro-6-(trifluoromethyl)isonicotinonitrile <b>22</b> with methyl 3-hydroxybenzoate in the presence of K<sub>2</sub>CO<sub>3</sub> gave 2-(phenoxy)-6-(trifluoromethyl)pyridine derivative <b>23</b>. Reduction of the nitrile to the corresponding methylamine via treatment with NaBH<sub>4</sub> and CoCl<sub>2</sub>, followed by <i>N</i>-Boc protection then ester hydrolysis, afforded acid-containing derivative <b>24</b>. Desired compounds <b>25</b>–<b>33</b> were obtained via previously described amide-coupling procedures followed by <i>N</i>-Boc deprotection. Piperidine phenylurea-containing derivatives <b>36</b> and <b>37</b> were prepared as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Treatment of 2-chloro-6-(trifluoromethyl)isonicotinonitrile <b>22</b> with either (<i>R</i>)- or (<i>S</i>)-1-<i>N</i>-Boc-3-hydroxypiperidine and NaH, followed by <i>N</i>-Boc deprotection, afforded NH-piperidine derivatives <b>34</b> and <b>35</b>, respectively. Subsequent reaction with phenyl isocyanate followed by reduction of the nitrile, afforded final compounds <b>36</b> and <b>37</b>. In addition, the 3-phenoxyphenyl-containing derivative <b>39</b> was prepared from 2-chloro-6-(trifluoromethyl)isonicotinonitrile <b>22</b> and 3-phenoxyphenol via a simple two-step S<sub>N</sub>Ar/reduction procedure (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Optically pure <i>trans</i>-4-fluoro-3-pyrrolidinol-containing derivatives <b>43</b> and <b>44</b> were prepared as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The aforementioned acid derivative <b>24</b> was coupled with racemic <i>trans</i>-4-fluoro-3-pyrrolidinol to give the racemate <b>40</b>. At the time this work was performed, only racemic <i>trans</i>-4-fluoro-3-pyrrolidinol was commercially available. Thus, the individual enantiomers (of <b>40</b>) were obtained via preparative normal-phase chiral HPLC separation, wherein the (<i>R</i>,<i>R</i>)-enantiomer <b>41</b> and (<i>S</i>,<i>S</i>)-enantiomer <b>42</b> were the first and second to elute, respectively. Subsequent <i>N</i>-Boc deprotection of <b>41</b> and <b>42</b> afforded optically pure final compounds <b>43</b> and <b>44</b>, respectively. The absolute stereochemistry of <b>41</b> was confirmed via its preparation from <b>24</b> and optically pure (<i>R</i>,<i>R</i>)-<i>trans</i>-4-fluoro-3-pyrrolidinol 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartrate <b>47</b> (under identical HATU mediated conditions used previously). Optically pure <b>47</b> was readily obtained in 94.4% ee from racemate <b>46</b> via diastereomeric salt crystallization with 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartaric acid (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>), and the (<i>R</i>,<i>R</i>)-configuration of the 4-fluoro-3-pyrrolidinol <b>47</b> was confirmed via X-ray crystallography (see <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-(Methylamino)-2-phenoxypyridine Derivatives <b>6</b>, <b>9</b>, <b>10</b>, and <b>13</b>–<b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phenol, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 80 °C, 95%; (b) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc-MeOH, rt, 91%; (c) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 100%; (d) methyl 4-hydroxybenzoate or methyl-3-hydroxybenzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 80 °C, 58–60%; (e) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc-MeOH, rt, 94–100%; (f) Boc<sub>2</sub>O, DIEA, THF, rt, 67–80%; (g) LiOH, THF-H<sub>2</sub>O, rt, 83–100%; (h) R<sup>1</sup>R<sup>2</sup>NH, HATU, DIEA, DCM, rt; (i) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 9–84% (over 2-steps); (j) methyl 4-aminobenzoate, HATU, DIEA, DMF, rt, 68%; (k) LiOH, THF-H<sub>2</sub>O, rt, 59%; (l) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 52%.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 4-(Methylamino)-6-(trifluoromethyl)pyridine Derivatives <b>25</b>–<b>33</b>, <b>36</b>, <b>37</b>, and <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 3-hydroxybenzoate, K<sub>2</sub>CO<sub>3</sub>, THF-DMF, 60 °C, 91%; (b) CoCl<sub>2</sub>, NaBH<sub>4</sub>, THF-MeOH, 0 °C, 92%; (c) Boc<sub>2</sub>O, DIEA, THF, rt, 78%; (d) LiOH, THF-H<sub>2</sub>O, rt, 87%; (e) R<sup>1</sup>R<sup>2</sup>NH, HATU, DIEA, DCM-DMF, rt; (f) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 53–89% (over 2-steps); (g) (<i>R</i>)- or (<i>S</i>)-1-<i>N</i>-Boc-3-hydroxypiperidine, NaH, THF, 0 °C-rt, 47–53%; (h) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 96–100%; (i) PhNCO, DIEA, THF, rt, 62–80%; (j) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc-MeOH, rt, 50–73%; (k) 3-phenoxyphenol, K<sub>2</sub>CO<sub>3</sub>, THF, 90 °C, 45%; (l) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc, rt, 83%.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 4-(Methylamino)-6-(trifluoromethyl)pyridine Derivatives <b>43</b> and <b>44</b> via Preparative Normal-Phase Chiral HPLC Separation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) racemic-<i>trans</i>-4-fluoro-3-hydroxypyrrolidine·HCl, HATU, DIEA, DCM-DMF, rt, 87%; (b) separation via preparative normal-phase chiral HPLC, 59–68%; (c) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 100%.</p></p></figure><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Optically Pure (<i>R</i>,<i>R</i>)-<i>trans</i>-4-Fluoro-3-pyrrolidinol <b>47</b> via Diastereomeric Salt Crystallization<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, EtOH, rt, 94%; (b) 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartaric acid, THF, reflux to rt. Obtained precipitate was repeatedly recrystallized from MeOH; 6% overall yield, 94.4% ee.</p></p></figure><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of (<i>R</i>,<i>R</i>)-<i>trans-</i>4-fluoro-3-pyrrolidinol 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartrate <b>47</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All compounds (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) were profiled for inhibitory activity against human LOXL2 and counter-screened against human LOX. The LOXL2 assay was carried out using serum-free concentrated conditioned media (CCM) from CHO cells stably expressing human LOXL2, and amine oxidase activity was determined via measurement of hydrogen peroxide released during the oxidative deamination of the artificial substrate 1,5-diaminopentane (DAP).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The pan-LOX(L) inhibitor <b>1</b> exhibits time-dependent inhibition of LOXL2 with IC<sub>50</sub> values shifting from 0.24 to 0.066 μM when the preincubation period is increased from 15 min to 2 h. We observed no further significant change in potency upon extending the preincubation out to 4 h.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In order to allow for any time-dependent inhibition with our compounds, amine oxidase activity for both LOXL2 and LOX was measured after a 2 h preincubation with test compounds. To assess the selectivity of compounds versus human LOX, a slightly modified assay was used which required the addition of BSA to the serum-free media from HEK cells stably expressing human LOX in order to obtain measurable activity. The corresponding LOXL2 assay (+ BSA in serum-free conditioned media) was also run in order to generate an accurate head-to-head comparison of selectivity. In addition, LOXL2 activity was assessed in a more clinically relevant human whole blood assay wherein recombinant human LOXL2 and test compounds were incubated for 2 h in whole blood prior to the addition of DAP and subsequent measurement of hydrogen peroxide release.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of 4-(Methylamino)pyridine-Derived LOXL2 Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Assay measuring inhibition of H<sub>2</sub>O<sub>2</sub> produced from the oxidative deamination of the substrate, DAP, after a 2 h preincubation with test compound. Reported IC<sub>50</sub> values are the geometric mean values ×/÷ geometric standard deviation from at least 3 separate experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Carried out using concentrated conditioned media (CCM) from CHO cells stably expressing hLOXL2.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Assay performed using CCM containing 0.1% BSA prior to concentration.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Carried out using CCM containing 0.1% BSA prior to concentration and collected from HEK cells stably expressing hLOX.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Carried out using fresh human blood spiked with purified recombinant hLOXL2.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of 4-(Methylamino)-6-(trifluoromethyl)-pyridine-Derived LOXL2 Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Assay measuring inhibition of H<sub>2</sub>O<sub>2</sub> produced from the oxidative deamination of the substrate, DAP, after a 2 h preincubation with test compound. Reported IC<sub>50</sub> values are the geometric mean values ×/÷ geometric standard deviation from at least 3 separate experiments.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Carried out using concentrated conditioned media (CCM) from CHO cells stably expressing hLOXL2.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Assay performed using CCM containing 0.1% BSA prior to concentration.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Carried out using CCM containing 0.1% BSA prior to concentration and collected from HEK cells stably expressing hLOX.</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Carried out using fresh human blood spiked with purified recombinant hLOXL2.</p></div><div class="footnote" id="t2fn6"><sup>Table f</sup><p class="last">C57BL/6 mice (<i>n</i> = 3 per time point) dosed orally (po) with 30 mg/kg of test compound (formulated in 0.5% methylcellulose). Reported values are the means from 3 animals.</p></div><div class="footnote" id="t2fn7"><sup>Table g</sup><p class="last">Calculated using CDD Vault software from Collaborative Drug Discovery, Burlingame, CA.</p></div><div class="footnote" id="t2fn8"><sup>Table h</sup><p class="last">ND indicates data not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Selectivity versus Other Amine Oxidases for LOXL2 Inhibitors <b>28</b>, <b>43</b>, and <b>44</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Assay measuring the inhibition of H<sub>2</sub>O<sub>2</sub> produced from the oxidative deamination of the substrate, DAP, after a 2 h preincubation with test compound. Reported IC<sub>50</sub> values are the geometric mean values ×/÷ geometric standard deviation from at least 3 separate experiments.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Carried out using fresh human blood spiked with purified recombinant hLOXL2.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Carried out using concentrated conditioned media (CCM) from CHO cells stably expressing hLOXL2.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">Assay performed using CCM containing 0.1% BSA prior to concentration.</p></div><div class="footnote" id="t3fn5"><sup>Table e</sup><p class="last">Carried out using CCM containing 0.1% BSA prior to concentration and collected from HEK cells stably expressing hLOX.</p></div><div class="footnote" id="t3fn6"><sup>Table f</sup><p class="last">Carried out using purified recombinant hLOXL3.</p></div><div class="footnote" id="t3fn7"><sup>Table g</sup><p class="last">Assay carried out using human plasma containing endogenous SSAO with benzylamine as substrate. Percent inhibition was determined after a 2 h preincubation with test compound and calculated relative to both vehicle control and control containing 1 μM PXS-4681A<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (a known SSAO inhibitor).</p></div><div class="footnote" id="t3fn8"><sup>Table h</sup><p class="last">Assay carried out using purified recombinant hDAO with DAP as substrate. Percent inhibition was determined after a 2 h preincubation with test compound and calculated relative to both vehicle and enzyme-free controls.</p></div><div class="footnote" id="t3fn9"><sup>Table i</sup><p class="last">Assay carried out using either purified recombinant hMAO-A or hMAO-B with tyramine and benzylamine as substrate, respectively. Percent inhibition was determined after a 2 h preincubation with test compounds and calculated relative to both vehicle and enzyme-free controls.</p></div></div><div></div></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Structure–Activity Relationships of LOXL2 Inhibitors</h3><div class="NLM_p">Compound <b>2</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a and <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> is an attractive lead for several reasons including good <i>in vitro</i> potency for LOXL2 (IC<sub>50</sub> = 0.13 μM), selectivity for LOXL2 over LOX (∼30-fold vs 6-fold for <b>1</b>), and a modest 10-fold shift in potency in a human whole blood assay (IC<sub>50</sub> = 1.5 μM). In addition, the molecular properties of <b>2</b> fall well within the “rule of five” (RO5) criteria,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> thus an attractive starting point for allowing efficient access to compounds with excellent physicochemical and drug-like properties. The goals for our SAR campaign included improving LOXL2 potency and selectivity, generating a compound with acceptable bioavailability to demonstrate <i>in vivo</i> efficacy in a mouse model of fibrosis, and, ultimately, selecting a clinical development candidate. Initial studies focused on the 2-position of the pyridine, as summarized in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. We first investigated the replacement of the 2-Cl moiety (of <b>2</b>) with other small groups of varying electronic and lipophilic character such as CF<sub>3</sub> (<b>48</b>), OMe (<b>49</b>), or O-cyclohexyl (<b>50</b>). This led to a 6 to 9-fold drop in potency for LOXL2, although selectivity over LOX was improved for the more electronegative CF<sub>3</sub>-containing derivative <b>48</b> (40-fold selective). Potency in human whole blood was also significantly reduced, particularly for both OMe (<b>49</b>, hWB IC<sub>50</sub> = 35 μM) and <i>O</i>-cyclohexyl (<b>50</b>, hWB IC<sub>50</sub> = 29 μM) derivatives. However, replacement of <i>O</i>-cyclohexyl with an aromatic <i>O</i>-phenyl (<b>6</b>) led to improved potency at LOXL2 (versus <b>49</b> and <b>50</b>), particularly in blood where <b>6</b> (hWB IC<sub>50</sub> = 6.7 μM) was ∼4-fold more potent than <b>50</b>. One hypothesis is that the phenyl group is picking up a favorable interaction with the enzyme, so we explored substitution of the phenyl ring of <b>6</b>. Numerous derivatives were initially prepared incorporating a variety of substituents on the phenyl ring (not shown). From these, it was found that substitution with a functionalized amide moiety proved particularly productive and that the position of the substituent amide is important for potency. Derivatives incorporating the amide substituent <i>meta</i> to the pyridine O-linker exhibited improved potency for LOXL2 compared to the corresponding <i>para</i>-substituted analogues (compare <b>9</b> and <b>10</b> with <b>13</b> and <b>14</b>, respectively). This was particularly apparent in the blood assay. For example, the <i>meta</i>-benzamide derivative <b>14</b> (LOXL2 CCM IC<sub>50</sub> = 0.056 μM; hWB IC<sub>50</sub> = 1.3 μM) was 30-fold more potent in human whole blood than the corresponding <i>para</i>-benzamide derivative <b>10</b> (LOXL2 CCM IC<sub>50</sub> = 0.27 μM; hWB IC<sub>50</sub> = 39 μM). Additional <i>meta</i>-amide containing analogues demonstrated that substituents of varying sizes and lipophilicities may be incorporated while maintaining good potency for LOXL2. For example, benzyl <b>15</b> (LOXL2 CCM IC<sub>50</sub> = 0.062 μM) and 2-(methylene)benzothiophene <b>17</b> (LOXL2 CCM IC<sub>50</sub> = 0.079 μM) derivatives were equipotent to benzamide derivative <b>14</b>. Furthermore, substitution of the benzamide ring (of <b>14</b>) with groups of varying electronic character proved well tolerated as, for example, incorporation of either an electron-donating OMe (<b>18</b>) or an electron-withdrawing fluoro (<b>19</b>) had little effect on overall LOXL2 potency or selectivity. Even the incorporation of ionizable groups such as amidine (<b>20</b>) or carboxylic acid (<b>21</b>) proved well tolerated by the enzyme. Overall, these data suggest that the amide is important for potency; however, substituents on the amide nitrogen are not directly involved in critical binding interactions with the enzyme. Rather, this area of the molecule probably sits in a relatively open (solvent exposed) region next to the LTQ-containing active site, which is presumably the same region normally occupied by the protein backbone immediately adjacent to the active lysine or hydroxylysine residues of both collagen and elastin substrates (illustrated in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>c).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This is the case for the related topaquinone (TPQ) containing copper amine oxidase, <i>Pichia pastoris</i> LOX, which has a broad funnel leading to the active site, thus allowing access to (and subsequent oxidation of) lysine residues in polypeptides.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The identification of a region within our small molecule scaffold amenable to significant structural variation proved an important finding and ultimately allowed for the efficient modulation and optimization of key physicochemical properties of this series without affecting potency at LOXL2 (vide infra). Despite having identified a series of potent pyridine-derived LOXL2 inhibitors (in both serum-free and human whole blood assays), we felt that the selectivity over LOX (∼30-fold) could be further improved, particularly given the physiological role of LOX in normal healthy tissue.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Key structural differences between the catalytic domains of LOX and LOXL2 are known. In particular, the catalytic domain of LOXL2 contains a predicted N-glycosylated asparagine residue (N644) close to the LTQ-Cu active site, which is absent in LOX.<a onclick="showRef(event, 'ref2 cit10a'); return false;" href="javascript:void(0);" class="ref ref2 cit10a">(2, 10a)</a> This may result in structural differences between the active site binding pockets of LOX and LOXL2, leading to differential binding of small-molecule inhibitors. Using our hypothesis that the pyridine-4-ylmethylamino group (or warhead) of our inhibitors covalently binds to the quinone carbonyl of the active site LTQ (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b), we reasoned that targeted modification around the warhead may further reduce LOX activity while maintaining potency for LOXL2. Substitution at either the warhead amine nitrogen (−CH<sub>2</sub>NHR) or the adjacent carbon (−CHRNH<sub>2</sub>) resulted in significant loss in potency for LOXL2 (data not shown), further supporting our hypothesis that inhibition is driven via Schiff base formation between the primary amine and the LTQ carbonyl. We had previously identified the 2-CF<sub>3</sub> (<b>48</b>) derivative as being the most selective versus LOX (∼40-fold) and reasoned that the combination of this with the OPh of <b>6</b> may be beneficial, i.e., incorporation of both CF<sub>3</sub> (at C-6 of the pyridine) and a phenoxy moiety (at C-2) may allow access to potent LOXL2 compounds with an improved selectivity profile. Gratifyingly, this idea proved successful, as the 6-CF<sub>3</sub>-pyridine-containing derivatives <b>25</b> and <b>26</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) maintained potency at LOXL2 and were 177- and 110-fold selective over LOX, respectively. The corresponding 6-<i>H</i>-pyridine-containing derivatives <b>14</b> and <b>17</b> were only ∼25-fold selective. This observed improvement in selectivity over LOX may be due to the increase in steric bulk at C-6 of the pyridine (H → CF<sub>3</sub>) or a combination effect with the reduced basicity/HBA capability of the pyridine ring nitrogen. This represented a major finding and resulted in the 6-CF<sub>3</sub>-pyridine moiety being incorporated into subsequent molecules. Unfortunately, both <b>25</b> and <b>26</b> exhibited a significant reduction in potency in the human blood assay (69 and 291-fold, respectively), presumably as a result of high protein binding. The calculated LogP (cLogP)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> values for <b>25</b> and <b>26</b> are 4.3 and 5.1, respectively, and it is known that highly lipophilic molecules often exhibit high blood protein binding. In order to identify suitable candidates for <i>in vivo</i> efficacy evaluation, whole blood potency needed to be improved, presumably by reducing overall lipophilicity and therefore protein binding.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This was achieved by fine-tuning of the overall lipophilicity through modification of the pendant amide substituents, and the results are shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> where compounds are listed in order of decreasing lipophilicity (cLogP of 5.1 to 0.8). Most compounds proved potent for LOXL2 under serum-free conditions with IC<sub>50</sub> values between 0.034 and 0.11 μM. An outlier was compound <b>36</b> (CCM IC<sub>50</sub> = 0.57 μM) which contains the (3<i>R</i>)-piperidine ring in place of phenyl. However, potency was restored with the corresponding (3<i>S</i>)-piperidine enantiomer <b>37</b> (CCM IC<sub>50</sub> = 0.13 μM), suggesting that relative spatial orientation of both pyridine and piperidine rings in the enzyme binding pocket is important. As predicted, the decrease in lipophilicity was accompanied by a significant improvement in whole blood potency for LOXL2. For instance, for cLogP values ∼5 (compounds <b>26</b> and <b>39</b>) the blood shift is ∼300-fold. When cLogP values are reduced by just 1 log unit to 4.3 (<b>25</b>), the blood shift is reduced to ∼70-fold, and for compounds with cLogP values <3, the human blood potency is shifted only ∼10-fold (compounds <b>27</b> through <b>33</b>). The observed improvement in whole blood potency correlates with the reduction in protein binding as, for example, compound <b>28</b> (cLogP = 2.0; hWB IC<sub>50</sub> = 0.87 μM) had measured human protein-binding of 68%, compared with 96% for the more lipophilic <b>25</b> (cLogP = 4.3; hWB IC<sub>50</sub> = 2.9 μM).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Importantly, variation of overall lipophilicity did not erode selectivity versus LOX, further supporting the role of the 6-CF<sub>3</sub>-pyridine as a key selectivity driving motif. Having identified a series of potent compounds, we wanted to understand if these were irreversible inhibitors of LOXL2, especially given that they contain a primary amine similar to that for the mechanism-based inhibitor BAPN <b>1</b>. It has been hypothesized that formation of the irreversible complex between LOX and <b>1</b> proceeds via a product Schiff base intermediate (see <b>III</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b), which can rearrange to a more stable enamine product (<b>V</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b) potentially allowing for an additional covalent interaction between the nitrile and a nearby nucleophilic residue in the LOX active site.<a onclick="showRef(event, 'cit13b'); return false;" href="javascript:void(0);" class="ref cit13b">(13b)</a> Our inhibitors are likely to form a Schiff base complex with LOXL2; however, these inhibitors are unlikely to form additional covalent bonds with the enzyme as proposed in <b>V</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b). Instead, we believe multiple noncovalent binding interactions help drive the formation of a tightly bound Schiff base complex and irreversibly lock down the enzyme in an inactive form. A major advantage of irreversible inhibition is the potential for an extended pharmacodynamic (PD) response that outlasts systemic drug levels (PK). This assumes that the target protein is not rapidly regenerated <i>in vivo</i> at the site of action. Such minimization of overall exposure <i>in vivo</i> helps limit any off-target activities and can lead to an improved safety profile and higher therapeutic index.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Select compounds, including <b>1</b>, were assessed in a human LOXL2 reversibility assay, and the results are shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a. Briefly, purified recombinant human LOXL2 bound to the bottom of 96-well plates was incubated with the inhibitor compound (1000 × IC<sub>50</sub> concentration) for 2 h at 37 °C. After repeated washing with PBS to remove any unbound inhibitor, incubation was continued for a further 2 h at 37 °C to allow for any bound compound to dissociate. Total LOXL2 activity was then measured, and % recovery of LOXL2 activity was obtained via direct comparison with the corresponding nonwashed controls. As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a, a 2 h preincubation with test compounds results in >90% inhibition of LOXL2 activity (solid bars, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a). Washing, followed by a 2 h equilibration, in most cases, led to minimal (10 to 20%) recovery of LOXL2 activity (open bars, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>a) when compared with the corresponding nonwashed controls, thus indicating that these are irreversible inhibitors of LOXL2. The exception was the initial lead 4-(methylamino)pyridine <b>2</b>, which was found to be largely reversible at LOXL2, exhibiting ∼65% recovery of enzyme activity after a 2 h postwash equilibration.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> We speculate that the observed difference in reversibility between <b>2</b> and the 2-(phenoxy)-6-(trifluoromethyl)pyridine containing inhibitors is due to the presence of additional bulky substituents, which upon formation of the initial substrate Schiff base complex can participate in additional noncovalent binding interactions further facilitating the formation and stabilization of a more tightly bound product Schiff base complex.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Given that increased levels of LOXL2 have been observed in lung tissue and serum samples from patients with IPF and that LOXL2 has been implicated as a pro-fibrotic mediator of fibrosis in murine lung fibrosis models,<a onclick="showRef(event, 'cit10b ref26'); return false;" href="javascript:void(0);" class="ref cit10b ref26">(10b, 26)</a> the mouse oropharyngeal bleomycin lung fibrosis model was chosen as our primary <i>in vivo</i> efficacy screen. A key consideration for advancing candidates into <i>in vivo</i> studies is ensuring that appropriate drug concentrations are achieved in tissues of interest. Normal C57BL/6 mice were administered the compound as a single oral dose (30 mg/kg), and both lung and plasma concentrations were assessed over time (<i>C</i><sub>max</sub> data are shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compounds <b>28</b> and <b>37</b> showed the greatest concentrations in lung tissue with <i>C</i><sub>max</sub> values of 21 and 30 μM, respectively, with compounds <b>25</b>, <b>27</b>, and <b>29</b> also exhibiting reasonable lung concentrations (<i>C</i><sub>max</sub> ∼10 μM). However, compounds <b>30</b> through <b>33</b> exhibited significantly lower lung concentrations; in particular, <b>33</b> resulted in an average lung concentration of only 0.54 μM. In general, the lung to plasma ratios proved greater for compounds of a more lipophilic nature. Compounds with cLogP values ≥2 (<b>25</b>, <b>27</b>, <b>28</b>, and <b>37</b>) displayed between 7- to 16-fold higher maximal concentrations in lung tissue versus plasma, whereas compounds with cLogP < 2 (<b>29</b> through <b>33</b>) had lung concentrations only 0.5 to 1.8 times that seen in plasma. It is known that the lungs are a site for both uptake and accumulation of certain drugs. In particular, lipophilic amines with p<i>K</i><sub>a</sub> values ≥8 often exhibit significant pulmonary uptake (for example, fentanyl and propranolol).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The p<i>K</i><sub>a</sub> of the aminomethyl group of these 6-CF<sub>3</sub>-pyridine derivatives is ∼8,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> which is in line with known lung-penetrable compounds. The above data indicate that for this series of basic amine-containing inhibitors, a cLogP of at least 1.8 is required to ensure good distribution to mouse lung. Furthermore, the combined data set presented in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> shows that by “tuning” overall lipophilicity, one can readily access compounds with both optimal lung exposure and high potency in human whole blood. This suggests that, for this series, the lipophilic sweet spot sits in a narrow range between cLogP of ∼1.8 to 3, and compound <b>28</b> (cLogP = 2.0) emerged as the lead compound suitable for advancement in to the mouse lung bleomycin model. Additionally, we measured the potency of <b>28</b> in mouse blood to ensure that the concentrations observed in mouse lung tissue would be sufficient to fully inhibit lung LOXL2. The mouse blood LOXL2 IC<sub>50</sub> and IC<sub>90</sub> values were 0.86 μM and 5.6 μM, respectively, which is very similar to the human blood IC<sub>50</sub> and IC<sub>90</sub> values of 0.87 μM and 5.4 μM, respectively. Therefore, we reasoned that a single 30 mg/kg dose should be sufficient to cover the LOXL2 IC<sub>90</sub> in mouse lung for at least 2 h, thus allowing adequate time for irreversible binding to the enzyme.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Assessment of irreversible inhibition of human LOXL2 for select compounds. Solid bars represent % inhibition of LOXL2 after a single 2 h incubation at 37 °C with the inhibitor (nonwashed controls). Open bars represent % inhibition of LOXL2 after treatment with inhibitor for 2 h at 37 °C followed by extensive washing with buffer, then an additional 2 h at 37 °C of incubation in buffer before the addition of substrate and assaying of catalytic activity. Bars represent triplicate data points with compounds tested in direct comparison to one another in one experiment. All compounds were tested in subsequent independent experiments to confirm irreversibility at least two times. (b) Assessment of irreversible inhibition of human LOXL2 activity for compound <b>43</b> after either a 2, 4, 6, or 24 h postwashout. Data bar plotted for the unwashed group is representative of 12 replicate points, and the data bar plotted for each postwash time point is representative of 3 replicate points from one experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Evaluation of Compound <b>28</b> in the Mouse Bleomycin Lung Fibrosis Model</h3><div class="NLM_p">Lung fibrosis was induced in 6 to 7-week old male C57BL/6 mice via the oropharyngeal administration of a single dose of bleomycin (1.5 U/kg). Compound <b>28</b> was administered orally (PO) once daily (QD) at 3, 10, 30, or 60 mg/kg for a total of 15 days, beginning 1 day prior to the instillation of bleomycin (prophylactic dosing regimen). At day 14 post-bleomycin administration, lungs from each animal were removed for histological examination of lung slices stained with H&E and Masson’s trichrome and an Ashcroft score of fibrosis and inflammatory damage determined.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> All doses were well tolerated with no mortality or significant body weight loss (<5% relative to vehicle matched controls) observed during treatment. Fibrosis was consistently present in the mice administered bleomycin and treated with vehicle, and the mean fibrotic index of this group was 3.6. Prophylactic treatment with <b>28</b> dose-dependently reduced lung fibrosis in mice as evidenced by a reduction in mean Ashcroft score (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Dosing at 3 mg/kg QD had little effect on fibrosis compared with the bleomycin only group (mean Ashcroft score = 3.2); however, dosing at 10 or 30 mg/kg QD did result in significantly reduced lung fibrosis with mean Ashcroft scores for those groups of 2.1 and 1.5, respectively. No further antifibrotic efficacy was seen at 60 mg/kg; therefore, the maximally efficacious dose was determined to be 30 mg/kg QD.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ashcroft scores from oropharyngeal bleomycin-instilled C57BL/6 mice (10 per group), dosed with either vehicle control (0.5% methylcellulose, QD days −1 to 14) or compound <b>28</b> (3, 10, 30, or 60 mg/kg PO QD days −1 to 14). Shown is the mean Ashcroft score ± standard error of the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Profiling of the Individual Enantiomers of <b>28</b></h3><div class="NLM_p last">Given the robust antifibrotic efficacy observed with compound <b>28</b> (racemate), we prepared and profiled the individual (<i>R</i>,<i>R</i>; <b>43</b>) and (<i>S</i>,<i>S</i>; <b>44</b>) enantiomers with the aim of selecting a single isomer for further preclinical evaluation (see <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The racemate and its enantiomers are equipotent (CCM IC<sub>50</sub> values ∼80 nM) irreversible inhibitors of LOXL2, showing significant inhibition of enzyme activity out to 24 h (as illustrated by compound <b>43</b>, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>b). That the enzyme does not differentiate between either enantiomer further supports our hypothesis that the pendent amide substituent does not participate in key binding interactions with the active site. In the human blood assay, the (<i>R</i>,<i>R</i>)-enantiomer (<b>43</b>) is slightly more potent than the (<i>S</i>,<i>S</i>)-enantiomer (<b>44</b>), with average IC<sub>50</sub> values of 0.71 and 1.1 μM, respectively. Both enantiomers were also assessed for selectivity across a broader panel of related human amine oxidases (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). As expected, both <b>43</b> and <b>44</b> proved highly selective for LOXL2 over LOX (>400-fold). For the more closely related LOXL isoforms, activity was only evaluated against LOXL3, where both compounds exhibit IC<sub>50</sub> values of ∼1.2 μM. Attempts to generate stable cell lines for LOXL1 and LOXL4 were unsuccessful, so potencies against these two enzymes were not determined. Compounds <b>43</b> and <b>44</b> also proved highly selective for LOXL2 over other key members of the amine oxidase family, including the copper-dependent amine oxidases semicarbazide-sensitive amine oxidase (SSAO) and diamine oxidase (DAO), as well as the flavin-dependent monoamine oxidases A (MAO-A) and B (MAO-B). They all showed <10% inhibition at 10 μM. In addition, after oral administration (30 mg/kg) to C57BL/6 mice, both enantiomers exhibited lung and plasma concentrations very similar to those observed with the corresponding racemate <b>28</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Although the enantiomers (<b>43</b> and <b>44</b>) have a very similar profile, the (<i>R</i>,<i>R</i>)-enantiomer <b>43</b> was chosen for further profiling based upon its slightly improved whole blood potency. In line with the observed high potency for human LOXL2, <b>43</b> was also potent against mouse, rat, and dog LOXL2 (average IC<sub>50</sub> values of 0.10, 0.12, and 0.16 μM, respectively) which are key efficacy and toxicological species. Compound <b>43</b> also exhibits a reasonable CYP450 inhibition profile, with measured IC<sub>50</sub> values of 1.8, 1.7, 2.4, 12, and 30 μM versus 1A2, 2C9, 2C19, 2D6, and 3A4, respectively. In addition, <b>43</b> was inactive when screened against a panel of 55 diverse receptors, ion channels, and transporters (all <50% at 10 μM).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Also, given that <b>43</b> contains a basic amine flanked by an aromatic moiety, a known pharmacophore for inhibitors of the hERG potassium channel,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> it was screened for activity in a patch-clamp assay. Compound <b>43</b> proved inactive against hERG (<10% inhibition at 10 μM), thus limiting the potential for cardiotoxicity. Similarly, compound <b>43</b> proved negative in both <i>in vitro</i> genetox (Ames mutagenicity; ± S-9 metabolic activation) and hepatotoxicity (glutathione trapping in HLM) assays, suggesting minimal risk for the formation of reactive metabolites. Given its very attractive profile, <b>43</b> was selected for advanced efficacy, DMPK, and toxicological profiling, the results of which will be the subject of subsequent publications.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have described the SAR studies leading to the identification of potent, selective, and orally efficacious small-molecule inhibitors of LOXL2. Commencing with 4-(aminomethyl)-2-chloropyridine <b>2</b>, the introduction of the 3-(amido)phenoxy moiety improved potency at LOXL2, and further substitution with CF<sub>3</sub> at C-6 of the pyridine ring allowed access to compounds with very high selectivity for LOXL2 over LOX. Lastly, “tuning” overall cLogP to between ∼1.8 to 3 through variation of the amide substituent yielded compounds with both good blood potency and distribution to lung. The compound with the best overall profile, racemic-<i>trans</i>-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone (<b>28</b>) significantly reduced lung fibrosis in a 14-day mouse lung bleomycin model when dosed orally (QD). The individual (<i>R</i>,<i>R</i>)-enantiomer <b>43</b> (LOXL2 IC<sub>50</sub> = 0.074 μM; > 400-fold selective over LOX) was ultimately selected as the clinical compound and has since progressed into healthy volunteer Phase 1 trials, thus making it the “first-in-class” small-molecule LOXL2 inhibitor to enter clinical development with the potential to treat a number of fibrotic diseases.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> General Methods</h4><div class="NLM_p">All commercially available solvents and reagents were used as received. Where appropriate, reactions were carried out under an argon atmosphere. Reactions were monitored by either analytical thin-layer chromatography (TLC) or by analytical liquid chromatography–mass spectrometry (LC-MS) recorded on a Shimadzu LC-MS 2020 instrument using reverse-phase conditions (acetonitrile/water, containing 0.1% formic acid). Flash column chromatography was conducted under medium pressure either on silica (Merck silica gel 40–63 μm) or on prepacked silica gel cartridges using a flash chromatography system (Biotage, Uppsala, Sweden), and eluents were monitored by UV light (λ = 254 nm). Unless otherwise stated, preparative reverse-phase HPLC was performed using Shimadzu HPLC systems employing a Waters XTerra 5 μm preparative C<sub>18</sub> OBD 50 × 100 mm column, eluting with acetonitrile/water (containing 0.1% TFA) at a flow rate of 30 mL/min, and eluents monitored by UV light (λ = 254 nm). <sup>1</sup>H NMR spectra were recorded using either a Varian Mercury Plus 300 MHz or Bruker 400 MHz NMR spectrometer. Chemical shifts (δ) are reported as parts per million (ppm) relative to tetramethylsilane (TMS; internal standard), and coupling constants (<i>J</i>) are reported in Hz. The following abbreviations are used for multiplicities: s = singlet; br s = broad singlet; d = doublet; t = triplet; q = quartet; m = multiplet; and br m = broad multiplet. Low resolution mass spectra (MS) were obtained as electrospray ionization (ESI) mass spectra, which were recorded on a Shimadzu LC-MS 2020 instrument using reverse-phase conditions (acetonitrile/water, containing 0.1% formic acid). The purity of all tested compounds (synthesized and purchased) was determined to be ≥95% by analytical reverse-phase LC-MS, which was performed on a Shimadzu LC-MS 2020 EV (ESI probe) instrument, using an Agilent Zorbax SB-C8 5 μm 2.1 × 50 mm column, eluting with a gradient of 5–100% acetonitrile in water (containing 0.1% formic acid) over 7 min (at 27 °C), with a flow rate of 0.5 mL/min and visualized using a wavelength of 254 nm.</div><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> 3-Aminopropionitrile Fumarate Salt (<b>1</b>)</h5><div class="NLM_p last">The title compound was obtained from a commercial source and used without further purification. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O): δ 6.50 (s, 2 × 1/2H), 3.40 (m, 2H), 2.95 (m, 2H).</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19"> 1-(2-Chloro-4-pyridinyl)methanamine Hydrochloride (<b>2</b>)</h5><div class="NLM_p last">The title compound was obtained from a commercial source and used without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.71 (br s, 3H), 8.45 (m, 1H), 7.70 (m, 1H), 7.55 (m, 1H), 4.11 (s, 2H). LC-MS <i>m</i>/<i>z</i> 143.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> 2-Phenoxyisonicotinonitrile (<b>5</b>)</h5><div class="NLM_p last">A mixture of phenol (679 mg, 7.22 mmol), Cs<sub>2</sub>CO<sub>3</sub> (3.53 g, 10.83 mmol), and DMA (10 mL) was stirred at rt for 30 min. 2-Chloro-4-pyridinecarbonitrile <b>4</b> (1.0 g, 7.22 mmol) was added and the mixture heated at 80 °C for 20 h. After cooling the mixture to rt, water (100 mL) was added followed by brine (15 mL) and aq 2 M HCl (15 mL). The mixture was extracted with EtOAc (2 × 50 mL), and the combined organic layers were dried (MgSO<sub>4</sub>), filtered, and then concentrated under reduced pressure to afford the title compound as a white solid (1.34 g, 95%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.35 (m, 1H), 7.62 (m, 1H), 7.55 (m, 1H), 7.40–7.46 (m, 2H), 7.24 (m, 1H), 7.14–7.17 (m, 2H). LC-MS <i>m</i>/<i>z</i> 197.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> (2-Phenoxypyridin-4-yl)methanamine Hydrochloride (<b>6</b>)</h5><div class="NLM_p last">To a solution of 2-phenoxyisonicotinonitrile <b>5</b> (250 mg, 1.27 mmol) in a 1:1 mixture of MeOH/EtOAc (4 mL) was added 10% palladium on activated carbon (5 mol %). The mixture was stirred under hydrogen (1 atm) at rt for 2 h. After removal of hydrogen, the mixture was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure to afford (2-phenoxypyridin-4-yl)methanamine as a yellow oil (231 mg, 91%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.02 (m, 1H), 7.34–7.44 (m, 2H), 6.99–7.21 (m, 5H), 3.71–3.73 (m, 2H). A mixture of (2-phenoxypyridin-4-yl)methanamine (231 mg, 1.15 mmol), DCM (2 mL), and 2 M HCl in Et<sub>2</sub>O (2 mL, 4.0 mmol) was stirred at rt for 15 min. The mixture was concentrated under reduced pressure to afford the title compound as a white solid (272 mg, 100%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.61 (m, 1H), 8.17 (m, 1H), 7.00–7.50 (m, 6H), 4.00–4.30 (m, 2H). LC-MS <i>m</i>/<i>z</i> 201.0 (M<sup>+</sup>+1).</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Methyl 4-((4-Cyanopyridin-2-yl)oxy)benzoate (<b>7</b>)</h4><div class="NLM_p">To a stirred solution of 2-chloro-4-pyridinecarbonitrile <b>4</b> (1.0 g, 7.22 mmol) and methyl 4-hydroxybenzoate (1.10 g, 7.22 mmol) in DMA (10 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (3.53 g, 10.83 mmol). The reaction mixture was heated at 80 °C for 1 h. After cooling to rt, the mixture was partitioned between water (200 mL) and EtOAc (100 mL). The organic layer was separated, and the aq layer was re-extracted with EtOAc (100 mL). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–60% EtOAc in hexanes) to afford the title compound as a solid (1.07 g, 58%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.39 (m, 1H), 7.99–8.03 (m, 2H), 7.74 (m, 1H), 7.63 (m, 1H), 7.28–7.32 (m, 2H), 3.84 (s, 3H). LC-MS <i>m</i>/<i>z</i> 255.0 (M<sup>+</sup>+1).</div><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> 4-((4-(((<i>tert</i>-Butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic Acid (<b>8</b>)</h5><div class="NLM_p">To a solution of methyl 4-((4-cyanopyridin-2-yl)oxy)benzoate <b>7</b> (1.07 g, 4.21 mmol) in a 1:1 mixture of MeOH/EtOAc (60 mL) was added 10% palladium on activated carbon (5 mol %). The mixture was stirred under hydrogen (1 atm) at rt for 18 h. After the removal of hydrogen, the mixture was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure to afford methyl 4-((4-(aminomethyl)pyridin-2-yl)oxy)benzoate as a solid (1.08 g, 100%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.08 (m, 1H), 7.96–8.00 (m, 2H), 7.15–7.22 (m, 3H), 7.10 (m, 1H), 3.83 (s, 3H), 3.78 (s, 2H). LC-MS <i>m</i>/<i>z</i> 259.0 (M<sup>+</sup>+1).</div><div class="NLM_p last">A mixture of methyl 4-((4-(aminomethyl)pyridin-2-yl)oxy)benzoate (1.08 g, 4.18 mmol), DIEA (1.36 g, 10.54 mmol), di-<i>tert</i>-butyl dicarbonate (1.38 g, 6.32 mmol), and THF (30 mL) was stirred at rt for 2.5 h. The mixture was partitioned between DCM and aq 0.5 M HCl. The organic layer was separated, dried (MgSO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–60% EtOAc in hexanes) to afford methyl 4-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoate as an oil (1.01 g, 67%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.10 (m, 1H), 7.96–8.00 (m, 2H), 7.52 (m, 1H), 7.19–7.22 (m, 2H), 7.04 (m, 1H), 6.89 (m, 1H), 4.15–4.18 (m, 2H), 3.84 (s, 3H), 1.37 (s, 9H). LC-MS <i>m</i>/<i>z</i> 359.0 (M<sup>+</sup>+1). A mixture of methyl 4-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoate (1.0 g, 2.79 mmol), THF (18 mL), and aq 2 M LiOH (17 mL) was stirred at rt for 16 h. The mixture was diluted with water (25 mL) and adjusted to pH 3–4 via careful addition of aq 1 M HCl followed by saturated aq citric acid solution. The mixture was extracted with EtOAc (2 × 30 mL), and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure to afford the title compound as a white solid (800 mg, 83%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.83 (s, 1H), 8.08 (m, 1H), 7.96–7.99 (m, 2H), 7.52 (m, 1H), 7.15–7.17 (m, 2H), 7.02 (m, 1H), 6.88 (s, 1H), 4.13–4.18 (m, 2H), 1.36 (s, 9H). LC-MS <i>m</i>/<i>z</i> 345.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> 4-(Aminomethyl)pyridin-2-yl)oxy)phenyl-benzamides. General Procedure A. 4-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-(2-methoxyethyl)benzamide Hydrochloride (<b>9</b>)</h5><div class="NLM_p last">To a stirred solution of 4-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>8</b> (80 mg, 0.232 mmol) in DCM (2 mL) was added HATU (132 mg, 0.348 mmol), and the mixture was stirred at rt for 10 min. 2-Methoxyethylamine (23 mg, 0.302 mmol) and DIEA (90 mg, 0.697 mmol) were added and the mixture stirred at rt for 20 h. The mixture was concentrated under reduced pressure and the residue partitioned between water (20 mL) and EtOAc (20 mL). The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–100% EtOAc in hexanes) to afford <i>tert</i>-butyl ((2-(4-((2-methoxyethyl)carbamoyl)phenoxy)pyridine-4-yl)methyl)carbamate as a white solid (81 mg, 87%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.48 (m, 1H), 8.08 (m, 1H), 7.85–7.90 (m, 2H), 7.54 (m, 1H), 7.13–7.18 (m, 2H), 7.02 (m, 1H), 6.84 (m, 1H), 4.12–4.17 (m, 2H), 3.37–3.44 (m, 4H), 3.25 (s, 3H), 1.36 (s, 9H). LC-MS <i>m</i>/<i>z</i> 402.0 (M<sup>+</sup>+1). A mixture of <i>tert</i>-butyl ((2-(4-((2-methoxyethyl)carbamoyl)phenoxy)pyridine-4-yl)methyl)carbamate (81 mg, 0.202 mmol), DCM (2 mL), and 2 M HCl in Et<sub>2</sub>O (2.0 mL, 4.0 mmol) was stirred at rt for 16 h. The mixture was concentrated under reduced pressure to afford the title compound as a white solid (51 mg, 75%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.52–8.65 (br m, 4H), 8.17 (m, 1H), 7.87–7.92 (m, 2H), 7.14–7.28 (m, 4H), 4.05–4.12 (m, 2H), 3.35–3.44 (m, 4H), 3.24 (s, 3H). LC-MS <i>m</i>/<i>z</i> 302.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> 4-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-phenylbenzamide Hydrochloride (<b>10</b>)</h5><div class="NLM_p last">The title compound was prepared from 4-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>8</b> (80 mg, 0.232 mmol) and aniline (28 mg, 0.302 mmol) according to General Procedure A as a white solid (69 mg, 84%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (s, 1H), 8.68 (br s, 3H), 8.21 (m, 1H), 7.98–8.04 (m, 2H), 7.74–7.80 (m, 2H), 7.22–7.37 (m, 6H), 7.08 (m, 1H), 4.05–4.14 (m, 2H). LC-MS <i>m</i>/<i>z</i> 320.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> Methyl 3-((4-Cyanopyridin-2-yl)oxy)benzoate (<b>11</b>)</h5><div class="NLM_p last">To a stirred solution of 2-chloro-4-pyridinecarbonitrile <b>4</b> (1.0 g, 7.22 mmol) and methyl 3-hydroxybenzoate (1.10 g, 7.22 mmol) in DMA (10 mL) was added Cs<sub>2</sub>CO<sub>3</sub> (3.53 g, 10.83 mmol). The reaction mixture was heated at 80 °C for 1 h. After cooling to rt, the mixture was partitioned between water (200 mL) and EtOAc (100 mL). The organic layer was separated, and the aq layer was re-extracted with EtOAc (100 mL). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–60% EtOAc in hexanes) to afford the title compound as a solid (1.1 g, 60%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.35 (m, 1H), 7.83 (m, 1H), 7.67–7.71 (m, 2H), 7.57–7.62 (m, 2H), 7.48 (m, 1H), 3.83 (s, 3H). LC-MS <i>m</i>/<i>z</i> 255.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> 3-((4-(((<i>tert</i>-Butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic Acid (<b>12</b>)</h5><div class="NLM_p">To a solution of methyl 3-((4-cyanopyridin-2-yl)oxy)benzoate <b>11</b> (1.1 g, 4.32 mmol) in a 1:1 mixture of MeOH/EtOAc (30 mL) was added 10% palladium on activated carbon (5 mol %). The mixture was stirred under hydrogen (1 atm) at rt for 5 h. After the removal of hydrogen, the mixture was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure to afford methyl 3-((4-(aminomethyl)pyridin-2-yl)oxy)benzoate as a colorless oil (1.05 g, 94%), which did not require further purification. LC-MS <i>m</i>/<i>z</i> 259.0 (M<sup>+</sup>+1).</div><div class="NLM_p last">A mixture of methyl 3-((4-(aminomethyl)pyridin-2-yl)oxy)benzoate (1.05 g, 4.06 mmol), DIEA (1.31 g, 10.15 mmol), di-<i>tert</i>-butyl dicarbonate (1.33 g, 6.09 mmol), and THF (30 mL) was stirred at rt for 16 h. The mixture was concentrated under reduced pressure. The residue was partitioned between DCM and aq 0.5 M HCl. The organic layer was separated, dried (MgSO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–70% EtOAc in hexanes) to afford methyl 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoate as a colorless oil (1.17 g, 80%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.06 (m, 1H), 7.79 (m, 1H), 7.50–7.61 (m, 3H), 7.42 (m, 1H), 7.01 (m, 1H), 6.87 (s, 1H), 4.15–4.20 (m, 2H), 3.83 (s, 3H), 1.37 (s, 9H). LC-MS <i>m</i>/<i>z</i> 359.0 (M<sup>+</sup>+1). A mixture of methyl 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoate (1.17 g, 3.26 mmol), THF (20 mL), and aq 2 M LiOH (20 mL) was stirred at rt for 16 h. The mixture was diluted with water (25 mL) and adjusted to pH 3–4 via careful addition of aq 1 M HCl followed by saturated aq citric acid solution. The mixture was extracted with EtOAc (2 × 30 mL), and the combined organic layers were dried (MgSO<sub>4</sub>), filtered, and then concentrated under reduced pressure to afford the title compound as a white solid (1.12 g, 100%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.90 (s, 1H), 8.06 (m, 1H), 7.76 (m, 1H), 7.44–7.60 (m, 3H), 7.37 (m, 1H), 7.00 (m, 1H), 6.86 (s, 1H), 4.13–4.20 (m, 2H), 1.37 (s, 9H). LC-MS <i>m</i>/<i>z</i> 345.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> 3-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-(2-methoxyethyl)benzamide Hydrochloride (<b>13</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (80 mg, 0.232 mmol) and 2-methoxyethylamine (26 mg, 0.345 mmol) according to General Procedure A as a white solid (49 mg, 63%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.56–8.70 (br m, 4H), 8.16 (m, 1H), 7.72 (m, 1H), 7.57 (m, 1H), 7.50 (m, 1H), 7.23–7.29 (m, 3H), 4.03–4.07 (m, 2H), 3.34–3.46 (m, 4H), 3.23 (s, 3H). LC-MS <i>m</i>/<i>z</i> 302.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> 3-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-phenylbenzamide Hydrochloride (<b>14</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (80 mg, 0.232 mmol) and aniline (32 mg, 0.345 mmol) according to General Procedure A as a white solid (40 mg, 48%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.33 (s, 1H), 8.70 (br s, 3H), 8.17 (m, 1H), 7.84 (m, 1H), 7.72–7.80 (m, 2H), 7.69 (m, 1H), 7.57 (m, 1H), 7.27–7.36 (m, 5H), 7.08 (m, 1H), 4.05–4.13 (m, 2H). LC-MS <i>m</i>/<i>z</i> 320.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> 3-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-benzylbenzamide Hydrochloride (<b>15</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (80 mg, 0.232 mmol) and benzylamine (37 mg, 0.345 mmol) according to General Procedure A as a white solid (42 mg, 49%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.15 (m, 1H), 8.63 (br s, 3H), 8.16 (m, 1H), 7.77 (m, 1H), 7.61 (m, 1H), 7.52 (m, 1H), 7.20–7.30 (m, 8H), 4.42–4.48 (m, 2H), 4.04–4.14 (m, 2H). LC-MS <i>m</i>/<i>z</i> 334.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> (3-((4-(Aminomethyl)pyridin-2-yl)oxy)phenyl)(3,4-dihydroisoquinolin-2(1<i>H</i>)-yl)methanone Trifluoroacetate (<b>16</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (80 mg, 0.232 mmol) and 1,2,3,4-tetrahydroisoquinoline (46 mg, 0.345 mmol) according to General Procedure A. Additional purification via preparative reverse-phase HPLC afforded the title compound as a white solid (38 mg, 35%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.67 (br s, 3H), 8.17 (m, 1H), 7.43–7.58 (m, 2H), 7.12–7.30 (m, 8H), 4.52–4.78 (br m, 2H), 4.02–4.14 (m, 2H), 3.80 (br m, 1H), 3.57 (br m, 1H), 2.78–2.88 (m, 2H). LC-MS <i>m</i>/<i>z</i> 360.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> 3-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-(benzo[<i>b</i>]thiophen-2-ylmethyl)benzamide Hydrochloride (<b>17</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (80 mg, 0.232 mmol) and 1-benzothiophen-2-ylmethanamine (56 mg, 0.345 mmol) according to General Procedure A as a white solid (75 mg, 76%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.38 (m, 1H), 8.70 (br s, 3H), 8.16 (m, 1H), 7.82 (m, 1H), 7.72–7.80 (m, 2H), 7.62 (m, 1H), 7.53 (m, 1H), 7.24–7.35 (m, 6H), 4.67–4.74 (m, 2H), 4.06–4.12 (m, 2H). LC-MS <i>m</i>/<i>z</i> 390.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 3-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-(4-methoxyphenyl)benzamide Hydrochloride (<b>18</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (100 mg, 0.290 mmol) and 4-methoxyaniline (54 mg, 0.436 mmol) according to General Procedure A as a white solid (64 mg, 57%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.19 (s, 1H), 8.60 (br s, 3H), 8.18 (m, 1H), 7.82 (m, 1H), 7.54–7.67 (m, 4H), 7.33 (m, 1H), 7.24–7.26 (m, 2H), 6.88–6.92 (m, 2H), 4.05–4.12 (m, 2H), 3.72 (s, 3H). LC-MS <i>m</i>/<i>z</i> 350.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 3-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-(4-fluorophenyl)benzamide Hydrochloride (<b>19</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (100 mg, 0.290 mmol) and 4-fluoroaniline (48 mg, 0.436 mmol) according to General Procedure A as a white solid (71 mg, 66%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.39 (s, 1H), 8.65 (br s, 3H), 8.18 (m, 1H), 7.76–7.85 (m, 3H), 7.68 (m, 1H), 7.57 (m, 1H), 7.34 (m, 1H), 7.25–7.30 (m, 2H), 7.14–7.21 (m, 2H), 4.03–4.13 (m, 2H). LC-MS <i>m</i>/<i>z</i> 338.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 3-((4-(Aminomethyl)pyridin-2-yl)oxy)-<i>N</i>-(3-carbamimidoylbenzyl)benzamide Dihydrochloride (<b>20</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (100 mg, 0.290 mmol) and 3-(aminomethyl)benzamidine dihydrochloride (97 mg, 0.436 mmol) according to General Procedure A as a white solid (10 mg, 9%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.35 (m, 1H), 8.78 (br s, 3H), 8.49 (m, 1H), 8.14 (m, 1H), 7.70–7.82 (m, 3H), 7.64 (m, 1H), 7.46–7.58 (m, 3H), 7.26–7.32 (m, 3H), 4.49–4.51 (m, 2H), 4.05–4.15 (m, 2H). LC-MS <i>m</i>/<i>z</i> 376.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 4-(3-((4-(Aminomethyl)pyridin-2-yl)oxy)benzamido)benzoic Acid Hydrochloride (<b>21</b>)</h5><div class="NLM_p last">To a stirred solution of 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridin-2-yl)oxy)benzoic acid <b>12</b> (200 mg, 0.58 mmol) in DMF (4 mL) was added HATU (442 mg, 1.16 mmol), and the mixture was stirred at rt for 10 min. Methyl 4-aminobenzoate (132 mg, 0.87 mmol) and DIEA (224 mg, 1.74 mmol) were added and the mixture stirred at rt for 16 h. The mixture was diluted with water (15 mL) and brine (1 mL) then extracted with EtOAc (3 × 10 mL). The combined organic layers were separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–80% EtOAc in hexanes) to afford methyl 4-(3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridine-2-yl)oxy)benzamido)benzoate as a yellow foam (189 mg, 68%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.56 (s, 1H), 8.07 (m, 1H), 7.88–7.98 (m, 4H), 7.82 (m, 1H), 7.71 (m, 1H), 7.50–7.60 (m, 2H), 7.36 (m, 1H), 7.00 (m, 1H), 6.88 (m, 1H), 4.15–4.18 (m, 2H), 3.82 (s, 3H), 1.38 (s, 9H). LC-MS <i>m</i>/<i>z</i> 422.0 (MH<sup>+</sup>-C<sub>4</sub>H<sub>8</sub>). A mixture of methyl 4-(3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridine-2-yl)oxy)benzamido)benzoate (153 mg, 0.320 mmol), THF (1.5 mL), and aq 2 M LiOH (1.5 mL) was stirred at rt for 4 h. The mixture was diluted with water (4 mL) and adjusted to pH 3–4 with saturated aq citric acid. The mixture was extracted with EtOAc (2 × 30 mL), and the combined organic layers were dried (MgSO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–100% EtOAc in hexanes) to afford 4-(3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridine-2-yl)oxy)benzamido)benzoic acid as an off-white solid (87 mg, 59%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.70 (br s, 1H), 10.52 (s, 1H), 8.07 (m, 1H), 7.80–7.94 (m, 5H), 7.71 (m, 1H), 7.50–7.60 (m, 2H), 7.36 (m, 1H), 7.00 (m, 1H), 6.88 (m, 1H), 4.15–4.17 (m, 2H), 1.38 (s, 9H). LC-MS <i>m</i>/<i>z</i> 408.0 (MH<sup>+</sup>-C<sub>4</sub>H<sub>8</sub>). A mixture of 4-(3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)pyridine-2-yl)oxy)benzamido)benzoic acid (87 mg, 0.188 mmol), DCM (2 mL), and 2 M HCl in Et<sub>2</sub>O (2 mL, 4 mmol) was stirred at rt for 16 h. The mixture was concentrated under reduced pressure to afford the title compound as a white solid (39 mg, 52%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.60 (s, 1H), 8.55 (br s, 3H), 8.19 (m, 1H), 7.82–7.96 (m, 5H), 7.70 (m, 1H), 7.60 (m, 1H), 7.37 (m, 1H), 7.22–7.27 (m, 2H), 4.08–4.15 (m, 2H). LC-MS <i>m</i>/<i>z</i> 364.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> Methyl 3-((4-Cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate (<b>23</b>)</h5><div class="NLM_p last">To a stirred solution of 2-chloro-6-(trifluoromethyl)isonicotinonitrile <b>22</b> (4.0 g, 19.4 mmol) and methyl 3-hydroxybenzoate (3.24 g, 21.3 mmol) in a mixture of THF/DMF (4:1, 55 mL) was added K<sub>2</sub>CO<sub>3</sub> (8.0 g, 58 mmol). The reaction mixture was heated at 60 °C for 2 h. The THF was evaporated under reduced pressure, and the remaining mixture was partitioned between water (200 mL) and EtOAc (100 mL). The organic layer was separated, and the aq layer was re-extracted with EtOAc (100 mL). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–50% EtOAc in hexanes) to afford the title compound as a light yellow solid (5.63 g, 91%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.21 (m, 1H), 8.07 (m, 1H), 7.87 (m, 1H), 7.77 (m, 1H), 7.64 (m, 1H), 7.55 (m, 1H), 3.85 (s, 3H). LC-MS <i>m</i>/<i>z</i> 323.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 3-((4-(((<i>tert</i>-Butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic Acid (<b>24</b>)</h5><div class="NLM_p last">To a stirred solution of methyl 3-((4-cyano-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate <b>23</b> (1.5 g, 4.65 mmol) in THF/MeOH (1:1, 140 mL) at 0 °C was added portion-wise CoCl<sub>2</sub> (1.8 g, 13.98 mmol) followed by NaBH<sub>4</sub> (1.77 g, 46.5 mmol). The reaction mixture was stirred at 0 °C for 20 min. The mixture was diluted with EtOAc (100 mL) and filtered through Celite. The filtrate was concentrated, and the resulting residue was partitioned between water (200 mL) and EtOAc (200 mL). The water–organic mixture was filtered through Celite, and the organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure to obtain methyl 3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate as an amber oil (1.38 g, 92%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.83 (m, 1H), 7.67 (m, 1H), 7.65 (br m, 1H), 7.60 (m, 1H), 7.47 (m, 1H), 7.33 (br m, 1H), 3.80–3.83 (m, 5H). LC-MS <i>m</i>/<i>z</i> 327.0 (M<sup>+</sup>+1). To a stirred solution of methyl 3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate (1.38 g, 4.24 mmol) in THF (25 mL) at 0 °C was added di-<i>tert</i>-butyl dicarbonate (1.29 g, 5.94 mmol) and DIEA (2.21 mL, 12.74 mmol). The mixture was warmed to rt and stirred for a further 4 h. The mixture was concentrated and the residue partitioned between EtOAc (50 mL) and water (50 mL). The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified (silica gel; 0–60% EtOAc in hexanes) to afford methyl 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate as an amber oil (1.42 g, 78%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.85 (m, 1H), 7.69 (m, 1H), 7.58–7.62 (m, 2H), 7.48–7.51 (m, 2H), 7.13 (br m, 1H), 4.20 (m, 2H), 3.84 (s, 3H), 1.36 (s, 9H). LC-MS <i>m</i>/<i>z</i> 427.0 (M<sup>+</sup>+1). To a stirred solution of methyl 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoate (1.42 g, 3.34 mmol) in a mixture of THF/H<sub>2</sub>O (6:1, 21 mL) was added aq 4 M LiOH (17 mL, 68 mmol). The mixture was stirred at rt for 16 h, then diluted with water (30 mL) and acidified to pH 3–4 using aq saturated citric acid. The mixture was extracted with EtOAc (2 × 50 mL), and the combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure to afford the title compound as an off-white solid (1.2 g, 87%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 13.17 (br s, 1H), 7.83 (m, 1H), 7.66 (br m, 1H), 7.53–7.62 (m, 2H), 7.44–7.51 (m, 2H), 7.12 (br m, 1H), 4.25 (m, 2H), 1.36 (s, 9H). LC-MS <i>m</i>/<i>z</i> 413.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl-benzamides. General Procedure B. 3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-phenylbenzamide Hydrochloride (<b>25</b>)</h5><div class="NLM_p last">To a stirred solution of 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (750 mg, 1.82 mmol) in a mixture of DCM/DMF (3:1, 12 mL) was added HATU (1.04 g, 2.74 mmol), and the mixture was stirred at rt for 20 min. Aniline (219 mg, 2.35 mmol) and DIEA (702 mg, 5.44 mmol) were added and the mixture stirred at rt for 18 h. The DCM was evaporated under reduced pressure, and the remaining reaction mixture was partitioned between water (100 mL) and EtOAc (100 mL). The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–60% EtOAc in hexanes) to afford <i>tert</i>-butyl ((2-(3-(phenylcarbamoyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (630 mg, 71%) as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.27 (s, 1H), 7.86 (m, 2H), 7.72–7.77 (m, 2H), 7.57–7.64 (m, 2H), 7.51 (m, 1H), 7.44 (m, 1H), 7.30–7.36 (m, 2H), 7.06–7.13 (m, 2H), 4.25 (m, 2H), 1.35 (s, 9H). LC-MS <i>m</i>/<i>z</i> 510.0 (M<sup>+</sup>+Na) and 432.0 (MH<sup>+</sup> – C<sub>4</sub>H<sub>8</sub>). To a stirred mixture of <i>tert</i>-butyl ((2-(3-(phenylcarbamoyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (630 mg, 1.29 mmol) in DCM (27 mL) at rt was added 2 M HCl in Et<sub>2</sub>O (9.69 mL, 19.38 mmol). The mixture was stirred at rt for 18 h. Additional 2 M HCl in Et<sub>2</sub>O (9 mL, 18.0 mmol) was added and the mixture stirred at rt for a further 2 h. The mixture was concentrated under reduced pressure to afford the title compound (375 mg, 69%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.35 (s, 1H), 8.56 (br s, 3H), 7.84–7.90 (m, 2H), 7.74–7.79 (m, 3H), 7.65 (m, 1H), 7.52 (m, 1H), 7.45 (m, 1H), 7.31–7.38 (m, 2H), 7.09 (m, 1H), 4.23 (m, 2H). LC-MS <i>m</i>/<i>z</i> 388.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-(benzo[<i>b</i>]thiophen-2-ylmethyl)benzamide Hydrochloride (<b>26</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (55 mg, 0.133 mmol) and 1-benzothiophen-2-ylmethylamine (28 mg, 0.173 mmol) according to General Procedure B as an off-white solid (56 mg, 83%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.38 (m, 1H), 8.52 (br s, 3H), 7.80–7.90 (m, 3H), 7.77 (m, 1H), 7.68 (m, 1H), 7.58 (m, 1H), 7.48 (m, 1H), 7.25–7.42 (m, 4H), 4.67–4.72 (m, 2H), 4.14–4.22 (m, 2H). LC-MS <i>m</i>/<i>z</i> 458.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-methoxybenzamide Hydrochloride (<b>27</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (150 mg, 0.364 mmol) and <i>O</i>-methylhydroxylamine (33 mg, 0.40 mmol) according to General Procedure B as an off-white solid (99 mg, 72%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.89 (s, 1H), 8.58 (br s, 3H), 7.84 (m, 1H), 7.66 (m, 1H), 7.45–7.60 (m, 3H), 7.39 (m, 1H), 4.15–4.25 (m, 2H), 3.64 (s, 3H). LC-MS <i>m</i>/<i>z</i> 342.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> Racemic-<i>trans</i>-(3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Hydrochloride (<b>28</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (50 mg, 0.121 mmol) and racemic-<i>trans</i>-4-fluoro-3-hydroxypyrrolidine hydrochloride (22 mg, 0.155 mmol) according to General Procedure B as an off-white solid (37 mg, 70%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.62 (br s, 3H), 7.86 (s, 1H), 7.51–7.57 (m, 2H), 7.41 (m, 1H), 7.30–7.40 (m, 2H), 5.62 (m, 1H), 4.95 (m, 1H), 4.12–4.30 (br m, 3H), 3.45–3.92 (m, 4H). LC-MS <i>m</i>/<i>z</i> 400.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> (<i>R</i>)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-hydroxypyrrolidin-1-yl)methanone Hydrochloride (<b>29</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (100 mg, 0.243 mmol) and (<i>R</i>)-3-pyrrolidinol hydrochloride (36 mg, 0.291 mmol) according to General Procedure B as an off-white solid (83 mg, 81%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.63 (br s, 3H), 7.85 (s, 1H), 7.49–7.56 (m, 2H), 7.40 (m, 1H), 7.27–7.34 (m, 2H), 4.15–4.25 (m, 3H), 3.18–3.58 (m, 5H), 1.70–1.95 (m, 2H). LC-MS <i>m</i>/<i>z</i> 382.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> (<i>R</i>)-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-aminopyrrolidin-1-yl)methanone Dihydrochloride (<b>30</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (100 mg, 0.243 mmol) and (<i>R</i>)-<i>tert</i>-butyl pyrrolidin-3-ylcarbamate (56 mg, 0.301 mmol) according to General Procedure B as an off-white solid (98 mg, 89%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.71 (br s, 3H), 8.20–8.40 (br m, 3H), 7.86 (s, 1H), 7.50–7.60 (m, 2H), 7.25–7.44 (m, 3H), 4.15–4.24 (m, 2H), 3.35–3.90 (m, 5H), 2.18 (m, 1H), 2.00 (m, 1H). LC-MS <i>m</i>/<i>z</i> 381.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>N</i>-(2-(1<i>H</i>-Tetrazol-1-yl)ethyl)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzamide Hydrochloride (<b>31</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (100 mg, 0.243 mmol) and 2-(1<i>H</i>-tetrazol-1-yl)ethanamine (44 mg, 0.389 mmol) according to General Procedure B as an off-white solid (70 mg, 65%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.39 (s, 1H), 8.75 (m, 1H), 8.55 (br s, 3H), 7.83 (s, 1H), 7.67 (m, 1H), 7.54–7.57 (m, 2H), 7.48 (m, 1H), 7.37 (m, 1H), 4.60–4.64 (m, 2H), 4.20–4.24 (m, 2H), 3.67–3.71 (m, 2H). LC-MS <i>m</i>/<i>z</i> 408.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> (<i>R</i>)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-(2,3-dihydroxypropyl)benzamide Hydrochloride (<b>32</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (100 mg, 0.243 mmol) and (<i>R</i>)-3-amino-1,2-propanediol (27 mg, 0.297 mmol) according to General Procedure B as an off-white solid (55 mg, 54%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.40–8.70 (br m, 4H), 7.70–7.83 (m, 2H), 7.65 (m, 1H), 7.40–7.60 (m, 2H), 7.36 (m, 1H), 4.14–4.25 (m, 2H), 3.10–3.70 (br m, 5H). LC-MS <i>m</i>/<i>z</i> 386.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-(2-sulfamoylethyl)benzamide Hydrochloride (<b>33</b>)</h5><div class="NLM_p last">The title compound was prepared from 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (100 mg, 0.243 mmol) and 2-aminoethane-1-sulfonamide (36 mg, 0.290 mmol) according to General Procedure B as an off-white solid (74 mg, 67%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.76 (m, 1H), 8.54 (br s, 3H), 7.82 (s, 1H), 7.75 (m, 1H), 7.62 (m, 1H), 7.57 (m, 1H), 7.49 (m, 1H), 7.37 (m, 1H), 6.94 (s, 2H), 4.19–4.23 (m, 2H), 3.59–3.63 (m, 2H), 3.20–3.24 (m, 2H). LC-MS <i>m</i>/<i>z</i> 419.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> (<i>R</i>)-2-(Piperidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrile Hydrochloride (<b>34</b>)</h5><div class="NLM_p last">To a stirred solution of (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)-3-hydroxypiperidine (200 mg, 0.994 mmol) in THF (5 mL) at 0 °C was added NaH (48 mg of a 60% dispersion in mineral oil, 1.20 mmol) and the mixture stirred at 0 °C for 20 min. 2-Chloro-6-(trifluoromethyl)isonicotinonitrile <b>22</b> (205 mg, 0.994 mmol) was added and the mixture stirred at rt for 72 h. The mixture was concentrated under reduced pressure, and the residue was partitioned between water and DCM. The organic layer was separated, dried (MgSO<sub>4</sub>) and filtered, and then the filtrate was concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–20% EtOAc in hexanes) to afford (<i>R</i>)-<i>tert</i>-butyl 3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)piperidine-1-carboxylate as a colorless oil (172 mg, 47%). LC-MS <i>m</i>/<i>z</i> 272.0 (MH<sup>+</sup>-Boc). To a stirred solution of (<i>R</i>)-<i>tert</i>-butyl 3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)piperidine-1-carboxylate (149 mg, 0.401 mmol) in DCM (2 mL) was added 2 M HCl in Et<sub>2</sub>O (2 mL, 4.0 mmol). The mixture was stirred at rt for 6 h. The mixture was concentrated under reduced pressure to afford the title compound as a white solid (123 mg, 100%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.30 (br s, 1H), 8.95 (br s, 1H), 8.08 (m, 1H), 7.75 (m, 1H), 5.30 (m, 1H), 3.20–3.40 (m, 2H), 2.95–3.18 (m, 2H), 1.62–2.05 (m, 4H). LC-MS <i>m</i>/<i>z</i> 272.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (<i>S</i>)-2-(Piperidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrile Hydrochloride (<b>35</b>)</h5><div class="NLM_p last">To a stirred solution of (<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)-3-hydroxypiperidine (975 mg, 4.84 mmol) in THF (24 mL) at 0 °C was added NaH (232 mg of a 60% dispersion in mineral oil, 5.80 mmol) and the mixture stirred at 0 °C for 15 min. 2-Chloro-6-(trifluoromethyl)isonicotinonitrile <b>22</b> (1 g, 4.84 mmol) was added and the mixture stirred at rt for 16 h. The mixture was concentrated under reduced pressure, and the residue was partitioned between water and DCM. The organic layer was separated, dried (MgSO<sub>4</sub>), and filtered, and then the filtrate was concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–30% EtOAc in hexanes) to afford (<i>S</i>)-<i>tert</i>-butyl 3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)piperidine-1-carboxylate as a yellow oil (951 mg, 53%). LC-MS <i>m</i>/<i>z</i> 272.0 (MH<sup>+</sup>-Boc). To a stirred solution of (<i>S</i>)-<i>tert</i>-butyl 3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)piperidine-1-carboxylate (2.04 g, 5.49 mmol) in DCM (6 mL) was added 2 M HCl in Et<sub>2</sub>O (6 mL, 12.0 mmol). The mixture was stirred at rt for 16 h. The mixture was concentrated under reduced pressure to afford the title compound as a foam (1.62 g, 96%), which did not require further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.35 (br s, 1H), 8.96 (br s, 1H), 8.08 (m, 1H), 7.75 (m, 1H), 5.30 (m, 1H), 3.20–3.40 (m, 2H), 2.95–3.18 (m, 2H), 1.62–2.05 (m, 4H). LC-MS <i>m</i>/<i>z</i> 272.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>R</i>)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide Trifluoroacetate (<b>36</b>)</h5><div class="NLM_p last">To a stirred solution of (<i>R</i>)-2-(piperidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrile hydrochloride <b>34</b> (104 mg, 0.338 mmol) in THF (2 mL) was added phenyl isocyanate (60 mg, 0.507 mmol) and DIEA (109 mg, 0.845 mmol). The mixture was stirred at rt for 16 h. The mixture was concentrated under reduced pressure, and the residue was purified (silica gel; eluting with 0–20% EtOAc in hexanes) to afford (<i>R</i>)-3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide as a colorless oil (81 mg, 62%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.46 (s, 1H), 7.95 (s, 1H), 7.68 (s, 1H), 7.30–7.36 (m, 2H), 7.13–7.20 (m, 2H), 6.88 (m, 1H), 5.08 (m, 1H), 3.62–3.75 (m, 2H), 3.38–3.48 (m, 2H), 2.00 (m, 1H), 1.72–1.88 (m, 2H), 1.52 (m, 1H). LC-MS <i>m</i>/<i>z</i> 391.0 (M<sup>+</sup>+1). To a solution of (<i>R</i>)-3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide (81 mg, 0.207 mmol) in a 1:1 mixture of MeOH/EtOAc (2 mL) was added 10% palladium on activated carbon (5 mol %). The mixture was stirred under hydrogen (1 atm) at rt for 3.5 h. After the removal of hydrogen, the mixture was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure. The residue was purified via preparative reverse-phase HPLC to afford the title compound as a solid (53 mg, 50%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.49 (s, 1H), 8.28 (br s, 3H), 7.57 (m, 1H), 7.33–7.42 (m, 2H), 7.13–7.22 (m, 3H), 6.89 (m, 1H), 5.10 (m, 1H), 4.04–4.15 (m, 2H), 3.38–3.70 (m, 4H), 2.00 (m, 1H), 1.70–1.82 (m, 2H), 1.55 (m, 1H). LC-MS <i>m</i>/<i>z</i> 395.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>S</i>)-3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide Hydrochloride (<b>37</b>)</h5><div class="NLM_p last">To a stirred mixture of (<i>S</i>)-2-(piperidin-3-yloxy)-6-(trifluoromethyl)isonicotinonitrile hydrochloride <b>35</b> (1.47 g, 4.78 mmol) in THF (24 mL) was added phenyl isocyanate (854 mg, 7.17 mmol) and DIEA (1.44 g, 11.19 mmol). The mixture was stirred at rt for 4 h. The mixture was concentrated under reduced pressure, and the residue was purified (silica gel; eluting with 0–20% EtOAc in hexanes) to afford (<i>S</i>)-3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide as a colorless oil (1.5 g, 80%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.46 (s, 1H), 7.95 (s, 1H), 7.68 (s, 1H), 7.30–7.36 (m, 2H), 7.13–7.20 (m, 2H), 6.88 (m, 1H), 5.08 (m, 1H), 3.62–3.75 (m, 2H), 3.38–3.55 (m, 2H), 2.00 (m, 1H), 1.72–1.88 (m, 2H), 1.52 (m, 1H). LC-MS <i>m</i>/<i>z</i> 391.0 (M<sup>+</sup>+1). To a solution of (<i>S</i>)-3-((4-cyano-6-(trifluoromethyl)pyridine-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide (1.5 g, 3.84 mmol) in a 1:1 mixture of MeOH/EtOAc (30 mL) was added 10% palladium on activated carbon (5 mol %). The mixture was stirred under hydrogen (1 atm) at rt for 16 h. After removal of hydrogen, the mixture was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–10% MeOH in DCM) to afford (<i>S</i>)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide as a colorless oil (1.1 g, 73%). LC-MS <i>m</i>/<i>z</i> 395.0 (M<sup>+</sup>+1). To a stirred solution of (<i>S</i>)-3-((4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)-<i>N</i>-phenylpiperidine-1-carboxamide (910 mg, 2.31 mmol) in DCM (12 mL) was added 2 M HCl in Et<sub>2</sub>O (6 mL, 12 mmol). The mixture was stirred at rt for 5 min then concentrated under reduced pressure to afford the title compound as a white solid (875 mg, 88%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.49–8.63 (br m, 4H), 7.63 (m, 1H), 7.38–7.41 (m, 2H), 7.13–7.22 (m, 3H), 6.89 (m, 1H), 5.07 (m, 1H), 4.04–4.15 (m, 2H), 3.40–3.80 (m, 4H), 2.01 (m, 1H), 1.70–1.82 (m, 2H), 1.56 (m, 1H). LC-MS <i>m</i>/<i>z</i> 395.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 2-(3-Phenoxyphenoxy)-6-(trifluoromethyl)isonicotinonitrile (<b>38</b>)</h5><div class="NLM_p last">A stirred mixture of 2-chloro-6-(trifluoromethyl)isonicotinonitrile <b>22</b> (75 mg, 363 mmol), 3-phenoxyphenol (81 mg, 0.436 mmol), K<sub>2</sub>CO<sub>3</sub> (150 mg, 1.09 mmol), and THF (3 mL) was heated at 90 °C for 32 h. The reaction mixture was partitioned between water (20 mL) and EtOAc (20 mL). The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 0–100% EtOAc in hexanes) to afford the title compound as a yellow oil (58 mg, 45%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 7.55–7.62 (m, 3H), 7.50–7.54 (m, 2H), 7.33–7.48 (m, 5H), 7.15 (m, 1H).</div></div><div id="sec5_1_2_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (2-(3-Phenoxyphenoxy)-6-(trifluoromethyl)pyridin-4-yl)methanamine Trifluoroacetate (<b>39</b>)</h5><div class="NLM_p last">To a solution of 2-(3-phenoxyphenoxy)-6-(trifluoromethyl)isonicotinonitrile <b>38</b> (58 mg, 0.163 mmol) in EtOAc (3 mL) was added 10% palladium on activated carbon (5 mol %). The mixture was stirred under hydrogen (1 atm) at rt for 2 h. After the removal of hydrogen, the mixture was filtered through a Celite pad, and the filtrate was concentrated under reduced pressure. The residue was purified via preparative reverse-phase HPLC to afford the title compound as a white solid (64 mg, 83%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.35 (br s, 3H), 7.77 (m, 1H), 7.67 (m, 1H), 7.34–7.61 (m, 5H), 7.16 (m, 1H), 7.05 (m, 1H), 6.94 (m, 1H), 6.81 (m, 1H), 4.15–4.24 (m, 2H). LC-MS <i>m</i>/<i>z</i> 361.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> Racemic-<i>trans</i>-<i>tert</i>-butyl ((2-(3-(3-Fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (<b>40</b>)</h5><div class="NLM_p last">Two separate equal reaction batches were set up as follows: To a stirred solution of 3-((4-(((<i>tert</i>-butoxycarbonyl)amino)methyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)benzoic acid <b>24</b> (750 mg, 1.82 mmol) in a mixture of DCM/DMF (3:1, 11 mL) was added HATU (1.0 g, 2.63 mmol), and the mixture was stirred at rt for 20 min. Racemic-<i>trans</i>-4-fluoro-3-hydroxypyrrolidine hydrochloride (304 mg, 2.14 mmol) and DIEA (938 mg, 7.27 mmol) were added and the mixture stirred at rt for 2.5 h. At this point, both reaction batches were combined, and the DCM was evaporated under reduced pressure. The remaining mixture was partitioned between water (200 mL) and EtOAc (200 mL). The organic layer was separated, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and then concentrated under reduced pressure. The residue was purified (silica gel; eluting with 10–100% EtOAc in hexanes) to afford the title compound as a white solid (1.58 g, 87%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.60 (m, 1H), 7.47–7.56 (m, 2H), 7.36–7.44 (m, 2H), 7.31 (m, 1H), 7.14 (s, 1H), 5.56 (m, 1H), 4.93 (m, 1H), 4.10–4.30 (m, 3H), 3.45–3.90 (m, 4H), 1.38 (s, 9H). LC-MS <i>m</i>/<i>z</i> 522.0 (M<sup>+</sup>+Na).</div></div><div id="sec5_1_2_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (<i>R</i>,<i>R</i>)-<i>trans</i>-<i>tert</i>-Butyl ((2-(3-(3-Fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (<b>41</b>) and (<i>S</i>,<i>S</i>)-<i>trans</i>-<i>tert</i>-Butyl ((2-(3-(3-Fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate (<b>42</b>)</h5><div class="NLM_p last">Single enantiomers (<i>R</i>,<i>R</i>)-<b>41</b> (102 mg, 68%) and (<i>S</i>,<i>S</i>)-<b>42</b> (88 mg, 59%) were obtained from racemate <b>40</b> (300 mg, 0.60 mmol) via preparative normal-phase chiral HPLC separation (Chiral Pak ADH 250 × 20 mm, 5 μm column; eluting isocratically with 10% MeOH/isopropanol (1:1) and 90% hexanes (containing 0.1% DEA); flow rate 18 mL/min; detecting at 230 nm), wherein (<i>R</i>,<i>R</i>)-<b>41</b> was the first to elute and (<i>S</i>,<i>S</i>)-<b>42</b> the second to elute. (<i>R</i>,<i>R</i>)-<b>41</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.59 (m, 1H), 7.47–7.56 (m, 2H), 7.35–7.45 (m, 2H), 7.31 (m, 1H), 7.16 (s, 1H), 5.56 (m, 1H), 4.94 (m, 1H), 4.25–4.30 (m, 2H), 4.17 (m, 1H), 3.45–3.90 (m, 4H), 1.39 (s, 9H). LC-MS <i>m</i>/<i>z</i> 500.0 (M<sup>+</sup>+1). Chiral HPLC analysis: <i>R</i><sub>t</sub> = 11.84 min (Chiral Pak ADH 250 × 4.6 mm, 5 μm column; eluting isocratically with 10% MeOH/EtOH (1:1) and 90% hexanes (containing 0.1% DEA) over 25 min; flow rate 1.0 mL/min; detecting at 230 nm). (<i>S</i>,<i>S</i>)-<b>42</b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.59 (m, 1H), 7.47–7.56 (m, 2H), 7.35–7.45 (m, 2H), 7.31 (m, 1H), 7.16 (s, 1H), 5.56 (m, 1H), 4.95 (m, 1H), 4.25–4.30 (m, 2H), 4.17 (m, 1H), 3.45–3.90 (m, 4H), 1.39 (s, 9H). LC-MS <i>m</i>/<i>z</i> 500.0 (M<sup>+</sup>+1). Chiral HPLC analysis: <i>R</i><sub>t</sub> = 14.71 min (Chiral Pak ADH 250 × 4.6 mm, 5 μm column; eluting isocratically with 10% MeOH/EtOH (1:1) and 90% hexanes (containing 0.1% DEA) over 25 min; flow rate 1.0 mL/min; detecting at 230 nm).</div></div><div id="sec5_1_2_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (<i>R</i>,<i>R</i>)-<i>trans</i>-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Hydrochloride (<b>43</b>)</h5><div class="NLM_p last">To a stirred mixture of (<i>R</i>,<i>R</i>)-<i>trans</i>-<i>tert</i>-butyl ((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate <b>41</b> (102 mg, 0.204 mmol) in DCM (2 mL) was added 2 M HCl in Et<sub>2</sub>O (2 mL, 4.0 mmol). The mixture was stirred at rt for 18 h. The mixture was concentrated under reduced pressure to afford the title compound as a white solid (89 mg, 100%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.61 (br s, 3H), 7.84 (s, 1H), 7.51–7.57 (m, 2H), 7.43 (m, 1H), 7.28–7.37 (m, 2H), 5.62 (br m, 1H), 4.95 (m, 1H), 4.12–4.30 (br m, 3H), 3.30–3.92 (m, 4H). LC-MS <i>m</i>/<i>z</i> 400.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (<i>S</i>,<i>S</i>)-<i>trans</i>-(3-((4-(Aminomethyl)-6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Hydrochloride (<b>44</b>)</h5><div class="NLM_p last">To a stirred mixture of (<i>S</i>,<i>S</i>)-<i>trans</i>-<i>tert</i>-butyl ((2-(3-(3-fluoro-4-hydroxypyrrolidine-1-carbonyl)phenoxy)-6-(trifluoromethyl)pyridin-4-yl)methyl)carbamate <b>42</b> (88 mg, 0.175 mmol) in DCM (2 mL) was added 2 M HCl in Et<sub>2</sub>O (2 mL, 4.0 mmol). The mixture was stirred at rt for 18 h. The mixture was concentrated under reduced pressure to afford the title compound as a white solid (77 mg, 100%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.61 (br s, 3H), 7.84 (s, 1H), 7.51–7.57 (m, 2H), 7.43 (m, 1H), 7.28–7.37 (m, 2H), 5.57 (br m, 1H), 4.95 (m, 1H), 4.12–4.30 (br m, 3H), 3.30–3.92 (m, 4H). LC-MS <i>m</i>/<i>z</i> 400.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Racemic-<i>trans</i>-4-fluoro-3-pyrrolidinol (<b>46</b>)</h5><div class="NLM_p last">To a stirred solution of NaOH (2.83 g, 70.6 mmol) in EtOH (100 mL) was added racemic-<i>trans</i>-4-fluoro-3-pyrrolidinol hydrochloride (10 g, 70.6 mmol). The solution was stirred at rt for 1h. The mixture was filtered, and the filtrate was concentrated to give the title compound (7.0 g, 94%) as a brown oil. LC-MS <i>m</i>/<i>z</i> 106.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (<i>R</i>,<i>R</i>)-<i>trans</i>-4-Fluoro-3-pyrrolidinol 2,3-Dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartrate (<b>47</b>)</h5><div class="NLM_p last">To a solution of racemic-<i>trans</i>-4-fluoro-3-pyrrolidinol <b>46</b> (5.0 g, 47.6 mmol) in THF (0.5 mL) at rt was added 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartaric acid (0.5 equiv). The mixture was heated at reflux then cooled to rt and stirred for 16 h. The obtained precipitate (11 g) was collected via filtration and was repeatedly recrystallized (total of 4 separate times) from MeOH to afford the title compound (638 mg, 6% overall yield) as a solid. <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub>4</sub>): δ 8.14–8.17 (m, 4H), 7.62–7.66 (m, 2H), 7.49–7.53 (m, 4H), 5.92 (s, 2H), 5.08 (m, 1H), 4.46 (m, 1H), 3.32–3.36 (m, 4H). LC-MS <i>m</i>/<i>z</i> 106.0 (M<sup>+</sup>+1). The % ee was obtained via derivatization of the title compound with Marfey’s Reagent (1-fluoro-2,4-dinitrophenyl-5-<span class="smallcaps smallerCapital">l</span>-alanine amide) followed by HPLC analysis. (<i>R</i>,<i>R</i>)-<i>trans</i>-4-Fluoro-3-pyrrolidinol 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartrate <b>47</b> (5 mg) was shaken with 0.5 M aq NaHCO<sub>3</sub> until a clear solution was obtained. Marfey’s Reagent (0.5 mL of a 2 mg/mL solution in acetone) was added and the mixture shaken at 50 °C for 20 min. The resulting solution was directly analyzed via chiral HPLC where % ee was determined to be 94.4%. HPLC analysis: <i>R</i><sub>t</sub> = 10.18 min (Agilent ZORBAX SB-C18 150 × 4.6 mm, 3.5 μm column; eluting with 10–80% MeCN in water (containing 0.025% formic acid) over 20 min; flow rate 1.0 mL/min; detecting at 340 nm; injection volume 1.0 μL).</div></div><div id="sec5_1_2_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 4-(Aminomethyl)-2-(trifluoromethyl)pyridine Hydrochloride (<b>48</b>)</h5><div class="NLM_p last">Obtained from a commercial source and used without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81 (m, 1H), 8.78 (br s, 3H), 8.12 (m, 1H), 7.85 (m, 1H), 4.17–4.24 (m, 2H). LC-MS <i>m</i>/<i>z</i> 177.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (2-Methoxypyridin-4-yl)methanamine (<b>49</b>)</h5><div class="NLM_p last">Obtained from a commercial source and used without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.04 (m, 1H), 6.92 (m, 1H), 6.77 (m, 1H), 3.81 (s, 3H), 3.65–3.69 (m, 2H), 1.94–2.21 (br m, 2H). LC-MS <i>m</i>/<i>z</i> 139.0 (M<sup>+</sup>+1).</div></div><div id="sec5_1_2_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> [2-(Cyclohexyloxy)pyridin-4-yl]methanamine (<b>50</b>)</h5><div class="NLM_p last">Obtained from a commercial source and used without further purification. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.99 (m, 1H), 6.86 (m, 1H), 6.71 (m, 1H), 4.95 (m, 1H), 3.60–3.68 (m, 2H), 2.06–2.34 (br m, 2H), 1.83–1.96 (m, 2H), 1.63–1.78 (m, 2H), 1.17–1.58 (m, 6H). LC-MS <i>m</i>/<i>z</i> 207.0 (M<sup>+</sup>+1).</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Biology</h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> General Materials and Reagents</h5><div class="NLM_p last">DMEM/F12 mix, penicillin/streptomycin, and Amplex Red were obtained from Thermo Fisher (Waltham, MA). CuCl<sub>2</sub>, bovine serum albumin (BSA), DMSO, 1,5-diaminopentane (DAP), horseradish peroxidase (HRP), β-aminopropionitrile (BAPN), benzylamine, tyramine, methyl cellulose, and human recombinant MAO-A and MAO-B were obtained from Sigma-Aldrich Corp. (St. Louis, MO). Purified recombinant human and mouse LOXL2 and DAO were obtained from Sino Biologicals (Beijing, China). Purified recombinant human LOXL3 was obtained from R&D systems (Minneapolis, MN), and bleomycin was obtained from Calbiochem/EMD Millipore (Billerica, MA).</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Preparation of Concentrated Conditioned Media (CCM)</h5><div class="NLM_p last">Human, mouse, rat, and dog LOXL2/CHO and human LOX/HEK stable cell lines were cultured under normal growth conditions in 15 cm tissue culture plates until cells were ∼80% confluent. Cells were then washed with PBS before the addition of 25–30 mL serum-free media. For the generation of LOX/HEK conditioned media, the serum-free media consisted of phenol red-free DMEM/F12 mix w/glutamax containing pen/strep, 10 μM CuCl<sub>2</sub>, and 0.1% BSA (BSA and 10 μM CuCl<sub>2</sub> were determined to be required for measurable LOX activity). For the generation of LOXL2 conditioned media, the serum-free media consisted of phenol red-free DMEM/F12 mix w/glutamax containing pen/strep and 100 μM CuCl<sub>2</sub> (this concentration of CuCl<sub>2</sub> was determined to be optimal for maximal LOXL2 activity) and ±0.1% BSA. Cells were incubated at 37 °C, with 5% CO<sub>2</sub> in serum-free media for 40–48 h before the conditioned media were removed and centrifuged at 2000 rpm for 5 min at 4 °C to pellet cells/debris. The media were concentrated 10–20× using 10–30 kDa MWCO centriprep columns (10 kDa MWCO for LOX containing CCM and 30 kDa MWCO for LOXL2 containing CCM) according to the manufacturer’s instructions (EMD Millipore, Billerica, MA) before aliquoting and storing at −80 °C.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> LOXL2 CCM Activity Assays</h5><div class="NLM_p last">LOXL2 amine oxidase activity was evaluated by measuring the hydrogen peroxide release during the reaction using Amplex Red reagent in horseradish peroxidase (HRP)-coupled reactions.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> 10 μL of CCM (either with or without BSA) from CHO cells stably expressing human, mouse, rat, or dog LOXL2 was incubated with 2 μL of test compound in DMSO and 73 μL assay buffer (50 mM borate buffer, pH 8) for 2 h at 37 °C. After the 2 h incubation, 5 μL of 10 mM DAP diluted in assay buffer and 10 μL of Amplex Red Mix (8.5 μL assay buffer + 0.5 μL of 10 mM Amplex Red + 1 μL of 500 U/ml HRP) were added and the plate mixed and immediately placed on a FlexStation 3 (Molecular Devices, Sunnyvale, CA) for fluorescence measurements. Fluorescence was read in kinetic mode every 2 min for 1 h at excitation = 544 nm and emission = 590 nm. The amine oxidase activity was calculated from the slope of the linear portion of the curve. Wells containing the vehicle (DMSO) represented maximum activity and were set to 0% inhibition and wells containing 100 μM BAPN represented no activity and were set to 100% inhibition. The % inhibition of LOXL2 activity was calculated relative to the vehicle and BAPN controls and graphed using Collaborative Drug Discovery Vault (Burlingame, CA).</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> LOXL2 Human and Mouse Whole Blood Assays</h5><div class="NLM_p last">The amine oxidase activity of human LOXL2 in the context of human whole blood was measured using Amplex Red reagent. Purified human recombinant LOXL2 (Sino Biologicals, Beijing, China) was resuspended to 0.25 μg/mL using sterile water, then 16 μL added to 182 μL of fresh human blood collected in heparin vacutainer tubes. 2 μL test compound in DMSO (or DMSO alone) was added and incubated at 37 °C for 2 h. After the 2 h incubation, the blood was centrifuged at 2000<i>g</i> for 15 min at rt to isolate the plasma, and 50 μL of plasma was removed and mixed with 25 μL of 40 mM DAP (diluted in water) and 25 μL of Amplex Red Mix (23.5 μL of 50 mM borate buffer, pH 8 + 0.5 μL of 10 mM Amplex Red + 1 μL of 500U/mL HRP). Plates were mixed immediately and read as described above and the amine oxidase activity calculated from the slope of the linear portion of the curve. Wells containing vehicle (DMSO) represented maximum activity and were set to 0% inhibition and wells containing blood with no added LOXL2 represented no activity and were set to 100% inhibition. The % inhibition of LOXL2 activity was calculated relative to the vehicle and no LOXL2 controls for each well. For the measurement of amine oxidase activity in the context of mouse whole blood, purified mouse recombinant LOXL2 (Sino Biologicals, Beijing, China) was resuspended to 0.25 μg/mL using sterile water, then 12.8 μL added to 66.4 μL of fresh mouse blood collected in heparin vacutainer tubes. 0.8 μL of test compound in DMSO (or DMSO alone) was added and incubated at 37 °C for 2 h. After the 2 h incubation, the blood was centrifuged at 2000<i>g</i> for 15 min at rt to isolate the plasma, and 25 μL of plasma was removed and mixed with 25 μL of 40 mM DAP (diluted in water) and 50 μL of Amplex Red Mix (48.5 μL of 100 mM borate buffer, pH 8 + 0.5 μL of 10 mM Amplex Red + 1 μL of 500U/mL HRP). Plates were read and amine oxidase activity calculated as described above.</div></div><div id="sec5_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> Human LOX CCM Assay</h5><div class="NLM_p last">LOX amine oxidase activity was evaluated using Amplex Red reagent and CCM from HEK cells stably expressing human LOX collected in the presence of 0.1% BSA. To assay for amine oxidase activity, 10 μL of CCM (+BSA) was incubated with 2 μL of test compound in DMSO and 73 μL of assay buffer (50 mM borate buffer, pH 8) for 2 h at 37 °C. After the 2 h incubation, DAP substrate and Amplex Red mix were added and the plates read and analyzed as described above.</div></div><div id="sec5_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> Human LOXL3 Purified Recombinant Protein Assay</h5><div class="NLM_p last">LOXL3 amine oxidase activity was evaluated using Amplex Red reagent and commercially available purified, recombinant human LOXL3. 10 μL of 0.075 μg/μL purified, recombinant LOXL3 diluted in assay buffer (50 mM borate buffer, pH 8) was incubated with 2 μL of test compound in DMSO and 73 μL of assay buffer for 2 h at 37 °C. After the 2 h incubation, DAP substrate and Amplex Red Mix were added and the plates read and analyzed as described above.</div></div><div id="sec5_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> Human SSAO Assay</h5><div class="NLM_p last">Amine oxidase activity of human plasma SSAO was evaluated using Amplex Red reagent and benzylamine as a substrate. 2 μL of test compound diluted in DMSO (or DMSO control) was added to 83 μL of assay buffer (50 mM HEPES, pH 7.5) and 15 μL of human plasma (prepared from normal donor whole blood collected in sodium heparin vacutainer tubes and frozen; Biological Specialty Corporation, Colmar, PA) in black-walled, clear bottomed 96-well optical plates. The plates were mixed and incubated for 2 h at 37 °C. After the 2 h incubation, 100 μL of assay buffer containing 2 mM benzylamine, 0.1 mM Amplex Red Reagent, and 10 U/mL HRP were added to each well. The plates were mixed and fluorescence read kinetically on a Flex Station 3 (Molecular Devices, Sunnyvale, CA) every 30 s for a total of 15 min at excitation = 544 nm and emission = 590 nm. The slope from the linear portion of the read was used as rate of the reaction. Maximal activity was determined from wells containing plasma incubated with vehicle, and this slope value was set to 0% inhibition. Maximal inhibition was determined from wells containing plasma incubated with 1 μM of PXS-4681A, a published SSAO inhibitor,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and this slope value was set to 100% inhibition. The % inhibition of SSAO activity was calculated relative to the vehicle and PXS-4681A controls for each well.</div></div><div id="sec5_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> Human DAO Assay</h5><div class="NLM_p last">Amine oxidase activity of DAO was evaluated using Amplex Red reagent and DAP as a substrate. 2 μL of test compound in DMSO (or DMSO control) was added to 85.5 μL of assay buffer (50 mM HEPES, pH 7.5) and 2.5 μL of 0.1 μg/μL human purified, recombinant DAO in black-walled, clear bottomed 96-well optical plates. The plates were mixed and incubated for 2 h at 37 °C. After the 2 h incubation, 10 μL of assay buffer containing 0.05 mM DAP, 0.5 mM Amplex Red Reagent, and 50 U/mL HRP were added to each well. The plates were mixed quickly and fluorescence read kinetically on a Flex Station 3 (Molecular Devices, Sunnyvale, CA) at rt every 30 s for a total of 30 min at excitation = 544 nm and emission = 590 nm. The slope from the linear portion of the read was used as the rate of the reaction. Maximal activity was determined from wells containing DAO incubated with vehicle, and this slope value was set to 0% inhibition. Maximal inhibition was determined from wells lacking recombinant DAO, and this slope value was set to 100% inhibition. The % inhibition of human DAO activity was calculated relative to the vehicle and no enzyme controls for each well.</div></div><div id="sec5_1_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> Human MAO-A and MAO-B Assays</h5><div class="NLM_p last">Amine oxidase activity of the MAO enzymes was evaluated using Amplex Red reagent and either tyramine (MAO-A) or benzylamine (MAO-B) as a substrate. 2 μL of test compound in DMSO (or DMSO control) was added to 88 μL of assay buffer (50 mM HEPES, pH 7.5) and 0.2 U of human recombinant MAO-A or MAO-B in black-walled, clear bottomed 96-well optical plates. The plates were mixed and incubated for 2 h at 37 °C. After the 2 h incubation, 10 μL of assay buffer containing 0.5 mM Amplex Red Reagent and 50 U/mL HRP and either 1 mM tyramine or 2 mM benzylamine was added to each well. The plates were mixed and kinetically read at rt on a Flex Station 3 (Molecular Devices, Sunnyvale, CA) every 30 s for a total of 10 min at excitation = 544 nm and emission = 590 nm. The slope from the linear portion of the read was used as the rate of the reaction. Maximal activity was determined from wells containing MAO incubated with vehicle, and this slope value was set to 0% inhibition. Maximal inhibition was determined from wells lacking recombinant MAO, and this slope value was set to 100% inhibition. The % inhibition of human MAO was calculated relative to the vehicle and no enzyme controls for each well.</div></div><div id="sec5_1_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Human LOXL2 Reversibility Assay</h5><div class="NLM_p last">The wells of a 96-well, F-bottomed, Fluotrac, polystyrene high binding black plate (Greiner Bio-one, Monroe, NC) were coated overnight at rt with 100 μL of 0.005 mg/mL purified recombinant human LOXL2 (diluted in 50 mM PBS, pH 7.4). Replicate wells for each compound to be tested were coated to serve as washed and nonwashed controls. Following the overnight coating, the wells were blocked with 150 μL of 1% BSA in 50 mM PBS, pH 7.4 for 1.5 h at rt. The wells were rinsed twice with 200 μL of 50 mM PBS, pH 7.4, and the wells emptied by aspirating the contents. The coated plate was immediately used for the assay to assess reversibility by adding 83 μL of assay buffer (50 mM sodium borate buffer, pH 8.0) into the wells (for both the washed and nonwashed samples) of the enzyme coated assay plate. In the washed sample wells only, 1000× the IC<sub>50</sub> concentration of test compound (2 μL diluted in DMSO) or vehicle (2 μL DMSO) was added to each well. The plates were mixed and incubated for 2 h at 37 °C. After the 2 h incubation, the washed sample wells that were incubated with test compound or vehicle were washed 4 times with 200 μL of 50 mM PBS, pH 7.4, and left in the fourth wash for 2–24 h. In wells to be used as the nonwashed controls, 1000× the IC<sub>50</sub> concentration of the test compound (2 μL diluted in DMSO) or vehicle was added to each well still containing 83 μL of assay buffer added in the first step. The plates were mixed and incubated for another 2 h at 37 °C. After the 2–24 h incubation, 200 μL of 50 mM PBS, pH 7.4, in the washed sample wells was aspirated and replaced with 85 μL of assay buffer. Then, 5 μL of 10 mM DAP (diluted in Assay Buffer) or vehicle (maximal inhibition control) and 10 μL of assay buffer (50 mM sodium borate buffer, pH 8.0) containing 50 U/mL HRP and 0.5 mM Amplex Red Reagent were added to each well. The plates were mixed quickly and read (via Flex Station 3) kinetically at 37 °C every 2 min for a total of 40 min at excitation = 544 nm and emission = 590 nm. The slope from the linear portion of the read was used as the rate of the reaction. Maximal activity for either washed or nonwashed wells was determined from enzyme coated wells incubated with vehicle and substrate added, and this slope value was set to 0% inhibition for each respective condition. Maximal inhibition for either washed or nonwashed wells was determined from enzyme coated wells incubated with vehicle with no substrate added, and this slope value was set to 0% inhibition. The % inhibition values of the washed and nonwashed test compounds were derived from their respective washed or nonwashed maximal activity and inhibition controls and graphed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA).</div></div><div id="sec5_1_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Mouse Oropharyngeal Bleomycin Model of Lung Fibrosis</h5><div class="NLM_p last">Male C57BL/6 mice (Simonsen Laboratories, Gilroy, CA) between 6–7 weeks of age were used for the bleomycin lung fibrosis studies. Mice were maintained on a 12 h light/dark cycle, given free access to standard chow and were allowed to acclimate for 1 week prior to study initiation. All procedures were approved by the local Institutional Animal Care and Use Committee and carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The number of mice used per group was 10. Fibrosis was induced in these mice by administering bleomycin (1.5 U/kg) via oropharyngeal instillation.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Test compound (in 0.5% methylcellulose) or vehicle was administered orally, once daily beginning 1 day prior to bleomycin instillation. At 14-days post-bleomycin administration, animals were anesthetized with isoflurane and blood collected into EDTA vacutainer tubes via cardiac puncture. The lungs from each animal were harvested and weighed and the bronchoalveolar lavage (BAL) fluid collected by lavaging the lung twice with 0.5 mL of Hank’s Balanced Salt Solution. Lungs were then inflated and fixed by instillation of 10% neutral buffered formalin and prepared for histological examination. For histological examination of fibrosis, lung slices were stained with Masson’s trichrome at Seventh Wave Laboratories, LLC (Maryland Heights, MO) and an Ashcroft score of lung fibrosis and inflammatory damage determined.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec5_1_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Cytochrome P450 Inhibition Assays</h5><div class="NLM_p last">Pooled human liver microsomes (50-donor pool) were purchased from BioreclamationIVT, Chestertown, MD. In general, microsomes at protein concentrations of 0.1 mg/mL were mixed with buffer (100 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4), MgCl<sub>2</sub> (6 mM), and a multiplexed substrate mixture (midazolam (5 μM final concentration)), diclofenac (10 μM), and dextromethorphan (5 μM) and were kept on melting ice. Aliquots of this mixture (89 μL) were delivered to each well of a 96-well polypropylene plate which contained an aliquot of individual inhibitors (1 μL) in acetonitrile/water (1:1, v/v). Final solvent concentrations were less than 1% (v/v). Incubations were initiated with the addition of 10 μL of β-NADPH (10 mM stock; as tetrasodium salt) to a final volume of 100 μL and incubated at 37 °C for 10 min. Incubations were terminated by the addition of 1.5–2× volumes of acetonitrile containing ISTD. Samples were centrifuged at 4 °C (4,000 rpm), and the supernatant was transferred into a 96 well polypropylene plate for LC-MS/MS analysis.</div></div><div id="sec5_1_3_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> hERG Inhibition Assay</h5><div class="NLM_p last">Assays were performed by ChanTest, a division of Charles River Laboratories (Cleveland, OH). HEK293 cells were transfected with hERG cDNA. Stable transfectants were selected by coexpression with the G418-resistance gene incorporated into the expression plasmid. Selection pressure was maintained by including G418 in the culture medium. Cells were cultured in Dulbecco’s Modified Eagle's Medium/Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, and 500 μg/mL G418. For the electrophysiology experiments, cells were transferred to the recording chamber and superfused with vehicle control solution. Micropipette (internal) solution for whole cell patch clamp recordings were composed of potassium aspartate, 130 mM; MgCl<sub>2</sub>, 5 mM; EGTA, 5 mM; ATP, 4 mM; HEPES, 10 mM; and pH adjusted to 7.2 with KOH. Cells stably expressing hERG were held at −80 mV. Onset and steady state inhibition of hERG potassium current due to each test article were measured using a pulse pattern with fixed amplitudes (conditioning prepulse: + 20 mV for 1 s; repolarizing test ramp to −80 mV (−0.5 V/s) repeated at 5 s intervals). Each recording was ended with a final application of a supramaximal concentration of the reference substance (E-4031, 500 nM) to assess the contribution of endogenous currents. The remaining uninhibited current was subtracted off-line digitally from the data to determine the potency of the test substance for hERG inhibition. Peak current was measured during the test ramp. A steady state was maintained for at least 20 s before applying each test article or positive control. Peak tail currents were measured until a new steady state was achieved. One or more test article concentrations were applied sequentially (without washout between test substance concentrations) in ascending order, to each cell (<i>n</i> > 1 where <i>n</i> = number of observations). The concentration–response relationship was determined within the limits imposed by the physiochemical effects of the test article.</div></div><div id="sec5_1_3_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> Human Liver Microsomal Glutathione Trap Assay</h5><div class="NLM_p last">Pooled human liver microsomes (50-donor pool) were purchased from BioreclamationIVT, Chestertown, MD. In general, microsomes at protein concentrations of 1 mg/mL were premixed with buffer (100 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4), MgCl<sub>2</sub> (6 mM)), substrate, and glutathione (GSH; 1 mM), and assays were initiated via the addition of β-NADPH (10 mM stock) to a final volume of 1 mL and incubated at 37 °C for 1 h. Incubations were terminated by the addition of 1.5× volumes of acetonitrile/methanol (7:3 v/v) containing ISTD. Samples were centrifuged at 4 °C (4,000 rpm) and dried down overnight with a nitrogen air stream. Samples were reconstituted in 300 μL of 50:50 acetonitrile/water, and the supernatant was transferred to a glass HPLC vial for LC-MS/MS analysis.</div></div><div id="sec5_1_3_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> Bacterial Reverse Mutation Assay (Ames)</h5><div class="NLM_p last">A standard bacterial Ames test for mutagenicity was performed by BioReliance (Rockville, MD) according to standard protocols.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Briefly, the <i>S. Typhimurium</i> bacterial strain was grown to late log phase (∼10<sup>9</sup> cells/mL) and exposed to vehicle alone or test article in duplicate, in both the presence and absence of rat S9 mix. Rat S9 contained the S9 fractions from rat liver homogenate (10% v/v) with 4 mM β-nicotinamide adenine dinucleotide phosphate, 5 mM glucose-6-phosphate, 33 mM potassium chloride, 8 mM magnesium chloride, and 100 mM phosphate buffer (pH 7.4). Test solution was added to agar plates and incubated for 48–72 h and scored for colony formation. Concentrations of test compound ranged from 1.5 to 5000 μg/plate. Toxicity was evaluated as a decrease in the number of revertant colonies per plate and/or a thinning or disappearance of bacterial background lawn.</div></div><div id="sec5_1_3_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> Mouse Pharmacokinetic Studies</h5><div class="NLM_p last">Mouse pharmacokinetics were conducted in accordance with the ILAR Guide for the Care and Use of Laboratory Animals and the USDA Animal Welfare Act and PharmAkea IACUC guidelines. Test compounds were formulated in 0.5% methylcellulose (MC) at 5 mg/mL. Formulated compounds were orally administered (2–6 mL/kg) to ad libitum fed male C57BL/6J mice (<i>n</i> = 3 per time point), in multiple experiments to cover a full time course in the oral (PO) dose range. Blood samples (approximately 0.6 mL total blood) were taken as a terminal cardiac puncture from each mouse. Samples were collected on wet ice in tubes containing potassium EDTA (Starstedt, S-Monovette EDTA). Plasma samples, prepared by centrifugation of whole blood were stored frozen (−20 °C) prior to analysis. Concentrations of test compound in mouse plasma and tissues were determined by LC-MS/MS after protein precipitation. The internal standard solution (ISTD) was prepared in acetonitrile/methanol (70/30 v/v). ISTD solution (200 μL) was added to 30 μL of plasma to precipitate proteins. Samples were vortexed and centrifuged (Eppendorf, Westbury, NY) for 10 min at approximately 4,000 rpm (110,000<i>g</i>) at 4 °C. Analyte mixture (20 μL) was injected for analysis by LC-MS/MS. Analysis was performed on an LC-MS/MS system comprising a Sciex API-4000Qt tandem mass spectrometer (AB Sciex, Foster City, CA) interfaced to a HPLC system consisting of a single Agilent 1200 Series quaternary system pump (Santa Clara, CA) and a LEAP PAL autoinjector (Greenville, SC). Analyses were performed using an Agilent Zorbax SB-C8 column (2.1 × 50 mm; 5 μm) for chromatographic separation at rt.</div></div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> X-ray Crystallography</h4><div id="sec5_1_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> General Parameters from the X-ray Diffraction of <b>47</b></h5><div class="NLM_p last">Structural formula: C<sub>22</sub>H<sub>22</sub>FNO<sub>9</sub>. Formula weight: 463.40. Crystal system: Orthorhombic. Space group: <i>P</i>21 21 21. Unit cell dimensions: <i>a</i> = 7.8831(6) Å, <i>b</i> = 16.3463(13) Å, <i>c</i> = 16.9488(12) Å, α = 90°, β = 90°, and γ = 90°. Volume: 2184.0(3) Å. Temperature of data collection: 130 K. Wavelength: 1.54178 Å. Other values: <i>Z</i> = 4, <i>R1</i> = 0.0329, w<i>R2</i> = 0.0764, and <i>GOF</i> = 1.112.</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00345">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00345" class="ext-link">10.1021/acs.jmedchem.7b00345</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Screening data for compound <b>43</b>; amine oxidase activity in CCM from hLOXL2/CHO and hLOX/HEK stable cell lines versus parent CHO and HEK cells; amine oxidase activity from LOXL2/CHO and LOX/HEK CCM collected in the presence or absence of BSA; Michaelis–Menten kinetics and compound <b>1</b> inhibition of hLOXL2 and hLOX using CCM as the enzyme source; concentration–response curves of compound <b>43</b>; photomicrographs for representative histological lung sections (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_001.pdf">jm7b00345_si_001.pdf (1.02 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_002.csv">jm7b00345_si_002.csv (4.84 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00345" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin W. Rowbottom</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3934-1948" title="Orcid link">http://orcid.org/0000-0003-3934-1948</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6c011e031b0e03181803012c1c040d1e010d07090d420f0301"><span class="__cf_email__" data-cfemail="a1ccd3ced6c3ced5d5cecce1d1c9c0d3ccc0cac4c08fc2cecc">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gretchen Bain</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Imelda Calderon</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Taylor Lasof</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Lonergan</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andiliy Lai</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fei Huang</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janice Darlington</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia Prodanovich</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angelina M. Santini</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher D. King</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lance Goulet</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristen E. Shannon</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gina L. Ma</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine Nguyen</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deidre A. MacKenna</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jilly F. Evans</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John H. Hutchinson</span> - <span class="hlFld-Affiliation affiliation">PharmAkea Therapeutics, San Diego Science Center, 3030 Bunker
Hill Street, Suite 300, San Diego, California 92109, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0462-1405" title="Orcid link">http://orcid.org/0000-0003-0462-1405</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i83" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i83"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i84" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i84"> Abbreviations Used</h2><tr><td class="NLM_term">BAL</td><td class="NLM_def"><p class="first last">bronchoalveolar lavage</p></td></tr><tr><td class="NLM_term">BAPN</td><td class="NLM_def"><p class="first last">β-aminopropionitrile</p></td></tr><tr><td class="NLM_term">CCM</td><td class="NLM_def"><p class="first last">concentrated conditioned media</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">Cmax</td><td class="NLM_def"><p class="first last">maximal concentration</p></td></tr><tr><td class="NLM_term">DAO</td><td class="NLM_def"><p class="first last">diamine oxidase</p></td></tr><tr><td class="NLM_term">DAP</td><td class="NLM_def"><p class="first last">1,5-diaminopentane</p></td></tr><tr><td class="NLM_term">DMEM/F12</td><td class="NLM_def"><p class="first last">Dulbecco’s modified Eagle’s medium/nutrient mixture F12</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">EGTA</td><td class="NLM_def"><p class="first last">ethylene glycol-bis(β-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>,<i>N</i>-tetraacetic acid</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial-mesenchymal transition</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HRP</td><td class="NLM_def"><p class="first last">horseradish peroxidase</p></td></tr><tr><td class="NLM_term">IPF</td><td class="NLM_def"><p class="first last">idiopathic pulmonary fibrosis</p></td></tr><tr><td class="NLM_term">ISTD</td><td class="NLM_def"><p class="first last">internal standard</p></td></tr><tr><td class="NLM_term">LOX</td><td class="NLM_def"><p class="first last">lysyl oxidase</p></td></tr><tr><td class="NLM_term">LOXL</td><td class="NLM_def"><p class="first last">lysyl oxidase-like</p></td></tr><tr><td class="NLM_term">LOXL2</td><td class="NLM_def"><p class="first last">lysyl oxidase-like 2</p></td></tr><tr><td class="NLM_term">LTQ</td><td class="NLM_def"><p class="first last">lysine tyrosylquinone</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">SRCR</td><td class="NLM_def"><p class="first last">scavenger receptor cysteine-rich</p></td></tr><tr><td class="NLM_term">SSAO</td><td class="NLM_def"><p class="first last">semicarbazide-sensitive amine oxidase</p></td></tr><tr><td class="NLM_term">TPQ</td><td class="NLM_def"><p class="first last">topaquinone</p></td></tr><tr><td class="NLM_term">WB</td><td class="NLM_def"><p class="first last">whole blood</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83787" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83787" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Grau-Bové, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Trillo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Pascual, F.</span><span> </span><span class="NLM_article-title">Origin and evolution of lysyl oxidases</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">10568</span><span class="refDoi"> DOI: 10.1038/srep10568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fsrep10568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=26024311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10568&author=X.+Grau-Bov%C3%A9author=I.+Ruiz-Trilloauthor=F.+Rodriguez-Pascual&title=Origin+and+evolution+of+lysyl+oxidases&doi=10.1038%2Fsrep10568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and evolution of lysyl oxidases</span></div><div class="casAuthors">Grau-Bove Xavier; Ruiz-Trillo Inaki; Rodriguez-Pascual Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl oxidases (LOX) are copper-dependent enzymes that oxidize primary amine substrates to reactive aldehydes.  The best-studied role of LOX enzymes is the remodeling of the extracellular matrix (ECM) in animals by cross-linking collagens and elastin, although intracellular functions have been reported as well.  Five different LOX enzymes have been identified in mammals, LOX and LOX-like (LOXL) 1 to 4, showing a highly conserved catalytic carboxy terminal domain and more divergence in the rest of the sequence.  Here we have surveyed a wide selection of genomes in order to infer the evolutionary history of LOX.  We identified LOX proteins not only in animals, but also in many other eukaryotes, as well as in bacteria and archaea - which reveals a pre-metazoan origin for this gene family.  LOX genes expanded during metazoan evolution resulting in two superfamilies, LOXL2/L3/L4 and LOX/L1/L5.  Considering the current knowledge on the function of mammalian LOX isoforms in ECM remodeling, we propose that LOXL2/L3/L4 members might have preferentially been involved in making cross-linked collagen IV-based basement membrane, whereas the diversification of LOX/L1/L5 forms contributed to chordate/vertebrate-specific ECM innovations, such as elastin and fibronectin.  Our work provides a novel view on the evolution of this family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHiDw73o3Ogn6oPH0mYWL1fW6udTcc2ebYAjq0AeIJZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D&md5=ca8f3e5364edb3e5d19742d09d78b82a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsrep10568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10568%26sid%3Dliteratum%253Aachs%26aulast%3DGrau-Bov%25C3%25A9%26aufirst%3DX.%26aulast%3DRuiz-Trillo%26aufirst%3DI.%26aulast%3DRodriguez-Pascual%26aufirst%3DF.%26atitle%3DOrigin%2520and%2520evolution%2520of%2520lysyl%2520oxidases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10568%26doi%3D10.1038%2Fsrep10568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Finney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, H. – J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnebaum, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mure, M.</span><span> </span><span class="NLM_article-title">Human copper-dependent amine oxidases</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">546</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1016/j.abb.2013.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2Fj.abb.2013.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24407025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2014&pages=19-32&author=J.+Finneyauthor=H.+%E2%80%93+J.+Moonauthor=T.+Ronnebaumauthor=M.+Lantzauthor=M.+Mure&title=Human+copper-dependent+amine+oxidases&doi=10.1016%2Fj.abb.2013.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Human copper-dependent amine oxidases</span></div><div class="casAuthors">Finney, Joel; Moon, Hee-Jung; Ronnebaum, Trey; Lantz, Mason; Mure, Minae</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-32</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Copper amine oxidases (CAOs) are a class of enzymes that contain Cu2+ and a tyrosine-derived quinone cofactor, and catalyze the conversion of a primary amine functional group to an aldehyde, generating H2O2 and NH3 as byproducts.  These enzymes can be classified into 2 non-homologous families: 2,4,5-trihydroxyphenylalanine quinone (TPQ)-dependent CAOs and the lysine tyrosylquinone (LTQ)-dependent lysyl oxidase (LOX) family of proteins.  Here, the authors focus on recent developments in the field of research concerning human CAOs and the LOX family of proteins.  The aberrant expression of these enzymes is linked to inflammation, fibrosis, tumor metastasis/invasion, and other diseases.  Consequently, there is a crit. need to understand the functions of these proteins at the mol. level, so that strategies targeting these enzymes can be developed to combat human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxp8xJQhX_qLVg90H21EOLACvtfcHk0li0lPV3atnFfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D&md5=f7ecc08c322917ac6c9bf96636b49575</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2013.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2013.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DH.%2B%25E2%2580%2593%2BJ.%26aulast%3DRonnebaum%26aufirst%3DT.%26aulast%3DLantz%26aufirst%3DM.%26aulast%3DMure%26aufirst%3DM.%26atitle%3DHuman%2520copper-dependent%2520amine%2520oxidases%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2014%26volume%3D546%26spage%3D19%26epage%3D32%26doi%3D10.1016%2Fj.abb.2013.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Yamauchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sricholpech, M.</span><span> </span><span class="NLM_article-title">Lysine post-translational modifications of collagen</span> <span class="citation_source-journal">Essays Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1042/bse0520113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1042%2Fbse0520113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=22708567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=113-133&author=M.+Yamauchiauthor=M.+Sricholpech&title=Lysine+post-translational+modifications+of+collagen&doi=10.1042%2Fbse0520113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine post-translational modifications of collagen</span></div><div class="casAuthors">Yamauchi, Mitsuo; Sricholpech, Marnisa</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">Lysine-Based Post-Translational Modification of Proteins</span>),
    <span class="NLM_cas:pages">113-133</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">0071-1365</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Type I collagen is the most abundant structural protein in vertebrates.  It is a heterotrimeric mol. composed of two α1 chains and one α2 chain, forming a long uninterrupted triple helical structure with short non-triple helical telopeptides at both the N- and C-termini.  During biosynthesis, collagen acquires a no. of post-translational modifications, including lysine modifications, that are crit. to the structure and biol. functions of this protein.  Lysine modifications of collagen are highly complicated sequential processes catalyzed by several groups of enzymes leading to the final step of biosynthesis, covalent intermol. crosslinking.  In the cell, specific lysine residues are hydroxylated to form hydroxylysine.  Then specific hydroxylysine residues located in the helical domain of the mol. are glycosylated by the addn. of galactose or glucose-galactose.  Outside the cell, lysine and hydroxylysine residues in the N- and C-telopeptides can be oxidatively deaminated to produce reactive aldehydes that undergo a series of non-enzymic condensation reactions to form covalent intra- and inter-mol. cross-links.  Owing to the recent advances in mol. and cellular biol., and anal. technologies, the biol. significance and mol. mechanisms of these modifications have been gradually elucidated.  This chapter provides an overview on these enzymic lysine modifications and subsequent crosslinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ1dEKotSOLVg90H21EOLACvtfcHk0lgm3oxwRwz7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK&md5=2aa838a0513d3ed1a8ea6e8ab579f56e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2Fbse0520113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbse0520113%26sid%3Dliteratum%253Aachs%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DSricholpech%26aufirst%3DM.%26atitle%3DLysine%2520post-translational%2520modifications%2520of%2520collagen%26jtitle%3DEssays%2520Biochem.%26date%3D2012%26volume%3D52%26spage%3D113%26epage%3D133%26doi%3D10.1042%2Fbse0520113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Funke-Chambour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiser, T.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: the turning point is now!</span> <span class="citation_source-journal">Swiss Med. Wkly.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">w14139</span><span class="refDoi"> DOI: 10.4414/smw.2015.14139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.4414%2Fsmw.2015.14139" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2015&pages=w14139&author=M.+Funke-Chambourauthor=T.+Geiser&title=Idiopathic+pulmonary+fibrosis%3A+the+turning+point+is+now%21&doi=10.4414%2Fsmw.2015.14139"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.4414%2Fsmw.2015.14139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4414%252Fsmw.2015.14139%26sid%3Dliteratum%253Aachs%26aulast%3DFunke-Chambour%26aufirst%3DM.%26aulast%3DGeiser%26aufirst%3DT.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520the%2520turning%2520point%2520is%2520now%2521%26jtitle%3DSwiss%2520Med.%2520Wkly.%26date%3D2015%26volume%3D145%26spage%3Dw14139%26doi%3D10.4414%2Fsmw.2015.14139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Datta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scotton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Novel therapeutic approaches for pulmonary fibrosis</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01247.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1111%2Fj.1476-5381.2011.01247.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=21265830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=141-172&author=A.+Dattaauthor=C.+J.+Scottonauthor=R.+C.+Chambers&title=Novel+therapeutic+approaches+for+pulmonary+fibrosis&doi=10.1111%2Fj.1476-5381.2011.01247.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic approaches for pulmonary fibrosis</span></div><div class="casAuthors">Datta, Arnab; Scotton, Chris J.; Chambers, Rachel C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-172</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pulmonary fibrosis represents the end stage of a no. of heterogeneous conditions and is, to a greater or lesser degree, the hallmark of the interstitial lung diseases.  It is characterized by the excessive deposition of extracellular matrix proteins within the pulmonary interstitium leading to the obliteration of functional alveolar units and in many cases, respiratory failure.  While a small no. of interstitial lung diseases have known etiologies, most are idiopathic in nature, and of these, idiopathic pulmonary fibrosis is the most common and carries with it an appalling prognosis - median survival from the time of diagnosis is less than 3 years.  This reflects the lack of any effective therapy to modify the course of the disease, which in turn is indicative of our incomplete understanding of the pathogenesis of this condition.  Current prevailing hypotheses focus on dysregulated epithelial-mesenchymal interactions promoting a cycle of continued epithelial cell injury and fibroblast activation leading to progressive fibrosis.  However, it is likely that multiple abnormalities in a myriad of biol. pathways affecting inflammation and wound repair - including matrix regulation, epithelial reconstitution, the coagulation cascade, neovascularization and antioxidant pathways - modulate this defective crosstalk and promote fibrogenesis.  This review aims to offer a pathogenetic rationale behind current therapies, briefly outlining previous and ongoing clin. trials, but will focus on recent and exciting advancements in our understanding of the pathogenesis of idiopathic pulmonary fibrosis, which may ultimately lead to the development of novel and effective therapeutic interventions for this devastating condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGZh6zcVDUa7Vg90H21EOLACvtfcHk0lgm3oxwRwz7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLc%253D&md5=a161ebe75b90c742137e12b92fbeee42</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01247.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01247.x%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DA.%26aulast%3DScotton%26aufirst%3DC.%2BJ.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DNovel%2520therapeutic%2520approaches%2520for%2520pulmonary%2520fibrosis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D141%26epage%3D172%26doi%3D10.1111%2Fj.1476-5381.2011.01247.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bataller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, D. A.</span><span> </span><span class="NLM_article-title">Liver fibrosis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1172/JCI24282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1172%2FJCI24282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=15690074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=209-218&author=R.+Batallerauthor=D.+A.+Brenner&title=Liver+fibrosis&doi=10.1172%2FJCI24282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Liver fibrosis</span></div><div class="casAuthors">Bataller, Ramon; Brenner, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-218</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases.  Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation.  Our knowledge of the cellular and mol. mechanisms of liver fibrosis has greatly advanced.  Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver.  These cells are activated by fibrogenic cytokines such as TGF-β1, angiotensin II, and leptin.  Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs.  Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins.  Although many therapeutic interventions are effective in exptl. models of liver fibrosis, their efficacy and safety in humans is unknown.  This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADNkKCYBJYLVg90H21EOLACvtfcHk0lgm3oxwRwz7JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D&md5=f96b24aca82750b66fc1cb05b4b6216b</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1172%2FJCI24282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24282%26sid%3Dliteratum%253Aachs%26aulast%3DBataller%26aufirst%3DR.%26aulast%3DBrenner%26aufirst%3DD.%2BA.%26atitle%3DLiver%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D209%26epage%3D218%26doi%3D10.1172%2FJCI24282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schuppan, D.</span><span> </span><span class="NLM_article-title">Liver fibrosis: common mechanisms and antifibrotic therapies</span> <span class="citation_source-journal">Clin. Res. Hepatol. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">S51</span><span class="NLM_x">–</span> <span class="NLM_lpage">S59</span><span class="refDoi"> DOI: 10.1016/j.clinre.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2Fj.clinre.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=26189980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVegu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=S51-S59&author=D.+Schuppan&title=Liver+fibrosis%3A+common+mechanisms+and+antifibrotic+therapies&doi=10.1016%2Fj.clinre.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Liver fibrosis: Common mechanisms and antifibrotic therapies</span></div><div class="casAuthors">Schuppan, Detlef</div><div class="citationInfo"><span class="NLM_cas:title">Clinics and Research in Hepatology and Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">Suppl._1</span>),
    <span class="NLM_cas:pages">S51-S59</span>CODEN:
                <span class="NLM_cas:coden">CRHGAQ</span>;
        ISSN:<span class="NLM_cas:issn">2210-7401</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Liver fibrosis and in particular cirrhosis have become major endpoints in clin. trials of patients with chronic liver diseases.  Here, viral hepatitis, alc. and non-alc. steatohepatitis have become the major etiologies.  We have made great progress in our understanding of the mechanisms and the cell biol. of liver fibrosis and have already made the transition from preclin. testing of antifibrotic agents and strategies towards clin. translation.  There continues to be an urgent need for specific antifibrotic therapies, despite the advent of highly potent antiviral agents that can even induce regression of advanced fibrosis.  This review addresses central mechanisms and cells to be targeted, current antifibrotic drug trials, and the state of non-invasive biomarker development that is key to rapid clin. progress and to a personalized treatment of fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlbfqxGvJu87Vg90H21EOLACvtfcHk0lggHRuoXYq4DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVegu77M&md5=304d9e38d2f9ace07e18d5cd8682a59a</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2Fj.clinre.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinre.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchuppan%26aufirst%3DD.%26atitle%3DLiver%2520fibrosis%253A%2520common%2520mechanisms%2520and%2520antifibrotic%2520therapies%26jtitle%3DClin.%2520Res.%2520Hepatol.%2520Gastroenterol.%26date%3D2015%26volume%3D39%26spage%3DS51%26epage%3DS59%26doi%3D10.1016%2Fj.clinre.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Genovese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manresa, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeming, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karsdal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boor, P.</span><span> </span><span class="NLM_article-title">The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="refDoi"> DOI: 10.1186/1755-1536-7-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1186%2F1755-1536-7-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24678881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFyitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=4&author=F.+Genoveseauthor=A.+A.+Manresaauthor=D.+J.+Leemingauthor=M.+A.+Karsdalauthor=P.+Boor&title=The+extracellular+matrix+in+the+kidney%3A+a+source+of+novel+non-invasive+biomarkers+of+kidney+fibrosis%3F&doi=10.1186%2F1755-1536-7-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?</span></div><div class="casAuthors">Genovese, Federica; Manresa, Alba A.; Leeming, Diana Julie; Karsdal, Morten Asser; Boor, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Fibrogenesis & Tissue Repair</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4/1-4/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">FTRIBS</span>;
        ISSN:<span class="NLM_cas:issn">1755-1536</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Interstitial fibrosis is the common endpoint of end-stage chronic kidney disease (CKD) leading to kidney failure.  The clin. course of many renal diseases, and thereby of CKD, is highly variable.  One of the major challenges in deciding which treatment approach is best suited for a patient but also in the development of new treatments is the lack of markers able to identify and stratify patients with stable vs. progressive disease.  At the moment renal biopsy is the only means of diagnosing renal interstitial fibrosis.  Novel biomarkers should improve diagnosis of a disease, est. its prognosis and assess the response to treatment, all in a non-invasive manner.  Existing markers of CKD do not fully and specifically address these requirements and in particular do not specifically reflect renal fibrosis.  The aim of this review is to give an insight of the involvement of the extracellular matrix (ECM) proteins in kidney diseases and as a source of potential novel biomarkers of renal fibrosis.  In particular the use of the protein fingerprint technol., that identifies neo-epitopes of ECM proteins generated by proteolytic cleavage by proteases or other post-translational modifications, might identify such novel biomarkers of renal fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyfy-NeSaIybVg90H21EOLACvtfcHk0lggHRuoXYq4DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFyitLY%253D&md5=e1ce57b98ffccf936c1b9da94b01b947</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-7-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-7-4%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DF.%26aulast%3DManresa%26aufirst%3DA.%2BA.%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DBoor%26aufirst%3DP.%26atitle%3DThe%2520extracellular%2520matrix%2520in%2520the%2520kidney%253A%2520a%2520source%2520of%2520novel%2520non-invasive%2520biomarkers%2520of%2520kidney%2520fibrosis%253F%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2014%26volume%3D7%26spage%3D4%26doi%3D10.1186%2F1755-1536-7-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Ho, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laǵares, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, M.</span><span> </span><span class="NLM_article-title">Fibrosis – a lethal component of systemic sclerosis</span> <span class="citation_source-journal">Nat. Rev. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span><span class="refDoi"> DOI: 10.1038/nrrheum.2014.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnrrheum.2014.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24752182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2hu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=390-402&author=Y.+Y.+Hoauthor=D.+La%C7%B5aresauthor=A.+M.+Tagerauthor=M.+Kapoor&title=Fibrosis+%E2%80%93+a+lethal+component+of+systemic+sclerosis&doi=10.1038%2Fnrrheum.2014.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrosis-a lethal component of systemic sclerosis</span></div><div class="casAuthors">Ho, Yuen Yee; Lagares, David; Tager, Andrew M.; Kapoor, Mohit</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">390-402</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis is a pathol. process characterized by excessive accumulation of connective tissue components in an organ or tissue.  Fibrosis is produced by deregulated wound healing in response to chronic tissue injury or chronic inflammation, the hallmarks of rheumatic diseases.  Progressive fibrosis, which distorts tissue architecture and results in progressive loss of organ function, is now recognized to be one of the major causes of morbidity and mortality in individuals with one of the most lethal rheumatic disease, systemic sclerosis (SSc).  In this Review, we discuss the pathol. role of fibrosis in SSc.  We discuss the involvement of endothelium and pericyte activation, aberrant immune responses, endoplasmic reticulum stress and chronic tissue injury in the initiation of fibrosis in SSc.  We then discuss fibroblast activation and myofibroblast differentiation that occurs in response to these initiating processes and is responsible for excessive accumulation of extracellular matrix.  Finally, we discuss the chem. and mech. signals that drive fibroblast activation and myofibroblast differentiation, which could serve as targets for new therapies for fibrosis in SSc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3CKGgf3Yn8rVg90H21EOLACvtfcHk0lggHRuoXYq4DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2hu7s%253D&md5=1b9a8a7aab0ca5ea4ee2ee310189f86d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2014.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2014.53%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BY.%26aulast%3DLa%25C7%25B5ares%26aufirst%3DD.%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DKapoor%26aufirst%3DM.%26atitle%3DFibrosis%2520%25E2%2580%2593%2520a%2520lethal%2520component%2520of%2520systemic%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2014%26volume%3D10%26spage%3D390%26epage%3D402%26doi%3D10.1038%2Fnrrheum.2014.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Maulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2082</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1056%2FNEJMoa1402584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24836310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2071-2082&author=L.+Richeldiauthor=R.+M.+du+Boisauthor=G.+Raghuauthor=A.+Azumaauthor=K.+K.+Brownauthor=U.+Costabelauthor=V.+Cottinauthor=K.+R.+Flahertyauthor=D.+M.+Hansellauthor=Y.+Inoueauthor=D.+S.+Kimauthor=M.+Kolbauthor=A.+G.+Nicholsonauthor=P.+W.+Nobleauthor=M.+Selmanauthor=H.+Taniguchiauthor=M.+Brunauthor=F.+Le+Maulfauthor=M.+Girardauthor=S.+Stowasserauthor=R.+Schlenker-Hercegauthor=B.+Disseauthor=H.+R.+Collard&title=Efficacy+and+safety+of+nintedanib+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1402584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; du Bois, Roland M.; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, David M.; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moises; Taniguchi, Hiroyuki; Brun, Michele; Le Maulf, Florence; Girard, Mannaig; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Disse, Bernd; Collard, Harold R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2071-2082, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases.  A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.  Methods: We conducted two replicate 52-wk, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St.  George's Respiratory Questionnaire, both assessed over a 52-wk period.  Results: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo.  The adjusted annual rate of change in FVC was -114.7 mL with nintedanib vs. -239.9 mL with placebo (difference, 125.3 mL; 95% confidence interval [CI], 77.7 to 172.8; P < 0.001) in INPULSIS-1 and -113.6 mL with nintedanib vs. -207.3 mL with placebo (difference, 93.7 mL; 95% CI, 44.8 to 142.7; P < 0.001) in INPULSIS-2.  In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P = 0.67); in INPULSIS-2, there was a significant benefit with nintedanib vs. placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).  The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, resp., in INPULSIS-1 and 63.2% and 18.3% in the two groups, resp., in INPULSIS-2.  Conclusions: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently assocd. with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuOhVKeZaSrVg90H21EOLACvtfcHk0ljTLQ8_AUdt5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK&md5=be977cd3b402c7c401f4a3dfaa0f484f</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402584%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DLe%2BMaulf%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520nintedanib%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2071%26epage%3D2082%26doi%3D10.1056%2FNEJMoa1402584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">King, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Bernardini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspole, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glassberg, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardatzke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span> </span><span class="NLM_article-title">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2092</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1056%2FNEJMoa1402582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24836312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2083-2092&author=T.+E.+Kingauthor=W.+Z.+Bradfordauthor=S.+Castro-Bernardiniauthor=E.+A.+Faganauthor=I.+Glaspoleauthor=M.+K.+Glassbergauthor=E.+Gorinaauthor=P.+M.+Hopkinsauthor=D.+Kardatzkeauthor=L.+Lancasterauthor=D.+J.+Ledererauthor=S.+D.+Nathanauthor=C.+A.+Pereiraauthor=S.+A.+Sahnauthor=R.+Sussmanauthor=J.+J.+Swigrisauthor=P.+W.+Noble&title=A+phase+3+trial+of+pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1402582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">King, Talmadge E.; Bradford, Williamson Z.; Castro-Bernardini, Socorro; Fagan, Elizabeth A.; Glaspole, Ian; Glassberg, Marilyn K.; Gorina, Eduard; Hopkins, Peter M.; Kardatzke, David; Lancaster, Lisa; Lederer, David J.; Nathan, Steven D.; Pereira, Carlos A.; Sahn, Steven A.; Sussman, Robert; Swigris, Jeffrey J.; Noble, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2083-2092, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved.  We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients.  Methods: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 wk.  The primary end point was the change in FVC or death at week 52.  Secondary end points were the 6-min walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis.  Results: In the pirfenidone group, as compared with the placebo group, there was a relative redn. of 47.9% in the proportion of patients who had an abs. decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P < 0.001).  Pirfenidone reduced the decline in the 6-min walk distance (P = 0.04) and improved progression-free survival (P < 0.001).  There was no significant between-group difference in dyspnea scores (P = 0.16) or in rates of death from any cause (P = 0.10) or from idiopathic pulmonary fibrosis (P = 0.23).  However, in a prespecified pooled anal. incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P = 0.01) and from idiopathic pulmonary fibrosis (P = 0.006).  Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation.  Conclusions: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.  Treatment was assocd. with an acceptable sideeffect profile and fewer deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBkQ8hqTWxxLVg90H21EOLACvtfcHk0ljTLQ8_AUdt5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ&md5=17bfe4782c11521d3b7890ae387bbaf6</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402582%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCastro-Bernardini%26aufirst%3DS.%26aulast%3DFagan%26aufirst%3DE.%2BA.%26aulast%3DGlaspole%26aufirst%3DI.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DGorina%26aufirst%3DE.%26aulast%3DHopkins%26aufirst%3DP.%2BM.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DNathan%26aufirst%3DS.%2BD.%26aulast%3DPereira%26aufirst%3DC.%2BA.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSussman%26aufirst%3DR.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26atitle%3DA%2520phase%25203%2520trial%2520of%2520pirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2083%26epage%3D2092%26doi%3D10.1056%2FNEJMoa1402582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijsenbeek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnolo, P.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives</span> <span class="citation_source-journal">BioMed Res. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">329481</span><span class="refDoi"> DOI: 10.1155/2015/329481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1155%2F2015%2F329481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=329481&author=M.+Kreuterauthor=F.+Bonellaauthor=M.+Wijsenbeekauthor=T.+M.+Maherauthor=P.+Spagnolo&title=Pharmacological+treatment+of+idiopathic+pulmonary+fibrosis%3A+current+approaches%2C+unsolved+issues%2C+and+future+perspectives&doi=10.1155%2F2015%2F329481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1155%2F2015%2F329481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F329481%26sid%3Dliteratum%253Aachs%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DBonella%26aufirst%3DF.%26aulast%3DWijsenbeek%26aufirst%3DM.%26aulast%3DMaher%26aufirst%3DT.%2BM.%26aulast%3DSpagnolo%26aufirst%3DP.%26atitle%3DPharmacological%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520approaches%252C%2520unsolved%2520issues%252C%2520and%2520future%2520perspectives%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D329481%26doi%3D10.1155%2F2015%2F329481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Moon, H. – J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnebaum, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mure, M.</span><span> </span><span class="NLM_article-title">Human lysyl oxidase-like 2</span> <span class="citation_source-journal">Bioorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1016/j.bioorg.2014.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2Fj.bioorg.2014.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=25146937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ntbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=231-241&author=H.+%E2%80%93+J.+Moonauthor=J.+Finneyauthor=T.+Ronnebaumauthor=M.+Mure&title=Human+lysyl+oxidase-like+2&doi=10.1016%2Fj.bioorg.2014.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Human lysyl oxidase-like 2</span></div><div class="casAuthors">Moon, Hee-Jung; Finney, Joel; Ronnebaum, Trey; Mure, Minae</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-241</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysyl oxidase like-2 (LOXL2) belongs to the lysyl oxidase (LOX) family, which comprises Cu2+- and lysine tyrosylquinone (LTQ)-dependent amine oxidases.  LOXL2 is proposed to function similarly to LOX in the extracellular matrix (ECM) by promoting crosslinking of collagen and elastin.  LOXL2 has also been proposed to regulate extracellular and intracellular cell signaling pathways.  Dysregulation of LOXL2 has been linked to many diseases, including cancer, pro-oncogenic angiogenesis, fibrosis and heart diseases.  In this review, we will give an overview of the current understandings and hypotheses regarding the mol. functions of LOXL2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocatU98HPEn7Vg90H21EOLACvtfcHk0ljTLQ8_AUdt5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ntbrE&md5=b6ded89bd69abcef395afb909f626b0e</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2014.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2014.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DMoon%26aufirst%3DH.%2B%25E2%2580%2593%2BJ.%26aulast%3DFinney%26aufirst%3DJ.%26aulast%3DRonnebaum%26aufirst%3DT.%26aulast%3DMure%26aufirst%3DM.%26atitle%3DHuman%2520lysyl%2520oxidase-like%25202%26jtitle%3DBioorg.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D231%26epage%3D241%26doi%3D10.1016%2Fj.bioorg.2014.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barry-Hamilton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyasu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikels, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaysberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghermazien, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velayo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biermann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaffryar-Eilot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neufeld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlasselaer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, V.</span><span> </span><span class="NLM_article-title">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1017</span><span class="refDoi"> DOI: 10.1038/nm.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnm.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=20818376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1009-1017&author=V.+Barry-Hamiltonauthor=R.+Spanglerauthor=D.+Marshallauthor=S.+McCauleyauthor=H.+M.+Rodriguezauthor=M.+Oyasuauthor=A.+Mikelsauthor=M.+Vaysbergauthor=H.+Ghermazienauthor=C.+Waiauthor=C.+A.+Garciaauthor=A.+C.+Velayoauthor=B.+Jorgensenauthor=D.+Biermannauthor=D.+Tsaiauthor=J.+Greenauthor=S.+Zaffryar-Eilotauthor=A.+Holzerauthor=S.+Oggauthor=D.+Thaiauthor=G.+Neufeldauthor=P.+Van+Vlasselaerauthor=V.+Smith&title=Allosteric+inhibition+of+lysyl+oxidase-like-2+impedes+the+development+of+a+pathologic+microenvironment&doi=10.1038%2Fnm.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span></div><div class="casAuthors">Barry-Hamilton, Vivian; Spangler, Rhyannon; Marshall, Derek; McCauley, Scott; Rodriguez, Hector M.; Oyasu, Miho; Mikels, Amanda; Vaysberg, Maria; Ghermazien, Haben; Wai, Carol; Garcia, Carlos A.; Velayo, Arleene C.; Jorgensen, Brett; Biermann, Donna; Tsai, Daniel; Green, Jennifer; Zaffryar-Eilot, Shelly; Holzer, Alison; Ogg, Scott; Thai, Dung; Neufeld, Gera; Van Vlasselaer, Peter; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathol. microenvironment of cancer and fibrotic disease.  Our anal. of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-assocd. stroma and limited expression in healthy tissues.  Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models.  Inhibition of LOXL2 resulted in a marked redn. in activated fibroblasts, desmoplasia and endothelial cells, decreased prodn. of growth factors and cytokines and decreased transforming growth factor-β (TGF-β) pathway signaling.  AB0023 outperformed the small-mol. lysyl oxidase inhibitor β-aminopropionitrile.  The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncol. and fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkE52VQCvcZrVg90H21EOLACvtfcHk0ljQsw30qkfMYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF&md5=7e69cbf26c2985ad03fbb620538a5f04</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1038%2Fnm.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2208%26sid%3Dliteratum%253Aachs%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DWai%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DTsai%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DOgg%26aufirst%3DS.%26aulast%3DThai%26aufirst%3DD.%26aulast%3DNeufeld%26aufirst%3DG.%26aulast%3DVan%2BVlasselaer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DAllosteric%2520inhibition%2520of%2520lysyl%2520oxidase-like-2%2520impedes%2520the%2520development%2520of%2520a%2520pathologic%2520microenvironment%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1009%26epage%3D1017%26doi%3D10.1038%2Fnm.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Barker, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erler, J. T.</span><span> </span><span class="NLM_article-title">The rationale for targeting the LOX family in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1038/nrc3319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnrc3319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=22810810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=540-552&author=H.+E.+Barkerauthor=T.+R.+Coxauthor=J.+T.+Erler&title=The+rationale+for+targeting+the+LOX+family+in+cancer&doi=10.1038%2Fnrc3319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale for targeting the LOX family in cancer</span></div><div class="casAuthors">Barker, Holly E.; Cox, Thomas R.; Erler, Janine T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-552</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumor microenvironment as pivotal in all aspects of tumor initiation and progression.  Members of the lysyl oxidase (LOX) family of proteins are secreted by tumors and are the subject of much effort to understand their roles in cancer.  In this Review we discuss the roles of members of this family in the remodelling of the tumor microenvironment and their paradoxical roles in tumorigenesis and metastasis.  We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcLr3Y7rPKLVg90H21EOLACvtfcHk0ljQsw30qkfMYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE&md5=455064ea8d5332b43fa6490a1aaa0c8f</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1038%2Fnrc3319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3319%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DCox%26aufirst%3DT.%2BR.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520rationale%2520for%2520targeting%2520the%2520LOX%2520family%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D540%26epage%3D552%26doi%3D10.1038%2Fnrc3319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ikenaga, N.; Peng, Z.-W.; Vaid, K. A.; Liu, S. B.; Yoshida, S.; Sverdlov, D. Y.; Mikels-Vigdal, A.; Smith, V.; Schuppan, D.; Popov, Y. V.</span><span> </span><span class="NLM_article-title">Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal</span>.  <span class="citation_source-journal">Gut</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1136/gutjnl-2016-312473</span> . Published Online: Jan 10, 2017. <a href="http://dx.doi.org/10.1136/gutjnl-2016-312473" class="extLink">http://dx.doi.org/10.1136/gutjnl-2016-312473</a> (accessed April 3,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1136%2Fgutjnl-2016-312473" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Ikenaga&author=Z.-W.+Peng&author=K.+A.+Vaid&author=S.+B.+Liu&author=S.+Yoshida&author=D.+Y.+Sverdlov&author=A.+Mikels-Vigdal&author=V.+Smith&author=D.+Schuppan&author=Y.+V.+Popov&title=Selective+targeting+of+lysyl+oxidase-like+2+%28LOXL2%29+suppresses+hepatic+fibrosis+progression+and+accelerates+its+reversal&doi=10.1136%2Fgutjnl-2016-312473"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-312473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-312473%26sid%3Dliteratum%253Aachs%26aulast%3DIkenaga%26aufirst%3DN.%26atitle%3DSelective%2520targeting%2520of%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%2520suppresses%2520hepatic%2520fibrosis%2520progression%2520and%2520accelerates%2520its%2520reversal%26jtitle%3DGut%26doi%3D10.1136%2Fgutjnl-2016-312473%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonte, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Montolio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deodhar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foot, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarolimek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timpson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erler, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, T. R.</span><span> </span><span class="NLM_article-title">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">26066</span><span class="NLM_x">–</span> <span class="NLM_lpage">26078</span><span class="refDoi"> DOI: 10.18632/oncotarget.15257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.18632%2Foncotarget.15257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=28199967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=26066-26078&author=J.+Changauthor=M.+C.+Lucasauthor=L.+E.+Leonteauthor=M.+Garcia-Montolioauthor=L.+B.+Singhauthor=A.+D.+Findlayauthor=M.+Deodharauthor=J.+S.+Footauthor=W.+Jarolimekauthor=P.+Timpsonauthor=J.+T.+Erlerauthor=T.+R.+Cox&title=Pre-clinical+evaluation+of+small+molecule+LOXL2+inhibitors+in+breast+cancer&doi=10.18632%2Foncotarget.15257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span></div><div class="casAuthors">Chang Joan; Leonte Lidia E; Garcia-Montolio Marc; Singh Lukram Babloo; Erler Janine T; Cox Thomas R; Lucas Morghan C; Timpson Paul; Cox Thomas R; Findlay Alison D; Deodhar Mandar; Foot Jonathan S; Jarolimek Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">26066-26078</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors.  Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer.  We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer.  Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis.  Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver.  Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOpqvFkfAy6suCWE5mhx1RfW6udTcc2eZvrLq2hojLFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D&md5=eda7044a327ae1746d7ae3ab2c2386fc</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15257%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLeonte%26aufirst%3DL.%2BE.%26aulast%3DGarcia-Montolio%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DL.%2BB.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26aulast%3DCox%26aufirst%3DT.%2BR.%26atitle%3DPre-clinical%2520evaluation%2520of%2520small%2520molecule%2520LOXL2%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D26066%26epage%3D26078%26doi%3D10.18632%2Foncotarget.15257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Peinado, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Carmen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Cruz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olmeda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csiszar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, K. S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieto, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portillo, F.</span><span> </span><span class="NLM_article-title">A molecular role for lysyl oxidase-like 2 enzyme in Snail regulation and tumor progression</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3446</span><span class="NLM_x">–</span> <span class="NLM_lpage">3458</span><span class="refDoi"> DOI: 10.1038/sj.emboj.7600781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fsj.emboj.7600781" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=3446-3458&author=H.+Peinadoauthor=M.+del+Carmenauthor=I.+de+la+Cruzauthor=D.+Olmedaauthor=K.+Csiszarauthor=K.+S.+K.+Fongauthor=S.+Vegaauthor=M.+A.+Nietoauthor=A.+Canoauthor=F.+Portillo&title=A+molecular+role+for+lysyl+oxidase-like+2+enzyme+in+Snail+regulation+and+tumor+progression&doi=10.1038%2Fsj.emboj.7600781"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600781%26sid%3Dliteratum%253Aachs%26aulast%3DPeinado%26aufirst%3DH.%26aulast%3Ddel%2BCarmen%26aufirst%3DM.%26aulast%3Dde%2Bla%2BCruz%26aufirst%3DI.%26aulast%3DOlmeda%26aufirst%3DD.%26aulast%3DCsiszar%26aufirst%3DK.%26aulast%3DFong%26aufirst%3DK.%2BS.%2BK.%26aulast%3DVega%26aufirst%3DS.%26aulast%3DNieto%26aufirst%3DM.%2BA.%26aulast%3DCano%26aufirst%3DA.%26aulast%3DPortillo%26aufirst%3DF.%26atitle%3DA%2520molecular%2520role%2520for%2520lysyl%2520oxidase-like%25202%2520enzyme%2520in%2520Snail%2520regulation%2520and%2520tumor%2520progression%26jtitle%3DEMBO%2520J.%26date%3D2005%26volume%3D24%26spage%3D3446%26epage%3D3458%26doi%3D10.1038%2Fsj.emboj.7600781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Herranz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dave, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millanes-Romero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Reguant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lórenz-Fonfría, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Gallego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerónimo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iturbide, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Croce, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García de Herreros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiró, S.</span><span> </span><span class="NLM_article-title">Lysyl oxidase-like-2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">4263</span><span class="NLM_x">–</span> <span class="NLM_lpage">4273</span><span class="refDoi"> DOI: 10.1111/febs.13922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1111%2Ffebs.13922" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=4263-4273&author=N.+Herranzauthor=N.+Daveauthor=A.+Millanes-Romeroauthor=L.+Pascual-Reguantauthor=L.+Moreyauthor=V.+M.+D%C3%ADazauthor=V.+L%C3%B3renz-Fonfr%C3%ADaauthor=R.+Gutierrez-Gallegoauthor=C.+Jer%C3%B3nimoauthor=A.+Iturbideauthor=L.+Di+Croceauthor=A.+Garc%C3%ADa+de+Herrerosauthor=S.+Peir%C3%B3&title=Lysyl+oxidase-like-2+%28LOXL2%29+oxidizes+trimethylated+lysine+4+in+histone+H3&doi=10.1111%2Ffebs.13922"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13922%26sid%3Dliteratum%253Aachs%26aulast%3DHerranz%26aufirst%3DN.%26aulast%3DDave%26aufirst%3DN.%26aulast%3DMillanes-Romero%26aufirst%3DA.%26aulast%3DPascual-Reguant%26aufirst%3DL.%26aulast%3DMorey%26aufirst%3DL.%26aulast%3DD%25C3%25ADaz%26aufirst%3DV.%2BM.%26aulast%3DL%25C3%25B3renz-Fonfr%25C3%25ADa%26aufirst%3DV.%26aulast%3DGutierrez-Gallego%26aufirst%3DR.%26aulast%3DJer%25C3%25B3nimo%26aufirst%3DC.%26aulast%3DIturbide%26aufirst%3DA.%26aulast%3DDi%2BCroce%26aufirst%3DL.%26aulast%3DGarc%25C3%25ADa%2Bde%2BHerreros%26aufirst%3DA.%26aulast%3DPeir%25C3%25B3%26aufirst%3DS.%26atitle%3DLysyl%2520oxidase-like-2%2520%2528LOXL2%2529%2520oxidizes%2520trimethylated%2520lysine%25204%2520in%2520histone%2520H3%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D4263%26epage%3D4273%26doi%3D10.1111%2Ffebs.13922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> See the Gilead website (<a href="http://www.gilead.com/research/pipeline" class="extLink">http://www.gilead.com/research/pipeline</a> and <a href="http://www.gilead.com/news/press-releases" class="extLink">http://www.gilead.com/news/press-releases</a>) accessed Dec 2,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+See+the+Gilead+website+%28http%3A%2F%2Fwww.gilead.com%2Fresearch%2Fpipeline+and+http%3A%2F%2Fwww.gilead.com%2Fnews%2Fpress-releases%29+accessed+Dec+2%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ACollard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, T. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuyts, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, T. G.</span><span> </span><span class="NLM_article-title">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomized, double-blind, controlled, phase 2 trial</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1016/S2213-2600(16)30421-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2FS2213-2600%2816%2930421-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=27939076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=22-32&author=G.+Raghuauthor=K.+K.+Brownauthor=H.+R.+ACollardauthor=V.+Cottinauthor=K.+F.+Gibsonauthor=R.+J.+Kanerauthor=D.+J.+Ledererauthor=F.+J.+Martinezauthor=P.+W.+Nobleauthor=J.+W.+Songauthor=A.+U.+Wellsauthor=T.+P.+M.+Whelanauthor=W.+Wuytsauthor=E.+Moreauauthor=S.+D.+Pattersonauthor=V.+Smithauthor=S.+Baylyauthor=J.+W.+Chienauthor=Q.+Gongauthor=J.+J.+Zhangauthor=T.+G.+O%E2%80%99Riordan&title=Efficacy+of+simtuzumab+versus+placebo+in+patients+with+idiopathic+pulmonary+fibrosis%3A+a+randomized%2C+double-blind%2C+controlled%2C+phase+2+trial&doi=10.1016%2FS2213-2600%2816%2930421-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial</span></div><div class="casAuthors">Raghu, Ganesh; Brown, Kevin K.; Collard, Harold R.; Cottin, Vincent; Gibson, Kevin F.; Kaner, Robert J.; Lederer, David J.; Martinez, Fernando J.; Noble, Paul W.; Song, Jin Woo; Wells, Athol U.; Whelan, Timothy P. M.; Wuyts, Wim; Moreau, Emmanuel; Patterson, Scott D.; Smith, Victoria; Bayly, Selina; Chien, Jason W.; Gong, Qi; Zhang, Jenny J.; O'Riordan, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-32</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lysyl oxidase-like 2 (LOXL2) catalyzes collagen crosslinking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).  The aim of this study was to investigate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF.  In this randomised, double-blind, phase 2 trial, we recruited patients aged 45-85 years with definite IPF diagnosed prior to 3 years of screening from 183 hospitals and respiratory clinics in 14 countries.  Eligible patients, stratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concns., and pirfenidone and nintedanib use, were randomly assigned (1:1) to inject 125 mg/mL simtuzumab or placebo s.c. once a week.  The primary endpoints were progression-free survival, defined as time to all-cause death or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, in patients with sLOXL2 concns. in the 50th percentile or higher, and in patients with sLOXL2 concns. in the 75th percentile or higher.  Treatment duration was event-driven, and interim analyses were planned and conducted after approx. 120 and 200 progression-free survival events, resp., occurred.  We compared treatment groups with the stratified log-rank test.  This study is registered with ClinicalTrials.gov, no. NCT01769196.  Patients with IPF were recruited between Jan 31, 2013, and June 1, 2015.  The intention-to-treat population included 544 randomly assigned patients (272 patients in both groups), and the safety population included 543 randomly assigned patients who received at least one dose of study medication.  The study was terminated when the second interim anal. met the prespecified futility stopping criteria in the intention-to-treat population.  We noted no difference in progression-free survival between simtuzumab and placebo in the intention-to-treat population (median progression free survival times of 12·6 mo and 15·4 mo for simtuzumab and placebo, resp.; stratified HR 1·13, 95% CI 0·88-1·45; p=0·329) and in patients with baseline sLOXL2 in the 50th percentile or higher (median progression-free survival 11·7 mo and 14·3 mo for simtuzumab and placebo, resp.; stratified HR 1·03, 95% CI 0·74-1·43; p=0·851), or in the 75th percentile or higher (median progression-free survival 11·6 mo and 16·9 mo for simtuzumab and placebo, resp.; stratified HR 1·20, 95% CI 0·72-2·00; p=0·475).  The incidence of adverse events and serious adverse events was similar between treatment groups.  The most common adverse events in both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and the most common grade 3 or 4 adverse events were worsening of IPF, dyspnoea, and pneumonia.  Simtuzumab did not improve progression-free survival in a well-defined population of patients with IPF.  Our data do not support the use of simtuzumab for patients with IPF.Gilead Sciences Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogXyb2IAh397Vg90H21EOLACvtfcHk0lhaCFQkNZvENQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK&md5=9ba5c10f1fc48f971010f7ed09fd3b62</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930421-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930421-0%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DACollard%26aufirst%3DH.%2BR.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DKaner%26aufirst%3DR.%2BJ.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSong%26aufirst%3DJ.%2BW.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DWhelan%26aufirst%3DT.%2BP.%2BM.%26aulast%3DWuyts%26aufirst%3DW.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPatterson%26aufirst%3DS.%2BD.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DBayly%26aufirst%3DS.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DGong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%2BG.%26atitle%3DEfficacy%2520of%2520simtuzumab%2520versus%2520placebo%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520randomized%252C%2520double-blind%252C%2520controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26spage%3D22%26epage%3D32%26doi%3D10.1016%2FS2213-2600%2816%2930421-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Meissner, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharib, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinkus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virtaneva, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturdevant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcella, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanwar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadigan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, C. G.</span><span> </span><span class="NLM_article-title">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1792</span><span class="refDoi"> DOI: 10.1111/liv.13177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1111%2Fliv.13177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=27232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=1783-1792&author=E.+G.+Meissnerauthor=M.+McLaughlinauthor=L.+Matthewsauthor=A.+M.+Gharibauthor=B.+J.+Woodauthor=E.+Levyauthor=R.+Sinkusauthor=K.+Virtanevaauthor=D.+Sturdevantauthor=C.+Martensauthor=S.+F.+Porcellaauthor=Z.+D.+Goodmanauthor=B.+Kanwarauthor=R.+Myersauthor=M.+Subramanianauthor=C.+Hadiganauthor=H.+Masurauthor=D.+E.+Kleinerauthor=T.+Hellerauthor=S.+Kottililauthor=J.+A.+Kovacsauthor=C.+G.+Morse&title=Simtuzumab+treatment+of+advanced+liver+fibrosis+in+HIV+and+HCV-infected+adults%3A+results+of+a+6-month+open-label+safety+trial&doi=10.1111%2Fliv.13177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span></div><div class="casAuthors">Meissner, Eric G.; McLaughlin, Mary; Matthews, Lindsay; Gharib, Ahmed M.; Wood, Bradford J.; Levy, Elliot; Sinkus, Ralph; Virtaneva, Kimmo; Sturdevant, Dan; Martens, Craig; Porcella, Stephen F.; Goodman, Zachary D.; Kanwar, Bittoo; Myers, Robert P.; Subramanian, Mani; Hadigan, Colleen; Masur, Henry; Kleiner, David E.; Heller, Theo; Kottilil, Shyam; Kovacs, Joseph A.; Morse, Caryn G.</div><div class="citationInfo"><span class="NLM_cas:title">Liver International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1783-1792</span>CODEN:
                <span class="NLM_cas:coden">LIINCM</span>;
        ISSN:<span class="NLM_cas:issn">1478-3223</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Chronic liver injury can result in fibrosis that may progress over years to end-stage liver disease.  The most effective anti-fibrotic therapy is treatment of the underlying disease, however when not possible, interventions to reverse or slow fibrosis progression are needed.  Aim : The aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, in subjects with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or HCV-HIV co-infection and advanced liver disease.  Methods : Eighteen subjects with advanced liver fibrosis received simtuzumab 700 mg i.v. every 2 wk for 22 wk.  Transjugular liver biopsies were performed during screening and at the end of treatment to measure hepatic venous pressure gradient (HVPG) and to stage fibrosis.  Results : Treatment was well-tolerated with no discontinuations due to adverse events.  No significant changes were seen in HVPG or liver biopsy fibrosis score after treatment.  Exploratory transcriptional and protein profiling using paired pre- and post-treatment liver biopsy and serum samples suggested up-regulation of TGF-β3 and IL-10 pathways with treatment.  Conclusion : In this open-label, pilot clin. trial, simtuzumab treatment was well-tolerated in HCV- and HIV-infected subjects with advanced liver disease.  Putative modulation of TGF-β3 and IL-10 pathways during simtuzumab treatment merits investigation in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh_oC46Qw8xrVg90H21EOLACvtfcHk0lhI_9MN8FhLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O&md5=3531ad0273e5e77dd501b2db201794a5</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1111%2Fliv.13177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13177%26sid%3Dliteratum%253Aachs%26aulast%3DMeissner%26aufirst%3DE.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DL.%26aulast%3DGharib%26aufirst%3DA.%2BM.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DLevy%26aufirst%3DE.%26aulast%3DSinkus%26aufirst%3DR.%26aulast%3DVirtaneva%26aufirst%3DK.%26aulast%3DSturdevant%26aufirst%3DD.%26aulast%3DMartens%26aufirst%3DC.%26aulast%3DPorcella%26aufirst%3DS.%2BF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DKanwar%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DR.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DHadigan%26aufirst%3DC.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DHeller%26aufirst%3DT.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DJ.%2BA.%26aulast%3DMorse%26aufirst%3DC.%2BG.%26atitle%3DSimtuzumab%2520treatment%2520of%2520advanced%2520liver%2520fibrosis%2520in%2520HIV%2520and%2520HCV-infected%2520adults%253A%2520results%2520of%2520a%25206-month%2520open-label%2520safety%2520trial%26jtitle%3DLiver%2520Int.%26date%3D2016%26volume%3D36%26spage%3D1783%26epage%3D1792%26doi%3D10.1111%2Fliv.13177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pinnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. R.</span><span> </span><span class="NLM_article-title">The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to α-aminoadipic-δ-semialdehyde (allysine) by an extract from bone</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span><span class="refDoi"> DOI: 10.1073/pnas.61.2.708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1073%2Fpnas.61.2.708" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1968&pages=708-716&author=S.+R.+Pinnellauthor=G.+R.+Martin&title=The+cross-linking+of+collagen+and+elastin%3A+enzymatic+conversion+of+lysine+in+peptide+linkage+to+%CE%B1-aminoadipic-%CE%B4-semialdehyde+%28allysine%29+by+an+extract+from+bone&doi=10.1073%2Fpnas.61.2.708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.61.2.708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.61.2.708%26sid%3Dliteratum%253Aachs%26aulast%3DPinnell%26aufirst%3DS.%2BR.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26atitle%3DThe%2520cross-linking%2520of%2520collagen%2520and%2520elastin%253A%2520enzymatic%2520conversion%2520of%2520lysine%2520in%2520peptide%2520linkage%2520to%2520%25CE%25B1-aminoadipic-%25CE%25B4-semialdehyde%2520%2528allysine%2529%2520by%2520an%2520extract%2520from%2520bone%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1968%26volume%3D61%26spage%3D708%26epage%3D716%26doi%3D10.1073%2Fpnas.61.2.708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tang, S. – S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trackman, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagan, H. M.</span><span> </span><span class="NLM_article-title">Reaction of aortic lysyl oxidase with β-aminopropionitrile</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">258</span><span class="NLM_x">, </span> <span class="NLM_fpage">4331</span><span class="NLM_x">–</span> <span class="NLM_lpage">4338</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1983&pages=4331-4338&author=S.+%E2%80%93+S.+Tangauthor=P.+C.+Trackmanauthor=H.+M.+Kagan&title=Reaction+of+aortic+lysyl+oxidase+with+%CE%B2-aminopropionitrile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2B%25E2%2580%2593%2BS.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26aulast%3DKagan%26aufirst%3DH.%2BM.%26atitle%3DReaction%2520of%2520aortic%2520lysyl%2520oxidase%2520with%2520%25CE%25B2-aminopropionitrile%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1983%26volume%3D258%26spage%3D4331%26epage%3D4338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Pischon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mäki, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisshaupt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palamakumbura, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">N’Guessan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radlanski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronckers, T. A. L. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myllyharju, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kielbassa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernimoulin, J. – P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trackman, P. C.</span><span> </span><span class="NLM_article-title">Lysyl oxidase (<i>Lox</i>) gene deficiency affects osteoblastic phenotype</span> <span class="citation_source-journal">Calcif. Tissue Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1007/s00223-009-9252-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1007%2Fs00223-009-9252-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=19458888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=119-126&author=N.+Pischonauthor=J.+M.+M%C3%A4kiauthor=P.+Weisshauptauthor=N.+Hengauthor=A.+H.+Palamakumburaauthor=P.+N%E2%80%99Guessanauthor=A.+Dingauthor=R.+Radlanskiauthor=H.+Renzauthor=T.+A.+L.+J.+J.+Bronckersauthor=J.+Myllyharjuauthor=A.+Kielbassaauthor=B.+M.+Kleberauthor=J.+%E2%80%93+P.+Bernimoulinauthor=P.+C.+Trackman&title=Lysyl+oxidase+%28Lox%29+gene+deficiency+affects+osteoblastic+phenotype&doi=10.1007%2Fs00223-009-9252-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase (Lox) Gene Deficiency Affects Osteoblastic Phenotype</span></div><div class="casAuthors">Pischon, N.; Maeki, J. M.; Weisshaupt, P.; Heng, N.; Palamakumbura, A. H.; N'Guessan, P.; Ding, A.; Radlanski, R.; Renz, H.; Bronckers, T. A. L. J. J.; Myllyharju, J.; Kielbassa, A. M.; Kleber, B. M.; Bernimoulin, J.-P.; Trackman, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) catalyzes crosslinking of elastin and collagen, which is essential for the structural integrity and function of bone tissue.  The present study examd. the role of Lox gene deficiency for the osteoblast phenotype in primary calvarial osteoblasts from E18.5 Lox knockout (Lox -/- ) and wild type (wt) (C57BL/6) mice.  Next to Lox gene depletion, mRNA expression of Lox isoforms, LOXL1-4, was significantly downregulated in Lox -/- bone tissue.  A significant decrease of DNA synthesis of Lox -/- osteoblasts compared to wt was found.  Early stages of osteoblastic apoptosis studied by annexin-V binding as well as later stages of DNA fragmentation were not affected.  However, mineral nodule formation and osteoblastic differentiation were markedly decreased, as revealed by significant downregulation of osteoblastic markers, type I collagen, bone sialoprotein, and Runx2/Cbfa1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj0YC3msIvIbVg90H21EOLACvtfcHk0lhI_9MN8FhLhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI&md5=fab4300b8ff8b116247836bdf6aae915</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00223-009-9252-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-009-9252-8%26sid%3Dliteratum%253Aachs%26aulast%3DPischon%26aufirst%3DN.%26aulast%3DM%25C3%25A4ki%26aufirst%3DJ.%2BM.%26aulast%3DWeisshaupt%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DN.%26aulast%3DPalamakumbura%26aufirst%3DA.%2BH.%26aulast%3DN%25E2%2580%2599Guessan%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DA.%26aulast%3DRadlanski%26aufirst%3DR.%26aulast%3DRenz%26aufirst%3DH.%26aulast%3DBronckers%26aufirst%3DT.%2BA.%2BL.%2BJ.%2BJ.%26aulast%3DMyllyharju%26aufirst%3DJ.%26aulast%3DKielbassa%26aufirst%3DA.%26aulast%3DKleber%26aufirst%3DB.%2BM.%26aulast%3DBernimoulin%26aufirst%3DJ.%2B%25E2%2580%2593%2BP.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26atitle%3DLysyl%2520oxidase%2520%2528Lox%2529%2520gene%2520deficiency%2520affects%2520osteoblastic%2520phenotype%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2009%26volume%3D85%26spage%3D119%26epage%3D126%26doi%3D10.1007%2Fs00223-009-9252-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Johnson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yukl, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klema, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilmot, C. M.</span><span> </span><span class="NLM_article-title">Structural snapshots from the oxidative half-reaction of a copper amine oxidase: implications for O<sub>2</sub> activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">28409</span><span class="NLM_x">–</span> <span class="NLM_lpage">28417</span><span class="refDoi"> DOI: 10.1074/jbc.M113.501791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1074%2Fjbc.M113.501791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=23940035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFenu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=28409-28417&author=B.+J.+Johnsonauthor=E.+T.+Yuklauthor=V.+J.+Klemaauthor=J.+P.+Klinmanauthor=C.+M.+Wilmot&title=Structural+snapshots+from+the+oxidative+half-reaction+of+a+copper+amine+oxidase%3A+implications+for+O2+activation&doi=10.1074%2Fjbc.M113.501791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Snapshots from the Oxidative Half-reaction of a Copper Amine Oxidase</span></div><div class="casAuthors">Johnson, Bryan J.; Yukl, Erik T.; Klema, Valerie J.; Klinman, Judith P.; Wilmot, Carrie M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">28409-28417</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The mechanism of mol. oxygen activation is the subject of controversy in the copper amine oxidase family.  At their active sites, copper amine oxidases contain both a mononuclear copper ion and a protein-derived quinone cofactor.  Proposals have been made for the activation of mol. oxygen via both a Cu(II)-aminoquinol catalytic intermediate and a Cu(I)-semiquinone intermediate.  Using protein crystallog. freeze-trapping methods under low oxygen conditions combined with single-crystal microspectrophotometry, we have detd. structures corresponding to the iminoquinone and semiquinone forms of the enzyme.  Methylamine redn. at acidic or neutral pH has revealed protonated and deprotonated forms of the iminoquinone that are accompanied by a bound oxygen species that is likely hydrogen peroxide.  However, methylamine redn. at pH 8.5 has revealed a copper-ligated cofactor proposed to be the semiquinone form.  A copper-ligated orientation, be it the sole identity of the semiquinone or not, blocks the oxygen-binding site, suggesting that accessibility of Cu(I) may be the basis of partitioning O2 activation between the aminoquinol and Cu(I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ8oxH0Fvp8bVg90H21EOLACvtfcHk0ljpVhLqx-pUFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFenu7%252FO&md5=0fac201279b477782e0596f9a4803c07</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.501791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.501791%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BJ.%26aulast%3DYukl%26aufirst%3DE.%2BT.%26aulast%3DKlema%26aufirst%3DV.%2BJ.%26aulast%3DKlinman%26aufirst%3DJ.%2BP.%26aulast%3DWilmot%26aufirst%3DC.%2BM.%26atitle%3DStructural%2520snapshots%2520from%2520the%2520oxidative%2520half-reaction%2520of%2520a%2520copper%2520amine%2520oxidase%253A%2520implications%2520for%2520O2%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D28409%26epage%3D28417%26doi%3D10.1074%2Fjbc.M113.501791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonergan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darlington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodanovich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, G.</span><span> </span><span class="NLM_article-title">Small molecule lysyl oxidase-like 2 (LOXL2) inhibitors: the identification of an inhibitor selective for LOXL2 over LOX</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFaltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=423-427&author=J.+H.+Hutchinsonauthor=M.+W.+Rowbottomauthor=D.+Lonerganauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=C.+D.+Kingauthor=J.+F.+Evansauthor=G.+Bain&title=Small+molecule+lysyl+oxidase-like+2+%28LOXL2%29+inhibitors%3A+the+identification+of+an+inhibitor+selective+for+LOXL2+over+LOX&doi=10.1021%2Facsmedchemlett.7b00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX</span></div><div class="casAuthors">Hutchinson, John H.; Rowbottom, Martin W.; Lonergan, David; Darlington, Janice; Prodanovich, Pat; King, Christopher D.; Evans, Jilly F.; Bain, Gretchen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">423-427</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Two series of novel LOXL2 enzyme inhibitors are described.  Benzylamines substituted with electron withdrawing groups in the para position and 2-substituted pyridine-4-ylmethanamines.  The most potent compd., (2-chloropyridin-4-yl)methanamine 20 (hLOXL2 IC50 = 126 nM) was shown to be selective for LOXL2 over LOX and three other amine oxidases (MAO-A, MAO-B and SSAO).  Compd. 20 is the first published small mol. inhibitor selective for LOXL2 over LOX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI9k75wz2jKrVg90H21EOLACvtfcHk0ljpVhLqx-pUFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFaltLs%253D&md5=64938315fde4a34c52020e4126636acc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00014%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DLonergan%26aufirst%3DD.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DBain%26aufirst%3DG.%26atitle%3DSmall%2520molecule%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%2520inhibitors%253A%2520the%2520identification%2520of%2520an%2520inhibitor%2520selective%2520for%2520LOXL2%2520over%2520LOX%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D423%26epage%3D427%26doi%3D10.1021%2Facsmedchemlett.7b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Rowbottom, M. W.; Hutchinson, J. H.; Calderon, I.</span> Fluorinated Lysyl Oxidase-Like 2 Inhibitors and Uses Thereof. Patent Application WO 2016/144703 A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Rowbottom%2C+M.+W.%3B+Hutchinson%2C+J.+H.%3B+Calderon%2C+I.+Fluorinated+Lysyl+Oxidase-Like+2+Inhibitors+and+Uses+Thereof.+Patent+Application+WO+2016%2F144703+A1%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Palamakumbura, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trackman, P. C.</span><span> </span><span class="NLM_article-title">A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">300</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">251</span><span class="refDoi"> DOI: 10.1006/abio.2001.5464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1006%2Fabio.2001.5464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=11779117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2002&pages=245-251&author=A.+H.+Palamakumburaauthor=P.+C.+Trackman&title=A+fluorometric+assay+for+detection+of+lysyl+oxidase+enzyme+activity+in+biological+samples&doi=10.1006%2Fabio.2001.5464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples</span></div><div class="casAuthors">Palamakumbura, Amitha H.; Trackman, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">300</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Lysyl oxidase (I) catalyzes the final known enzymic step required for collagen and elastin crosslinking in the biosynthesis of normal mature functional insol. extracellular matrixes.  In addn., I has been identified as a possible tumor suppressor.  I activity in biol. samples is traditionally and most reliably assessed by 3H release end-point assays using radiolabeled collagen or elastin substrates involving laborious vacuum distn. of the released tritiated water.  In addn., a less sensitive fluorometric method exists that employs nonpeptidyl amine I substrates and measures H2O2 prodn. with horseradish peroxidase coupled to homovanillate oxidn.  The present study describes a more sensitive fluorescent assay for I activity that utilizes 1,5-diaminopentane as substrate, and released H2O2 is detected using Amplex red in horseradish peroxidase-coupled reactions.  This method allowed the detection of 40 ng I/2 mL assay at 37° and was 7.5-fold more sensitive than the currently available fluorometric assay for enzyme activity.  Using this assay, the amt. of I produced by MC3T3 cell cultures was calcd.  This method eliminated the interference that occurs in some biol. samples and could be successfully used to detect I activity in cell culture expts.  (c) 2002 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorWq09Re0fZrVg90H21EOLACvtfcHk0ljGdnK3tBle2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFektw%253D%253D&md5=4c6438d2929764ab8922b78a4f1765e9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1006%2Fabio.2001.5464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.2001.5464%26sid%3Dliteratum%253Aachs%26aulast%3DPalamakumbura%26aufirst%3DA.%2BH.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26atitle%3DA%2520fluorometric%2520assay%2520for%2520detection%2520of%2520lysyl%2520oxidase%2520enzyme%2520activity%2520in%2520biological%2520samples%26jtitle%3DAnal.%2520Biochem.%26date%3D2002%26volume%3D300%26spage%3D245%26epage%3D251%26doi%3D10.1006%2Fabio.2001.5464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0ljGdnK3tBle2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. – Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span><span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+%E2%80%93+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0ljGdnK3tBle2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2B%25E2%2580%2593%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kim, Y. – M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. – C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span> </span><span class="NLM_article-title">The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin</span> <span class="citation_source-journal">Mol. Biol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1007/s11033-010-0088-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1007%2Fs11033-010-0088-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=20306300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FgvFWruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=145-149&author=Y.+%E2%80%93+M.+Kimauthor=E.+%E2%80%93+C.+Kimauthor=Y.+Kim&title=The+human+lysyl+oxidase-like+2+protein+functions+as+an+amine+oxidase+toward+collagen+and+elastin&doi=10.1007%2Fs11033-010-0088-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin</span></div><div class="casAuthors">Kim Young-Mi; Kim Eun-Cheol; Kim Youngho</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology reports</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The lysyl oxidase-like 2 (LOXL2) protein is a human paralogue of lysyl oxidase (LOX) that functions as an amine oxidase for formation of lysine-derived cross-links found in collagen and elastin.  In addition to the C-terminal domains characteristic to the LOX family members, LOXL2 contains four scavenger receptor cysteine-rich (SRCR) domains in the N-terminus.  In order to assess the amine oxidase activity of LOXL2, we expressed a series of recombinant LOXL2 proteins with deletions in the SRCR domains, using an Escherichia coli expression system.  All of the purified recombinant LOXL2 proteins, with or without the SRCR domains in the N-terminus, showed significant amine oxidase activity toward several different types of collagen and elastin in in vitro amine oxidase assays, indicating deletion of the SRCR domains does not interfere with amine oxidase activity of LOXL2.  Further, amine oxidase activity of LOXL2 was not susceptible to inhibition by β-aminopropionitrile, an irreversible inhibitor of LOX, suggesting a different enzymatic mechanism between these two paralogues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXYuLX7VGhbzC850By6mxpfW6udTcc2eaGJAGMD9DjXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FgvFWruw%253D%253D&md5=f90539a5efc5af32da720a782572a7e4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs11033-010-0088-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-010-0088-0%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2B%25E2%2580%2593%2BM.%26aulast%3DKim%26aufirst%3DE.%2B%25E2%2580%2593%2BC.%26aulast%3DKim%26aufirst%3DY.%26atitle%3DThe%2520human%2520lysyl%2520oxidase-like%25202%2520protein%2520functions%2520as%2520an%2520amine%2520oxidase%2520toward%2520collagen%2520and%2520elastin%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2011%26volume%3D38%26spage%3D145%26epage%3D149%26doi%3D10.1007%2Fs11033-010-0088-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Duff, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchar, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guss, J. M.</span><span> </span><span class="NLM_article-title">The crystal structure of <i>Pichia pastoris</i> lysyl oxidase</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">15148</span><span class="NLM_x">–</span> <span class="NLM_lpage">15157</span><span class="refDoi"> DOI: 10.1021/bi035338v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi035338v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=15148-15157&author=A.+P.+Duffauthor=A.+E.+Cohenauthor=P.+J.+Ellisauthor=J.+A.+Kucharauthor=D.+B.+Langleyauthor=E.+M.+Shepardauthor=D.+M.+Dooleyauthor=H.+C.+Freemanauthor=J.+M.+Guss&title=The+crystal+structure+of+Pichia+pastoris+lysyl+oxidase&doi=10.1021%2Fbi035338v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fbi035338v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi035338v%26sid%3Dliteratum%253Aachs%26aulast%3DDuff%26aufirst%3DA.%2BP.%26aulast%3DCohen%26aufirst%3DA.%2BE.%26aulast%3DEllis%26aufirst%3DP.%2BJ.%26aulast%3DKuchar%26aufirst%3DJ.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BB.%26aulast%3DShepard%26aufirst%3DE.%2BM.%26aulast%3DDooley%26aufirst%3DD.%2BM.%26aulast%3DFreeman%26aufirst%3DH.%2BC.%26aulast%3DGuss%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520crystal%2520structure%2520of%2520Pichia%2520pastoris%2520lysyl%2520oxidase%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D15148%26epage%3D15157%26doi%3D10.1021%2Fbi035338v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">Calculated using CDD Vault software from Collaborative Drug Discovery, Burlingame, CA.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bohnert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L. – S.</span><span> </span><span class="NLM_article-title">Plasma protein binding: from discovery to development</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2953</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span><span class="refDoi"> DOI: 10.1002/jps.23614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1002%2Fjps.23614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=23798314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2013&pages=2953-2994&author=T.+Bohnertauthor=L.+%E2%80%93+S.+Gan&title=Plasma+protein+binding%3A+from+discovery+to+development&doi=10.1002%2Fjps.23614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma protein binding: From discovery to development</span></div><div class="casAuthors">Bohnert, Tonika; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2953-2994</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The importance of plasma protein binding (PPB) in modulating the effective drug concn. at pharmacol. target sites has been the topic of significant discussion and debate amongst drug development groups over the past few decades.  Free drug theory, which states that in absence of energy-dependent processes, after steady state equil. has been attained, free drug concn. in plasma is equal to free drug concn. at the pharmacol. target receptor(s) in tissues, has been used to explain pharmacokinetics/pharmacodynamics relationships in a large no. of cases.  Any sudden increase in free concn. of a drug could potentially cause toxicity and may need dose adjustment.  Free drug concn. is also helpful to est. the effective concn. of drugs that potentially can ppt. metab. (or transporter)-related drug-drug interactions.  Disease models are extensively validated in animals to progress a compd. into development.  Unbound drug concn., and therefore PPB information across species is very informative in establishing safety margins and guiding selection of First in Human (FIH) dose and human efficacious dose.  The scope of this review is to give an overview of reported role of PPB in several therapeutic areas, highlight cases where PPB changes are clin. relevant, and provide drug metab. and pharmacokinetics recommendations in discovery and development settings. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqobJp8eG98XrVg90H21EOLACvtfcHk0lj0DRgupLSw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D&md5=d676f7490c6e0f09c8acf7cce5183b17</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fjps.23614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23614%26sid%3Dliteratum%253Aachs%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DGan%26aufirst%3DL.%2B%25E2%2580%2593%2BS.%26atitle%3DPlasma%2520protein%2520binding%253A%2520from%2520discovery%2520to%2520development%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D102%26spage%3D2953%26epage%3D2994%26doi%3D10.1002%2Fjps.23614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><div class="note"><p class="first last">Human plasma-protein binding measurements determined by Eurofins Panlabs (Redmond, WA) using the methods noted by</p></div><span class="NLM_contrib-group">Banker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. A.</span><span> </span><span class="NLM_article-title">Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span><span class="refDoi"> DOI: 10.1002/jps.10332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1002%2Fjps.10332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=12712416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=967-974&author=M.+J.+Bankerauthor=T.+H.+Clarkauthor=J.+A.+Williams&title=Development+and+validation+of+a+96-well+equilibrium+dialysis+apparatus+for+measuring+plasma+protein+binding&doi=10.1002%2Fjps.10332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding</span></div><div class="casAuthors">Banker, Michael J.; Clark, Tracey H.; Williams, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">967-974</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A 96-well equil. dialysis block was designed and constructed that is compatible with most std. 96-well format lab. supplies and instruments.  The unique design of the dialysis app. allows one to dispense and aspirate from either or both the sample and dialyzate sides from the top of the app., which is not possible with systems currently on the market.  This feature permits the investigator to analyze a large no. of samples, time points, or replicates in the same expt.  The novel alignment of the dialysis membrane vertically in the well maximizes the surface-to-vol. ratio, eliminates problems assocd. with trapped air pockets, and allows one to add or remove samples independently or all at once.  Furthermore, the design of the app. allows both the sample and dialyzate sides of the dialysis well to be accessible by robotic systems, so assays can be readily automated.  Teflon construction is used to minimize nonspecific binding of test samples to the app.  The device is reusable, easily assembled, and can be shaken in controlled temp. environments to decrease the time required to reach equil. as well as facilitate dissoln. of test compds.  Plasma protein binding values obtained for 10 diverse compds. using std. dialysis equipment and the 96-well dialysis block validates this method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp9qyX_9tHHrVg90H21EOLACvtfcHk0lj0DRgupLSw5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D&md5=0948f0a11373c57be06be9e0d604ad40</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fjps.10332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.10332%26sid%3Dliteratum%253Aachs%26aulast%3DBanker%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DT.%2BH.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%252096-well%2520equilibrium%2520dialysis%2520apparatus%2520for%2520measuring%2520plasma%2520protein%2520binding%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2003%26volume%3D92%26spage%3D967%26epage%3D974%26doi%3D10.1002%2Fjps.10332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0li56T2SbxuDwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Chien, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindell, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyman, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamkewicz, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, T.</span><span> </span><span class="NLM_article-title">Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1430</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span><span class="refDoi"> DOI: 10.1183/09031936.00141013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1183%2F09031936.00141013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24177001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1430-1438&author=J.+W.+Chienauthor=T.+J.+Richardsauthor=K.+F.+Gibsonauthor=Y.+Zhangauthor=K.+O.+Lindellauthor=L.+Shaoauthor=S.+K.+Lymanauthor=J.+I.+Adamkewiczauthor=V.+Smithauthor=N.+Kaminskiauthor=T.+O%E2%80%99Riordan&title=Serum+lysyl+oxidase-like+2+levels+and+idiopathic+pulmonary+fibrosis+disease+progression&doi=10.1183%2F09031936.00141013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Serum lysyl, oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span></div><div class="casAuthors">Chien, Jason W.; Richards, Thomas J.; Gibson, Kevin F.; Zhang, Yingze; Lindell, Kathleen O.; Shao, Lixin; Lyman, Susan K.; Adamkewicz, Joanne I.; Smith, Victoria; Kaminski, Naftali; O'Riordan, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes crosslinking of collagen in pathol. stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression.  Patients from the ARTEMIS-IPF (n=69) and the Genomic and Proteomic Anal. of Disease Progression in IPF (GAP) (n=104) studies were analyzed.  Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clin. and physiol. surrogates of disease severity, and the assocn. with IPF disease progression was assessed using a classification and regression tree (CART) method.  SLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24-0.05) in both cohorts.  CART-detd. thresholds were similar: ARTEMIS-IPF 800 pg·mL-1 and GAP 700 pg·mL-1.  In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL-1) was assocd. with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65-17.73).  Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL-1) were assocd. with more disease progression events (HR 1.78, 95% CI 1.01-3.11).  Among all GAP subjects, higher sLOXL2 levels were assocd. with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38).  These results suggest that higher sLOXL2 levels are assocd. with increased risk for IPF disease progression.  However, due to multiple limitations, these results require validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8WyURMNVsBLVg90H21EOLACvtfcHk0li56T2SbxuDwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I&md5=60faa18c94ef9c37937579571a905faa</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1183%2F09031936.00141013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00141013%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DRichards%26aufirst%3DT.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLindell%26aufirst%3DK.%2BO.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26atitle%3DSerum%2520lysyl%2520oxidase-like%25202%2520levels%2520and%2520idiopathic%2520pulmonary%2520fibrosis%2520disease%2520progression%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1430%26epage%3D1438%26doi%3D10.1183%2F09031936.00141013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bend, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpot, R. M.</span><span> </span><span class="NLM_article-title">The pulmonary uptake, accumulation, and metabolism of xenobiotics</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1146/annurev.pa.25.040185.000525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1146%2Fannurev.pa.25.040185.000525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1985&pages=97-125&author=J.+R.+Bendauthor=C.+J.+Serabjit-Singhauthor=R.+M.+Philpot&title=The+pulmonary+uptake%2C+accumulation%2C+and+metabolism+of+xenobiotics&doi=10.1146%2Fannurev.pa.25.040185.000525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.25.040185.000525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.25.040185.000525%26sid%3Dliteratum%253Aachs%26aulast%3DBend%26aufirst%3DJ.%2BR.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DPhilpot%26aufirst%3DR.%2BM.%26atitle%3DThe%2520pulmonary%2520uptake%252C%2520accumulation%252C%2520and%2520metabolism%2520of%2520xenobiotics%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1985%26volume%3D25%26spage%3D97%26epage%3D125%26doi%3D10.1146%2Fannurev.pa.25.040185.000525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Boer, F.</span><span> </span><span class="NLM_article-title">Drug handling by the lungs</span> <span class="citation_source-journal">Br. J. Anaesth.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1093/bja/aeg117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1093%2Fbja%2Faeg117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=12821565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVSqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2003&pages=50-60&author=F.+Boer&title=Drug+handling+by+the+lungs&doi=10.1093%2Fbja%2Faeg117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug handling by the lungs</span></div><div class="casAuthors">Boer, F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-60</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review describes how the pharmacokinetic function of the lungs can be studied, which anesthetics are taken up by the lungs, how the pharmacokinetic function of the lungs is affected and how this can be related to systemic pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmTAtvDIYUWbVg90H21EOLACvtfcHk0li56T2SbxuDwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVSqtL8%253D&md5=8a320e8652870164ff6e96656f9af79e</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1093%2Fbja%2Faeg117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252Faeg117%26sid%3Dliteratum%253Aachs%26aulast%3DBoer%26aufirst%3DF.%26atitle%3DDrug%2520handling%2520by%2520the%2520lungs%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2003%26volume%3D91%26spage%3D50%26epage%3D60%26doi%3D10.1093%2Fbja%2Faeg117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="note"><p class="first last">For example, compound <b>28</b> had a measured p<i>K</i><sub>a</sub> = 7.8. Data were generated on a Sirius GLpKa instrument with a D-PAS attachment. Measurements were made at 25 °C in aqueous solution by UV. The titration media were of ionic-strength adjusted (ISA) with aqueous 0.15 M KCl. The data were refined using Refinement Pro software v2.2.3.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Hübner, R. – H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitter, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Mokhtari, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Both, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolte, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freitag-Wolf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bewig, B.</span><span> </span><span class="NLM_article-title">Standardized quantification of pulmonary fibrosis in histological samples</span> <span class="citation_source-journal">BioTechniques</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.2144/000112729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.2144%2F000112729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=18476815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslymtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=507-517&author=R.+%E2%80%93+H.+H%C3%BCbnerauthor=W.+Gitterauthor=N.+E.+El+Mokhtariauthor=M.+Mathiakauthor=M.+Bothauthor=H.+Bolteauthor=S.+Freitag-Wolfauthor=B.+Bewig&title=Standardized+quantification+of+pulmonary+fibrosis+in+histological+samples&doi=10.2144%2F000112729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Standardized quantification of pulmonary fibrosis in histological samples</span></div><div class="casAuthors">Huebner, Ralf-Harto; Gitter, Wolfram; El Mokhtari, Nour Eddine; Mathiak, Micaela; Both, Marcus; Bolte, Hendrik; Freitag-Wolf, Sandra; Bewig, Burkhard</div><div class="citationInfo"><span class="NLM_cas:title">BioTechniques</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">507-511,514-517</span>CODEN:
                <span class="NLM_cas:coden">BTNQDO</span>;
        ISSN:<span class="NLM_cas:issn">0736-6205</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The Ashcroft scale for the evaluation of bleomycin-induced lung fibrosis is the anal. of stained histol. samples by visual assessment.  Based on the knowledge that this procedure is not standardized in animals and results are highly variable, the authors hypothesized that modification of this method may improve quantification of lung fibrosis in small animals.  To prove the hypothesis, the authors evaluated pulmonary fibrosis in Lewis rats induced by a single intratracheal injection of 0.3 mg/kg body wt. bleomycin (n = 13) compared with the same amt. of saline in a control group (n = 4).  The authors modified the Ashcroft scale by precised defining the assignment of grades from 0 to 8 for the increasing extent of fibrosis in lung histol. samples.  Thirty-two observers were randomly assigned to evaluate 108 photographs of slides using either the Ashcroft scale or the modified scale.  Consistent with the authors' hypothesis, there was a significant redn. in the variability of std. deviations with the modified scale compared with the Ashcroft scale (mean of variability 0.25 vs. 0.62, P < 0.0001).  Applying the κ index, the Ashcroft scale showed only a fair to moderate agreement (0.23-0.59) between the observers and a low intra-observer agreement (0.51-0.74) in contrast to the modified scale, which demonstrated a moderate to good agreement between the observers (0.65-0.93, P < 0.0001) and a high intra-observer agreement (0.87-0.91, P < 0.05).  To test the modified scale in vivo, the authors compared both scales with the results of computed tomog. (CT) of the lungs obtained from the same mice.  In agreement, the modified scale demonstrated a better correlation to CT scans (R = 0.58) compared with the Ashcroft scale (R = 0.33).  In summary, quantification of lung fibrosis in histol. lung sections using the modified scale is reliable and reproducible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyLtTZGYVlSLVg90H21EOLACvtfcHk0ljZUfH64MFpUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslymtLk%253D&md5=171841380870b8c990a4a17e07a7e858</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2144%2F000112729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2144%252F000112729%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25BCbner%26aufirst%3DR.%2B%25E2%2580%2593%2BH.%26aulast%3DGitter%26aufirst%3DW.%26aulast%3DEl%2BMokhtari%26aufirst%3DN.%2BE.%26aulast%3DMathiak%26aufirst%3DM.%26aulast%3DBoth%26aufirst%3DM.%26aulast%3DBolte%26aufirst%3DH.%26aulast%3DFreitag-Wolf%26aufirst%3DS.%26aulast%3DBewig%26aufirst%3DB.%26atitle%3DStandardized%2520quantification%2520of%2520pulmonary%2520fibrosis%2520in%2520histological%2520samples%26jtitle%3DBioTechniques%26date%3D2008%26volume%3D44%26spage%3D507%26epage%3D517%26doi%3D10.2144%2F000112729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="note"><p class="first last">ExpressProfile screen carried out by Eurofins Cerep Panlabs (Redmond, WA).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0ljZUfH64MFpUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Foot, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yow, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schilter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deodhar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarolimek, W.</span><span> </span><span class="NLM_article-title">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1124/jpet.113.207613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1124%2Fjpet.113.207613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=23943052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=365-374&author=J.+S.+Footauthor=T.+T.+Yowauthor=H.+Schilterauthor=A.+Busonauthor=M.+Deodharauthor=A.+D.+Findlayauthor=L.+Guoauthor=I.+A.+McDonaldauthor=C.+I.+Turnerauthor=W.+Zhouauthor=W.+Jarolimek&title=PXS-4681A%2C+a+potent+and+selective+mechanism-based+inhibitor+of+SSAO%2FVAP-1+with+anti-inflammatory+effects+in+vivo&doi=10.1124%2Fjpet.113.207613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span></div><div class="casAuthors">Foot, Jonathan S.; Yow, Tin T.; Schilter, Heidi; Buson, Alberto; Deodhar, Mandar; Findlay, Alison D.; Guo, Lily; McDonald, Ian A.; Turner, Craig I.; Zhou, Wenbin; Jarolimek, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">365-374</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), is a member of the copper-dependent amine oxidase family that is assocd. with various forms of inflammation and fibrosis.  To investigate the therapeutic potential of SSAO/VAP-1 inhibition, potent and selective inhibitors with drug-like properties are required.  PXS-4681A [(Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)benzenesulfonamide hydrochloride] is a mechanism-based inhibitor of enzyme function with a pharmacokinetic and pharmacodynamic profile that ensures complete, long-lasting inhibition of the enzyme after a single low dose in vivo.  PXS-4681A irreversibly inhibits the enzyme with an apparent Ki of 37 nM and a kinact of 0.26 min-1 with no obsd. turnover in vitro.  It is highly selective for SSAO/VAP-1 when profiled against related amine oxidases, ion channels, and seven-transmembrane domain receptors, and is superior to previously reported inhibitors.  In mouse models of lung inflammation and localized inflammation, dosing of this mol. at 2 mg/kg attenuates neutrophil migration, tumor necrosis factor-α, and interleukin-6 levels.  These results demonstrate the drug-like properties of PXS-4681A and its potential use in the treatment of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUjl7gonLQrVg90H21EOLACvtfcHk0ljZUfH64MFpUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L&md5=d3c24925c4b717c9405d46be9a82f2d9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207613%26sid%3Dliteratum%253Aachs%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DBuson%26aufirst%3DA.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DPXS-4681A%252C%2520a%2520potent%2520and%2520selective%2520mechanism-based%2520inhibitor%2520of%2520SSAO%252FVAP-1%2520with%2520anti-inflammatory%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D365%26epage%3D374%26doi%3D10.1124%2Fjpet.113.207613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Walters, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleeberger, S. R.</span><span> </span><span class="NLM_article-title">Mouse models of bleomycin-induced pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Protoc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">5.46.1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5.46.17</span><span class="refDoi"> DOI: 10.1002/0471141755.ph0546s40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1002%2F0471141755.ph0546s40" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=5.46.1-5.46.17&author=D.+M.+Waltersauthor=S.+R.+Kleeberger&title=Mouse+models+of+bleomycin-induced+pulmonary+fibrosis&doi=10.1002%2F0471141755.ph0546s40"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph0546s40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471141755.ph0546s40%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DD.%2BM.%26aulast%3DKleeberger%26aufirst%3DS.%2BR.%26atitle%3DMouse%2520models%2520of%2520bleomycin-induced%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Protoc.%2520Pharmacol.%26date%3D2008%26volume%3D40%26spage%3D5.46.1%26epage%3D5.46.17%26doi%3D10.1002%2F0471141755.ph0546s40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Maron, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, B. N.</span><span> </span><span class="NLM_article-title">Revised methods for the <i>Salmonella</i> mutagenicity test</span> <span class="citation_source-journal">Mutat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1016/0165-1161(83)90010-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2F0165-1161%2883%2990010-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=6341825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADyaL3sXhvFarsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1983&pages=173-215&author=D.+M.+Maronauthor=B.+N.+Ames&title=Revised+methods+for+the+Salmonella+mutagenicity+test&doi=10.1016%2F0165-1161%2883%2990010-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Revised methods for the Salmonella mutagenicity test</span></div><div class="casAuthors">Maron, Dorothy M.; Ames, Bruce N.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Environmental Mutagenesis and Related Subjects </span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">173-215</span>CODEN:
                <span class="NLM_cas:coden">MEMSE8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A revision of methods for detecting carcinogens and mutagens with the Salmonella mutagenicity test (A. et al., 1975b) is described.  Two new tester strains, a frameshift strain (TA 97) and a strain carrying an ochre mutation on a multicopy plasmid (TA 102), are added to the std. tester set.  TA 97 replaces TA 1537.  TA 1535 and 1538 are removed from the recommended set, but can be retained at the option of the investigator.  TA 98 and 100 are retained.  Other special purpose strains are discussed and minor changes in procedure, (principally in the growth, storage, and preservation of the tester strains) are presented.  Two substitutions are made in diagnostic mutagens to eliminate MNNG and 9-aminoacridine.  Some test modifications are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzIjKbxaVZYrVg90H21EOLACvtfcHk0lgZA5qSHGLWMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhvFarsb4%253D&md5=415285947b98c9ddbbd79bbe000c9dca</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0165-1161%2883%2990010-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-1161%252883%252990010-9%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DD.%2BM.%26aulast%3DAmes%26aufirst%3DB.%2BN.%26atitle%3DRevised%2520methods%2520for%2520the%2520Salmonella%2520mutagenicity%2520test%26jtitle%3DMutat.%2520Res.%26date%3D1983%26volume%3D113%26spage%3D173%26epage%3D215%26doi%3D10.1016%2F0165-1161%2883%2990010-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10a','cit10b','cit10c','cit10d','cit10e'],'ref11':['cit11a','cit11b'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19a','cit19b'],'ref20':['cit20'],'ref21':['cit21'],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':[],'ref29':['cit29'],'ref30':[],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 27 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, <span class="NLM_string-name hlFld-ContribAuthor">Randall L. Halcomb</span>. </span><span class="cited-content_cbyCitation_article-title">The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5031-5073. <a href="https://doi.org/10.1021/acs.jmedchem.9b01701" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01701%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BRace%252Bto%252BBash%252BNASH%25253A%252BEmerging%252BTargets%252Band%252BDrug%252BDevelopment%252Bin%252Ba%252BComplex%252BLiver%252BDisease%26aulast%3DRomero%26aufirst%3DF.%2BAnthony%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14102019%26date%3D29012020%26date%3D13012020%26volume%3D63%26issue%3D10%26spage%3D5031%26epage%3D5073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Deborah A. Smithen, Leo M. H. Leung, Mairi Challinor, Rae Lawrence, HaoRan Tang, Dan Niculescu-Duvaz, Simon P. Pearce, Robert Mcleary, Filipa Lopes, Mohammed Aljarah, Michael Brown, Louise Johnson, Graeme Thomson, Richard Marais, <span class="NLM_string-name hlFld-ContribAuthor">Caroline Springer</span>. </span><span class="cited-content_cbyCitation_article-title">2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 2308-2324. <a href="https://doi.org/10.1021/acs.jmedchem.9b01112" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01112%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-Aminomethylene-5-sulfonylthiazole%252BInhibitors%252Bof%252BLysyl%252BOxidase%252B%252528LOX%252529%252Band%252BLOXL2%252BShow%252BSignificant%252BEfficacy%252Bin%252BDelaying%252BTumor%252BGrowth%26aulast%3DSmithen%26aufirst%3DDeborah%2BA.%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D11072019%26date%3D04092019%26date%3D20082019%26volume%3D63%26issue%3D5%26spage%3D2308%26epage%3D2324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alison D. Findlay, Jonathan S. Foot, Alberto Buson, Mandar Deodhar, Andrew G. Jarnicki, Philip M. Hansbro, Gang Liu, Heidi Schilter, Craig I. Turner, Wenbin Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Wolfgang Jarolimek</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (21)
                                     , 9874-9889. <a href="https://doi.org/10.1021/acs.jmedchem.9b01283" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01283</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01283%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Band%252BOptimization%252Bof%252BMechanism-Based%252BFluoroallylamine%252BInhibitors%252Bof%252BLysyl%252BOxidase-like%252B2%25252F3%26aulast%3DFindlay%26aufirst%3DAlison%2BD.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07082019%26date%3D16102019%26date%3D03102019%26volume%3D62%26issue%3D21%26spage%3D9874%26epage%3D9889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Leo Leung, Dan Niculescu-Duvaz, Deborah Smithen, Filipa Lopes, Cedric Callens, Robert McLeary, Grazia Saturno, Lawrence Davies, Mohammed Aljarah, Michael Brown, Louise Johnson, Alfonso Zambon, Tim Chambers, Delphine Ménard, Natasha Bayliss, Ruth Knight, Laura Fish, Rae Lawrence, Mairi Challinor, HaoRan Tang, Richard Marais, <span class="NLM_string-name hlFld-ContribAuthor">Caroline Springer</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (12)
                                     , 5863-5884. <a href="https://doi.org/10.1021/acs.jmedchem.9b00335" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00335%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAnti-metastatic%252BInhibitors%252Bof%252BLysyl%252BOxidase%252B%252528LOX%252529%25253A%252BDesign%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%26aulast%3DLeung%26aufirst%3DLeo%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D23052019%26date%3D09052019%26volume%3D62%26issue%3D12%26spage%3D5863%26epage%3D5884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guodong  Rao</span>, <span class="hlFld-ContribAuthor ">Sandhya  Bansal</span>, <span class="hlFld-ContribAuthor ">Wen Xuan  Law</span>, <span class="hlFld-ContribAuthor ">Bing  O’Dowd</span>, <span class="hlFld-ContribAuthor ">Sergei A.  Dikanov</span>, and <span class="hlFld-ContribAuthor ">Eric  Oldfield</span>  . </span><span class="cited-content_cbyCitation_article-title">Pulsed Electron Paramagnetic Resonance Insights into the Ligand Environment of Copper in Drosophila Lysyl Oxidase. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2017,</strong> <em>56 </em>
                                    (29)
                                     , 3770-3779. <a href="https://doi.org/10.1021/acs.biochem.7b00308" title="DOI URL">https://doi.org/10.1021/acs.biochem.7b00308</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.7b00308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.7b00308%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DPulsed%252BElectron%252BParamagnetic%252BResonance%252BInsights%252Binto%252Bthe%252BLigand%252BEnvironment%252Bof%252BCopper%252Bin%252BDrosophila%252BLysyl%252BOxidase%26aulast%3DRao%26aufirst%3DGuodong%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D06042017%26date%3D28062017%26date%3D12072017%26date%3D25072017%26date%3D29062017%26volume%3D56%26issue%3D29%26spage%3D3770%26epage%3D3779" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huilei  Wang</span>, <span class="hlFld-ContribAuthor ">Alan  Poe</span>, <span class="hlFld-ContribAuthor ">Lydia  Pak</span>, <span class="hlFld-ContribAuthor ">Kavitha  Nandakumar</span>, <span class="hlFld-ContribAuthor ">Sandeep  Jandu</span>, <span class="hlFld-ContribAuthor ">Jochen  Steppan</span>, <span class="hlFld-ContribAuthor ">Reik  Löser</span>, <span class="hlFld-ContribAuthor ">Lakshmi  Santhanam</span>. </span><span class="cited-content_cbyCitation_article-title">An in situ activity assay for lysyl oxidases. </span><span class="cited-content_cbyCitation_journal-name">Communications Biology</span><span> <strong>2021,</strong> <em>4 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s42003-021-02354-0" title="DOI URL">https://doi.org/10.1038/s42003-021-02354-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s42003-021-02354-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs42003-021-02354-0%26sid%3Dliteratum%253Aachs%26jtitle%3DCommunications%2520Biology%26atitle%3DAn%252Bin%252Bsitu%252Bactivity%252Bassay%252Bfor%252Blysyl%252Boxidases%26aulast%3DWang%26aufirst%3DHuilei%26date%3D2021%26date%3D2021%26volume%3D4%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huilin  Yang</span>, <span class="hlFld-ContribAuthor ">Yun‐Huai  Kuo</span>, <span class="hlFld-ContribAuthor ">Zion I.  Smith</span>, <span class="hlFld-ContribAuthor ">Jamie  Spangler</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting cancer metastasis with antibody therapeutics. </span><span class="cited-content_cbyCitation_journal-name">WIREs Nanomedicine and Nanobiotechnology</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     <a href="https://doi.org/10.1002/wnan.1698" title="DOI URL">https://doi.org/10.1002/wnan.1698</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/wnan.1698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fwnan.1698%26sid%3Dliteratum%253Aachs%26jtitle%3DWIREs%2520Nanomedicine%2520and%2520Nanobiotechnology%26atitle%3DTargeting%252Bcancer%252Bmetastasis%252Bwith%252Bantibody%252Btherapeutics%26aulast%3DYang%26aufirst%3DHuilin%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Farjana  Ahmed</span>, <span class="hlFld-ContribAuthor ">Torsten  Kleffmann</span>, <span class="hlFld-ContribAuthor ">Matloob  Husain</span>. </span><span class="cited-content_cbyCitation_article-title">Acetylation, Methylation and Allysine Modification Profile of Viral and Host Proteins during Influenza A Virus Infection. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2021,</strong> <em>13 </em>
                                    (7)
                                     , 1415. <a href="https://doi.org/10.3390/v13071415" title="DOI URL">https://doi.org/10.3390/v13071415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v13071415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv13071415%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DAcetylation%25252C%252BMethylation%252Band%252BAllysine%252BModification%252BProfile%252Bof%252BViral%252Band%252BHost%252BProteins%252Bduring%252BInfluenza%252BA%252BVirus%252BInfection%26aulast%3DAhmed%26aufirst%3DFarjana%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D7%26spage%3D1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Sepulveda-Crespo</span>, <span class="hlFld-ContribAuthor ">Salvador  Resino</span>, <span class="hlFld-ContribAuthor ">Isidoro  Martinez</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2021,</strong> <em>81 </em>
                                    (4)
                                     , 419-443. <a href="https://doi.org/10.1007/s40265-020-01458-x" title="DOI URL">https://doi.org/10.1007/s40265-020-01458-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-020-01458-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-020-01458-x%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DStrategies%252BTargeting%252Bthe%252BInnate%252BImmune%252BResponse%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus-Associated%252BLiver%252BFibrosis%26aulast%3DSepulveda-Crespo%26aufirst%3DDaniel%26date%3D2021%26date%3D2021%26volume%3D81%26issue%3D4%26spage%3D419%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tatiana  Kisseleva</span>, <span class="hlFld-ContribAuthor ">David  Brenner</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular and cellular mechanisms of liver fibrosis and its regression. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Gastroenterology & Hepatology</span><span> <strong>2021,</strong> <em>18 </em>
                                    (3)
                                     , 151-166. <a href="https://doi.org/10.1038/s41575-020-00372-7" title="DOI URL">https://doi.org/10.1038/s41575-020-00372-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41575-020-00372-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41575-020-00372-7%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DMolecular%252Band%252Bcellular%252Bmechanisms%252Bof%252Bliver%252Bfibrosis%252Band%252Bits%252Bregression%26aulast%3DKisseleva%26aufirst%3DTatiana%26date%3D2021%26date%3D2020%26volume%3D18%26issue%3D3%26spage%3D151%26epage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayako  Matsuo</span>, <span class="hlFld-ContribAuthor ">Ryota  Tanida</span>, <span class="hlFld-ContribAuthor ">Shigehisa  Yanagi</span>, <span class="hlFld-ContribAuthor ">Hironobu  Tsubouchi</span>, <span class="hlFld-ContribAuthor ">Ayako  Miura</span>, <span class="hlFld-ContribAuthor ">Takafumi  Shigekusa</span>, <span class="hlFld-ContribAuthor ">Nobuhiro  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Masamitsu  Nakazato</span>. </span><span class="cited-content_cbyCitation_article-title">Significance of nuclear LOXL2 inhibition in fibroblasts and myofibroblasts in the fibrotic process of acute respiratory distress syndrome. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2021,</strong> <em>892 </em>, 173754. <a href="https://doi.org/10.1016/j.ejphar.2020.173754" title="DOI URL">https://doi.org/10.1016/j.ejphar.2020.173754</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2020.173754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2020.173754%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DSignificance%252Bof%252Bnuclear%252BLOXL2%252Binhibition%252Bin%252Bfibroblasts%252Band%252Bmyofibroblasts%252Bin%252Bthe%252Bfibrotic%252Bprocess%252Bof%252Bacute%252Brespiratory%252Bdistress%252Bsyndrome%26aulast%3DMatsuo%26aufirst%3DAyako%26date%3D2021%26volume%3D892%26spage%3D173754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandra  Ferreira</span>, <span class="hlFld-ContribAuthor ">Nuno  Saraiva</span>, <span class="hlFld-ContribAuthor ">Patrícia  Rijo</span>, <span class="hlFld-ContribAuthor ">Ana S.  Fernandes</span>. </span><span class="cited-content_cbyCitation_article-title">LOXL2 Inhibitors and Breast Cancer Progression. </span><span class="cited-content_cbyCitation_journal-name">Antioxidants</span><span> <strong>2021,</strong> <em>10 </em>
                                    (2)
                                     , 312. <a href="https://doi.org/10.3390/antiox10020312" title="DOI URL">https://doi.org/10.3390/antiox10020312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/antiox10020312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fantiox10020312%26sid%3Dliteratum%253Aachs%26jtitle%3DAntioxidants%26atitle%3DLOXL2%252BInhibitors%252Band%252BBreast%252BCancer%252BProgression%26aulast%3DFerreira%26aufirst%3DSandra%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D2%26spage%3D312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bing  Wen</span>, <span class="hlFld-ContribAuthor ">Li-Yan  Xu</span>, <span class="hlFld-ContribAuthor ">En-Min  Li</span>. </span><span class="cited-content_cbyCitation_article-title">LOXL2 in cancer: regulation, downstream effectors and novel roles. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2020,</strong> <em>1874 </em>
                                    (2)
                                     , 188435. <a href="https://doi.org/10.1016/j.bbcan.2020.188435" title="DOI URL">https://doi.org/10.1016/j.bbcan.2020.188435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2020.188435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2020.188435%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DLOXL2%252Bin%252Bcancer%25253A%252Bregulation%25252C%252Bdownstream%252Beffectors%252Band%252Bnovel%252Broles%26aulast%3DWen%26aufirst%3DBing%26date%3D2020%26volume%3D1874%26issue%3D2%26spage%3D188435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vriddhi  Chopra</span>, <span class="hlFld-ContribAuthor ">Ruth M.  Sangarappillai</span>, <span class="hlFld-ContribAuthor ">Isolda  Romero‐Canelón</span>, <span class="hlFld-ContribAuthor ">Alan M.  Jones</span>. </span><span class="cited-content_cbyCitation_article-title">Lysyl Oxidase Like‐2 (LOXL2): An Emerging Oncology Target. </span><span class="cited-content_cbyCitation_journal-name">Advanced Therapeutics</span><span> <strong>2020,</strong> <em>3 </em>
                                    (2)
                                     , 1900119. <a href="https://doi.org/10.1002/adtp.201900119" title="DOI URL">https://doi.org/10.1002/adtp.201900119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adtp.201900119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadtp.201900119%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Therapeutics%26atitle%3DLysyl%252BOxidase%252BLike%2525E2%252580%2525902%252B%252528LOXL2%252529%25253A%252BAn%252BEmerging%252BOncology%252BTarget%26aulast%3DChopra%26aufirst%3DVriddhi%26date%3D2020%26date%3D2020%26volume%3D3%26issue%3D2%26spage%3D1900119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica L.  Chitty</span>, <span class="hlFld-ContribAuthor ">Yordanos F.I.  Setargew</span>, <span class="hlFld-ContribAuthor ">Thomas R.  Cox</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the lysyl oxidases in tumour desmoplasia. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2019,</strong> <em>47 </em>
                                    (6)
                                     , 1661-1678. <a href="https://doi.org/10.1042/BST20190098" title="DOI URL">https://doi.org/10.1042/BST20190098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20190098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20190098%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DTargeting%252Bthe%252Blysyl%252Boxidases%252Bin%252Btumour%252Bdesmoplasia%26aulast%3DChitty%26aufirst%3DJessica%2BL.%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D1661%26epage%3D1678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cristina  Rodríguez</span>, <span class="hlFld-ContribAuthor ">José  Martínez-González</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Lysyl Oxidase Enzymes in Cardiac Function and Remodeling. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (12)
                                     , 1483. <a href="https://doi.org/10.3390/cells8121483" title="DOI URL">https://doi.org/10.3390/cells8121483</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8121483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8121483%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DThe%252BRole%252Bof%252BLysyl%252BOxidase%252BEnzymes%252Bin%252BCardiac%252BFunction%252Band%252BRemodeling%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DCristina%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D12%26spage%3D1483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">José  Martínez-González</span>, <span class="hlFld-ContribAuthor ">Saray  Varona</span>, <span class="hlFld-ContribAuthor ">Laia  Cañes</span>, <span class="hlFld-ContribAuthor ">María  Galán</span>, <span class="hlFld-ContribAuthor ">Ana  Briones</span>, <span class="hlFld-ContribAuthor ">Victoria  Cachofeiro</span>, <span class="hlFld-ContribAuthor ">Cristina  Rodríguez</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging Roles of Lysyl Oxidases in the Cardiovascular System: New Concepts and Therapeutic Challenges. </span><span class="cited-content_cbyCitation_journal-name">Biomolecules</span><span> <strong>2019,</strong> <em>9 </em>
                                    (10)
                                     , 610. <a href="https://doi.org/10.3390/biom9100610" title="DOI URL">https://doi.org/10.3390/biom9100610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biom9100610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiom9100610%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomolecules%26atitle%3DEmerging%252BRoles%252Bof%252BLysyl%252BOxidases%252Bin%252Bthe%252BCardiovascular%252BSystem%25253A%252BNew%252BConcepts%252Band%252BTherapeutic%252BChallenges%26aulast%3DMart%25C3%25ADnez-Gonz%25C3%25A1lez%26aufirst%3DJos%25C3%25A9%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D10%26spage%3D610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pratibha  Kalaramna</span>, <span class="hlFld-ContribAuthor ">Divya  Bhatt</span>, <span class="hlFld-ContribAuthor ">Himanshu  Sharma</span>, <span class="hlFld-ContribAuthor ">Avijit  Goswami</span>. </span><span class="cited-content_cbyCitation_article-title">An Atom‐Economical Approach to 2‐Aryloxypyridines and 2,2′/2,3′‐Diaryloxybipyridines
              via
              Ruthenium‐Catalyzed [2+2+2] Cycloadditions. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (18)
                                     , 4379-4385. <a href="https://doi.org/10.1002/adsc.201900553" title="DOI URL">https://doi.org/10.1002/adsc.201900553</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201900553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201900553%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DAn%252BAtom%2525E2%252580%252590Economical%252BApproach%252Bto%252B2%2525E2%252580%252590Aryloxypyridines%252Band%252B2%25252C2%2525E2%252580%2525B2%25252F2%25252C3%2525E2%252580%2525B2%2525E2%252580%252590Diaryloxybipyridines%252Bvia%252BRuthenium%2525E2%252580%252590Catalyzed%252B%25255B2%25252B2%25252B2%25255D%252BCycloadditions%26aulast%3DKalaramna%26aufirst%3DPratibha%26date%3D2019%26date%3D2019%26volume%3D361%26issue%3D18%26spage%3D4379%26epage%3D4385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">, <span class="hlFld-ContribAuthor ">Sylvain D.  Vallet</span>, <span class="hlFld-ContribAuthor ">Sylvie  Ricard-Blum</span>. </span><span class="cited-content_cbyCitation_article-title">Lysyl oxidases: from enzyme activity to extracellular matrix cross-links. </span><span class="cited-content_cbyCitation_journal-name">Essays in Biochemistry</span><span> <strong>2019,</strong> <em>63 </em>
                                    (3)
                                     , 349-364. <a href="https://doi.org/10.1042/EBC20180050" title="DOI URL">https://doi.org/10.1042/EBC20180050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/EBC20180050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FEBC20180050%26sid%3Dliteratum%253Aachs%26jtitle%3DEssays%2520in%2520Biochemistry%26atitle%3DLysyl%252Boxidases%25253A%252Bfrom%252Benzyme%252Bactivity%252Bto%252Bextracellular%252Bmatrix%252Bcross-links%26aulast%3DAdams%26aufirst%3DJosephine%26date%3D2019%26date%3D2019%26volume%3D63%26issue%3D3%26spage%3D349%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pier Giorgio  Amendola</span>, <span class="hlFld-ContribAuthor ">Raphael  Reuten</span>, <span class="hlFld-ContribAuthor ">Janine Terra  Erler</span>. </span><span class="cited-content_cbyCitation_article-title">Interplay Between LOX Enzymes and Integrins in the Tumor Microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 729. <a href="https://doi.org/10.3390/cancers11050729" title="DOI URL">https://doi.org/10.3390/cancers11050729</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11050729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11050729%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DInterplay%252BBetween%252BLOX%252BEnzymes%252Band%252BIntegrins%252Bin%252Bthe%252BTumor%252BMicroenvironment%26aulast%3DAmendola%26aufirst%3DPier%2BGiorgio%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heidi  Schilter</span>, <span class="hlFld-ContribAuthor ">Alison D.  Findlay</span>, <span class="hlFld-ContribAuthor ">Lara  Perryman</span>, <span class="hlFld-ContribAuthor ">Tin T.  Yow</span>, <span class="hlFld-ContribAuthor ">Joshua  Moses</span>, <span class="hlFld-ContribAuthor ">Amna  Zahoor</span>, <span class="hlFld-ContribAuthor ">Craig I.  Turner</span>, <span class="hlFld-ContribAuthor ">Mandar  Deodhar</span>, <span class="hlFld-ContribAuthor ">Jonathan S.  Foot</span>, <span class="hlFld-ContribAuthor ">Wenbin  Zhou</span>, <span class="hlFld-ContribAuthor ">Angelique  Greco</span>, <span class="hlFld-ContribAuthor ">Amar  Joshi</span>, <span class="hlFld-ContribAuthor ">Benjamin  Rayner</span>, <span class="hlFld-ContribAuthor ">Sarah  Townsend</span>, <span class="hlFld-ContribAuthor ">Alberto  Buson</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Jarolimek</span>. </span><span class="cited-content_cbyCitation_article-title">The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular and Molecular Medicine</span><span> <strong>2019,</strong> <em>23 </em>
                                    (3)
                                     , 1759-1770. <a href="https://doi.org/10.1111/jcmm.14074" title="DOI URL">https://doi.org/10.1111/jcmm.14074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcmm.14074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcmm.14074%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520and%2520Molecular%2520Medicine%26atitle%3DThe%252Blysyl%252Boxidase%252Blike%252B2%25252F3%252Benzymatic%252Binhibitor%25252C%252BPXS%2525E2%252580%2525905153A%25252C%252Breduces%252Bcrosslinks%252Band%252Bameliorates%252Bfibrosis%26aulast%3DSchilter%26aufirst%3DHeidi%26date%3D2019%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D1759%26epage%3D1770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isao  Kii</span>. </span><span class="cited-content_cbyCitation_article-title">Periostin Functions as a Scaffold for Assembly of Extracellular Proteins. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 23-32. <a href="https://doi.org/10.1007/978-981-13-6657-4_3" title="DOI URL">https://doi.org/10.1007/978-981-13-6657-4_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-13-6657-4_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-13-6657-4_3%26sid%3Dliteratum%253Aachs%26atitle%3DPeriostin%252BFunctions%252Bas%252Ba%252BScaffold%252Bfor%252BAssembly%252Bof%252BExtracellular%252BProteins%26aulast%3DKii%26aufirst%3DIsao%26date%3D2019%26date%3D2019%26spage%3D23%26epage%3D32%26pub%3DSpringer%2520Singapore%26atitle%3DPeriostin%26aulast%3DKudo%26aufirst%3DAkira%26date%3D2019%26volume%3D1132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mari  Kielosto</span>, <span class="hlFld-ContribAuthor ">Johanna  Eriksson</span>, <span class="hlFld-ContribAuthor ">Pirjo  Nummela</span>, <span class="hlFld-ContribAuthor ">Miao  Yin</span>, <span class="hlFld-ContribAuthor ">Erkki  Hölttä</span>. </span><span class="cited-content_cbyCitation_article-title">Divergent roles of lysyl oxidase family members in ornithine decarboxylase- and RAS-transformed mouse fibroblasts and human melanoma cells. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (102)
                                     , 37733-37752. <a href="https://doi.org/10.18632/oncotarget.26508" title="DOI URL">https://doi.org/10.18632/oncotarget.26508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26508%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDivergent%252Broles%252Bof%252Blysyl%252Boxidase%252Bfamily%252Bmembers%252Bin%252Bornithine%252Bdecarboxylase-%252Band%252BRAS-transformed%252Bmouse%252Bfibroblasts%252Band%252Bhuman%252Bmelanoma%252Bcells%26aulast%3DKielosto%26aufirst%3DMari%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D102%26spage%3D37733%26epage%3D37752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">István  Hajdú</span>, <span class="hlFld-ContribAuthor ">József  Kardos</span>, <span class="hlFld-ContribAuthor ">Balázs  Major</span>, <span class="hlFld-ContribAuthor ">Gabriella  Fabó</span>, <span class="hlFld-ContribAuthor ">Zsolt  Lőrincz</span>, <span class="hlFld-ContribAuthor ">Sándor  Cseh</span>, <span class="hlFld-ContribAuthor ">György  Dormán</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of the LOX enzyme family members with old and new ligands. Selectivity analysis revisited. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (18)
                                     , 3113-3118. <a href="https://doi.org/10.1016/j.bmcl.2018.07.001" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.07.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.07.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInhibition%252Bof%252Bthe%252BLOX%252Benzyme%252Bfamily%252Bmembers%252Bwith%252Bold%252Band%252Bnew%252Bligands.%252BSelectivity%252Banalysis%252Brevisited%26aulast%3DHajd%25C3%25BA%26aufirst%3DIstv%25C3%25A1n%26date%3D2018%26volume%3D28%26issue%3D18%26spage%3D3113%26epage%3D3118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dominic  Cosgrove</span>, <span class="hlFld-ContribAuthor ">Brianna  Dufek</span>, <span class="hlFld-ContribAuthor ">Daniel T.  Meehan</span>, <span class="hlFld-ContribAuthor ">Duane  Delimont</span>, <span class="hlFld-ContribAuthor ">Michael  Hartnett</span>, <span class="hlFld-ContribAuthor ">Gina  Samuelson</span>, <span class="hlFld-ContribAuthor ">Michael Anne  Gratton</span>, <span class="hlFld-ContribAuthor ">Grady  Phillips</span>, <span class="hlFld-ContribAuthor ">Deidre A.  MacKenna</span>, <span class="hlFld-ContribAuthor ">Gretchen  Bain</span>. </span><span class="cited-content_cbyCitation_article-title">Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice. </span><span class="cited-content_cbyCitation_journal-name">Kidney International</span><span> <strong>2018,</strong> <em>94 </em>
                                    (2)
                                     , 303-314. <a href="https://doi.org/10.1016/j.kint.2018.02.024" title="DOI URL">https://doi.org/10.1016/j.kint.2018.02.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.kint.2018.02.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.kint.2018.02.024%26sid%3Dliteratum%253Aachs%26jtitle%3DKidney%2520International%26atitle%3DLysyl%252Boxidase%252Blike-2%252Bcontributes%252Bto%252Brenal%252Bfibrosis%252Bin%2525C2%2525A0Col4%2525CE%2525B13%25252FAlport%252Bmice%26aulast%3DCosgrove%26aufirst%3DDominic%26date%3D2018%26volume%3D94%26issue%3D2%26spage%3D303%26epage%3D314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel H.  Craighead</span>, <span class="hlFld-ContribAuthor ">Huilei  Wang</span>, <span class="hlFld-ContribAuthor ">Lakshmi  Santhanam</span>, <span class="hlFld-ContribAuthor ">Lacy M.  Alexander</span>. </span><span class="cited-content_cbyCitation_article-title">Acute lysyl oxidase inhibition alters microvascular function in normotensive but not hypertensive men and women. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Heart and Circulatory Physiology</span><span> <strong>2018,</strong> <em>314 </em>
                                    (3)
                                     , H424-H433. <a href="https://doi.org/10.1152/ajpheart.00521.2017" title="DOI URL">https://doi.org/10.1152/ajpheart.00521.2017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajpheart.00521.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajpheart.00521.2017%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Heart%2520and%2520Circulatory%2520Physiology%26atitle%3DAcute%252Blysyl%252Boxidase%252Binhibition%252Balters%252Bmicrovascular%252Bfunction%252Bin%252Bnormotensive%252Bbut%252Bnot%252Bhypertensive%252Bmen%252Band%252Bwomen%26aulast%3DCraighead%26aufirst%3DDaniel%2BH.%26date%3D2018%26volume%3D314%26issue%3D3%26spage%3DH424%26epage%3DH433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Isao  Kii</span>, <span class="hlFld-ContribAuthor ">Harumi  Ito</span>. </span><span class="cited-content_cbyCitation_article-title">Periostin and its interacting proteins in the construction of extracellular architectures. </span><span class="cited-content_cbyCitation_journal-name">Cellular and Molecular Life Sciences</span><span> <strong>2017,</strong> <em>74 </em>
                                    (23)
                                     , 4269-4277. <a href="https://doi.org/10.1007/s00018-017-2644-4" title="DOI URL">https://doi.org/10.1007/s00018-017-2644-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00018-017-2644-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00018-017-2644-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520and%2520Molecular%2520Life%2520Sciences%26atitle%3DPeriostin%252Band%252Bits%252Binteracting%252Bproteins%252Bin%252Bthe%252Bconstruction%252Bof%252Bextracellular%252Barchitectures%26aulast%3DKii%26aufirst%3DIsao%26date%3D2017%26date%3D2017%26volume%3D74%26issue%3D23%26spage%3D4269%26epage%3D4277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Structures of the known pan-LOX(L) inhibitor BAPN <b>1</b>, and the LOXL2 inhibitor <b>2</b>. (b) Proposed mechanism for the oxidation of lysine amines by LTQ-containing lysyl oxidase enzymes. (c) Proposed complex between LOXL2 and either lysine residues or pyridine-derived inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 4-(Methylamino)-2-phenoxypyridine Derivatives <b>6</b>, <b>9</b>, <b>10</b>, and <b>13</b>–<b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) phenol, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 80 °C, 95%; (b) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc-MeOH, rt, 91%; (c) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 100%; (d) methyl 4-hydroxybenzoate or methyl-3-hydroxybenzoate, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 80 °C, 58–60%; (e) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc-MeOH, rt, 94–100%; (f) Boc<sub>2</sub>O, DIEA, THF, rt, 67–80%; (g) LiOH, THF-H<sub>2</sub>O, rt, 83–100%; (h) R<sup>1</sup>R<sup>2</sup>NH, HATU, DIEA, DCM, rt; (i) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 9–84% (over 2-steps); (j) methyl 4-aminobenzoate, HATU, DIEA, DMF, rt, 68%; (k) LiOH, THF-H<sub>2</sub>O, rt, 59%; (l) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 52%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 4-(Methylamino)-6-(trifluoromethyl)pyridine Derivatives <b>25</b>–<b>33</b>, <b>36</b>, <b>37</b>, and <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) methyl 3-hydroxybenzoate, K<sub>2</sub>CO<sub>3</sub>, THF-DMF, 60 °C, 91%; (b) CoCl<sub>2</sub>, NaBH<sub>4</sub>, THF-MeOH, 0 °C, 92%; (c) Boc<sub>2</sub>O, DIEA, THF, rt, 78%; (d) LiOH, THF-H<sub>2</sub>O, rt, 87%; (e) R<sup>1</sup>R<sup>2</sup>NH, HATU, DIEA, DCM-DMF, rt; (f) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 53–89% (over 2-steps); (g) (<i>R</i>)- or (<i>S</i>)-1-<i>N</i>-Boc-3-hydroxypiperidine, NaH, THF, 0 °C-rt, 47–53%; (h) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 96–100%; (i) PhNCO, DIEA, THF, rt, 62–80%; (j) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc-MeOH, rt, 50–73%; (k) 3-phenoxyphenol, K<sub>2</sub>CO<sub>3</sub>, THF, 90 °C, 45%; (l) 10 wt % Pd/C, H<sub>2</sub> gas (1 atm), EtOAc, rt, 83%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 4-(Methylamino)-6-(trifluoromethyl)pyridine Derivatives <b>43</b> and <b>44</b> via Preparative Normal-Phase Chiral HPLC Separation<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) racemic-<i>trans</i>-4-fluoro-3-hydroxypyrrolidine·HCl, HATU, DIEA, DCM-DMF, rt, 87%; (b) separation via preparative normal-phase chiral HPLC, 59–68%; (c) 2 M HCl in Et<sub>2</sub>O, DCM, rt, 100%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Optically Pure (<i>R</i>,<i>R</i>)-<i>trans</i>-4-Fluoro-3-pyrrolidinol <b>47</b> via Diastereomeric Salt Crystallization<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaOH, EtOH, rt, 94%; (b) 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartaric acid, THF, reflux to rt. Obtained precipitate was repeatedly recrystallized from MeOH; 6% overall yield, 94.4% ee.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray crystal structure of (<i>R</i>,<i>R</i>)-<i>trans-</i>4-fluoro-3-pyrrolidinol 2,3-dibenzoyl-<span class="smallcaps smallerCapital">d</span>-tartrate <b>47</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Assessment of irreversible inhibition of human LOXL2 for select compounds. Solid bars represent % inhibition of LOXL2 after a single 2 h incubation at 37 °C with the inhibitor (nonwashed controls). Open bars represent % inhibition of LOXL2 after treatment with inhibitor for 2 h at 37 °C followed by extensive washing with buffer, then an additional 2 h at 37 °C of incubation in buffer before the addition of substrate and assaying of catalytic activity. Bars represent triplicate data points with compounds tested in direct comparison to one another in one experiment. All compounds were tested in subsequent independent experiments to confirm irreversibility at least two times. (b) Assessment of irreversible inhibition of human LOXL2 activity for compound <b>43</b> after either a 2, 4, 6, or 24 h postwashout. Data bar plotted for the unwashed group is representative of 12 replicate points, and the data bar plotted for each postwash time point is representative of 3 replicate points from one experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/medium/jm-2017-00345p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Ashcroft scores from oropharyngeal bleomycin-instilled C57BL/6 mice (10 per group), dosed with either vehicle control (0.5% methylcellulose, QD days −1 to 14) or compound <b>28</b> (3, 10, 30, or 60 mg/kg PO QD days −1 to 14). Shown is the mean Ashcroft score ± standard error of the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-10/acs.jmedchem.7b00345/20170519/images/large/jm-2017-00345p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00345&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i85">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Grau-Bové, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Trillo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez-Pascual, F.</span><span> </span><span class="NLM_article-title">Origin and evolution of lysyl oxidases</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">10568</span><span class="refDoi"> DOI: 10.1038/srep10568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fsrep10568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=26024311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10568&author=X.+Grau-Bov%C3%A9author=I.+Ruiz-Trilloauthor=F.+Rodriguez-Pascual&title=Origin+and+evolution+of+lysyl+oxidases&doi=10.1038%2Fsrep10568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and evolution of lysyl oxidases</span></div><div class="casAuthors">Grau-Bove Xavier; Ruiz-Trillo Inaki; Rodriguez-Pascual Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl oxidases (LOX) are copper-dependent enzymes that oxidize primary amine substrates to reactive aldehydes.  The best-studied role of LOX enzymes is the remodeling of the extracellular matrix (ECM) in animals by cross-linking collagens and elastin, although intracellular functions have been reported as well.  Five different LOX enzymes have been identified in mammals, LOX and LOX-like (LOXL) 1 to 4, showing a highly conserved catalytic carboxy terminal domain and more divergence in the rest of the sequence.  Here we have surveyed a wide selection of genomes in order to infer the evolutionary history of LOX.  We identified LOX proteins not only in animals, but also in many other eukaryotes, as well as in bacteria and archaea - which reveals a pre-metazoan origin for this gene family.  LOX genes expanded during metazoan evolution resulting in two superfamilies, LOXL2/L3/L4 and LOX/L1/L5.  Considering the current knowledge on the function of mammalian LOX isoforms in ECM remodeling, we propose that LOXL2/L3/L4 members might have preferentially been involved in making cross-linked collagen IV-based basement membrane, whereas the diversification of LOX/L1/L5 forms contributed to chordate/vertebrate-specific ECM innovations, such as elastin and fibronectin.  Our work provides a novel view on the evolution of this family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHiDw73o3Ogn6oPH0mYWL1fW6udTcc2eZe-tijaczCurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D&md5=ca8f3e5364edb3e5d19742d09d78b82a</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsrep10568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10568%26sid%3Dliteratum%253Aachs%26aulast%3DGrau-Bov%25C3%25A9%26aufirst%3DX.%26aulast%3DRuiz-Trillo%26aufirst%3DI.%26aulast%3DRodriguez-Pascual%26aufirst%3DF.%26atitle%3DOrigin%2520and%2520evolution%2520of%2520lysyl%2520oxidases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10568%26doi%3D10.1038%2Fsrep10568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Finney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, H. – J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnebaum, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lantz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mure, M.</span><span> </span><span class="NLM_article-title">Human copper-dependent amine oxidases</span> <span class="citation_source-journal">Arch. Biochem. Biophys.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">546</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1016/j.abb.2013.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2Fj.abb.2013.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24407025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2014&pages=19-32&author=J.+Finneyauthor=H.+%E2%80%93+J.+Moonauthor=T.+Ronnebaumauthor=M.+Lantzauthor=M.+Mure&title=Human+copper-dependent+amine+oxidases&doi=10.1016%2Fj.abb.2013.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Human copper-dependent amine oxidases</span></div><div class="casAuthors">Finney, Joel; Moon, Hee-Jung; Ronnebaum, Trey; Lantz, Mason; Mure, Minae</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-32</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Copper amine oxidases (CAOs) are a class of enzymes that contain Cu2+ and a tyrosine-derived quinone cofactor, and catalyze the conversion of a primary amine functional group to an aldehyde, generating H2O2 and NH3 as byproducts.  These enzymes can be classified into 2 non-homologous families: 2,4,5-trihydroxyphenylalanine quinone (TPQ)-dependent CAOs and the lysine tyrosylquinone (LTQ)-dependent lysyl oxidase (LOX) family of proteins.  Here, the authors focus on recent developments in the field of research concerning human CAOs and the LOX family of proteins.  The aberrant expression of these enzymes is linked to inflammation, fibrosis, tumor metastasis/invasion, and other diseases.  Consequently, there is a crit. need to understand the functions of these proteins at the mol. level, so that strategies targeting these enzymes can be developed to combat human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxp8xJQhX_qLVg90H21EOLACvtfcHk0lj3HmeSeilJsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D&md5=f7ecc08c322917ac6c9bf96636b49575</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2013.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2013.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DH.%2B%25E2%2580%2593%2BJ.%26aulast%3DRonnebaum%26aufirst%3DT.%26aulast%3DLantz%26aufirst%3DM.%26aulast%3DMure%26aufirst%3DM.%26atitle%3DHuman%2520copper-dependent%2520amine%2520oxidases%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2014%26volume%3D546%26spage%3D19%26epage%3D32%26doi%3D10.1016%2Fj.abb.2013.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Yamauchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sricholpech, M.</span><span> </span><span class="NLM_article-title">Lysine post-translational modifications of collagen</span> <span class="citation_source-journal">Essays Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">113</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1042/bse0520113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1042%2Fbse0520113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=22708567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=113-133&author=M.+Yamauchiauthor=M.+Sricholpech&title=Lysine+post-translational+modifications+of+collagen&doi=10.1042%2Fbse0520113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine post-translational modifications of collagen</span></div><div class="casAuthors">Yamauchi, Mitsuo; Sricholpech, Marnisa</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">Lysine-Based Post-Translational Modification of Proteins</span>),
    <span class="NLM_cas:pages">113-133</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">0071-1365</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Type I collagen is the most abundant structural protein in vertebrates.  It is a heterotrimeric mol. composed of two α1 chains and one α2 chain, forming a long uninterrupted triple helical structure with short non-triple helical telopeptides at both the N- and C-termini.  During biosynthesis, collagen acquires a no. of post-translational modifications, including lysine modifications, that are crit. to the structure and biol. functions of this protein.  Lysine modifications of collagen are highly complicated sequential processes catalyzed by several groups of enzymes leading to the final step of biosynthesis, covalent intermol. crosslinking.  In the cell, specific lysine residues are hydroxylated to form hydroxylysine.  Then specific hydroxylysine residues located in the helical domain of the mol. are glycosylated by the addn. of galactose or glucose-galactose.  Outside the cell, lysine and hydroxylysine residues in the N- and C-telopeptides can be oxidatively deaminated to produce reactive aldehydes that undergo a series of non-enzymic condensation reactions to form covalent intra- and inter-mol. cross-links.  Owing to the recent advances in mol. and cellular biol., and anal. technologies, the biol. significance and mol. mechanisms of these modifications have been gradually elucidated.  This chapter provides an overview on these enzymic lysine modifications and subsequent crosslinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ1dEKotSOLVg90H21EOLACvtfcHk0lghtZTmKB6YhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK&md5=2aa838a0513d3ed1a8ea6e8ab579f56e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2Fbse0520113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbse0520113%26sid%3Dliteratum%253Aachs%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DSricholpech%26aufirst%3DM.%26atitle%3DLysine%2520post-translational%2520modifications%2520of%2520collagen%26jtitle%3DEssays%2520Biochem.%26date%3D2012%26volume%3D52%26spage%3D113%26epage%3D133%26doi%3D10.1042%2Fbse0520113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Funke-Chambour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geiser, T.</span><span> </span><span class="NLM_article-title">Idiopathic pulmonary fibrosis: the turning point is now!</span> <span class="citation_source-journal">Swiss Med. Wkly.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">145</span><span class="NLM_x">, </span> <span class="NLM_fpage">w14139</span><span class="refDoi"> DOI: 10.4414/smw.2015.14139</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.4414%2Fsmw.2015.14139" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2015&pages=w14139&author=M.+Funke-Chambourauthor=T.+Geiser&title=Idiopathic+pulmonary+fibrosis%3A+the+turning+point+is+now%21&doi=10.4414%2Fsmw.2015.14139"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.4414%2Fsmw.2015.14139&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4414%252Fsmw.2015.14139%26sid%3Dliteratum%253Aachs%26aulast%3DFunke-Chambour%26aufirst%3DM.%26aulast%3DGeiser%26aufirst%3DT.%26atitle%3DIdiopathic%2520pulmonary%2520fibrosis%253A%2520the%2520turning%2520point%2520is%2520now%2521%26jtitle%3DSwiss%2520Med.%2520Wkly.%26date%3D2015%26volume%3D145%26spage%3Dw14139%26doi%3D10.4414%2Fsmw.2015.14139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Datta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scotton, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, R. C.</span><span> </span><span class="NLM_article-title">Novel therapeutic approaches for pulmonary fibrosis</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01247.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1111%2Fj.1476-5381.2011.01247.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=21265830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=141-172&author=A.+Dattaauthor=C.+J.+Scottonauthor=R.+C.+Chambers&title=Novel+therapeutic+approaches+for+pulmonary+fibrosis&doi=10.1111%2Fj.1476-5381.2011.01247.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Novel therapeutic approaches for pulmonary fibrosis</span></div><div class="casAuthors">Datta, Arnab; Scotton, Chris J.; Chambers, Rachel C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-172</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Pulmonary fibrosis represents the end stage of a no. of heterogeneous conditions and is, to a greater or lesser degree, the hallmark of the interstitial lung diseases.  It is characterized by the excessive deposition of extracellular matrix proteins within the pulmonary interstitium leading to the obliteration of functional alveolar units and in many cases, respiratory failure.  While a small no. of interstitial lung diseases have known etiologies, most are idiopathic in nature, and of these, idiopathic pulmonary fibrosis is the most common and carries with it an appalling prognosis - median survival from the time of diagnosis is less than 3 years.  This reflects the lack of any effective therapy to modify the course of the disease, which in turn is indicative of our incomplete understanding of the pathogenesis of this condition.  Current prevailing hypotheses focus on dysregulated epithelial-mesenchymal interactions promoting a cycle of continued epithelial cell injury and fibroblast activation leading to progressive fibrosis.  However, it is likely that multiple abnormalities in a myriad of biol. pathways affecting inflammation and wound repair - including matrix regulation, epithelial reconstitution, the coagulation cascade, neovascularization and antioxidant pathways - modulate this defective crosstalk and promote fibrogenesis.  This review aims to offer a pathogenetic rationale behind current therapies, briefly outlining previous and ongoing clin. trials, but will focus on recent and exciting advancements in our understanding of the pathogenesis of idiopathic pulmonary fibrosis, which may ultimately lead to the development of novel and effective therapeutic interventions for this devastating condition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGZh6zcVDUa7Vg90H21EOLACvtfcHk0lghtZTmKB6YhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLc%253D&md5=a161ebe75b90c742137e12b92fbeee42</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01247.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01247.x%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DA.%26aulast%3DScotton%26aufirst%3DC.%2BJ.%26aulast%3DChambers%26aufirst%3DR.%2BC.%26atitle%3DNovel%2520therapeutic%2520approaches%2520for%2520pulmonary%2520fibrosis%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D141%26epage%3D172%26doi%3D10.1111%2Fj.1476-5381.2011.01247.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bataller, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brenner, D. A.</span><span> </span><span class="NLM_article-title">Liver fibrosis</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span><span class="refDoi"> DOI: 10.1172/JCI24282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1172%2FJCI24282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=15690074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=209-218&author=R.+Batallerauthor=D.+A.+Brenner&title=Liver+fibrosis&doi=10.1172%2FJCI24282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Liver fibrosis</span></div><div class="casAuthors">Bataller, Ramon; Brenner, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-218</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases.  Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation.  Our knowledge of the cellular and mol. mechanisms of liver fibrosis has greatly advanced.  Activated hepatic stellate cells, portal fibroblasts, and myofibroblasts of bone marrow origin have been identified as major collagen-producing cells in the injured liver.  These cells are activated by fibrogenic cytokines such as TGF-β1, angiotensin II, and leptin.  Reversibility of advanced liver fibrosis in patients has been recently documented, which has stimulated researchers to develop antifibrotic drugs.  Emerging antifibrotic therapies are aimed at inhibiting the accumulation of fibrogenic cells and/or preventing the deposition of extracellular matrix proteins.  Although many therapeutic interventions are effective in exptl. models of liver fibrosis, their efficacy and safety in humans is unknown.  This review summarizes recent progress in the study of the pathogenesis and diagnosis of liver fibrosis and discusses current antifibrotic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADNkKCYBJYLVg90H21EOLACvtfcHk0lghtZTmKB6YhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFyjs70%253D&md5=f96b24aca82750b66fc1cb05b4b6216b</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1172%2FJCI24282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI24282%26sid%3Dliteratum%253Aachs%26aulast%3DBataller%26aufirst%3DR.%26aulast%3DBrenner%26aufirst%3DD.%2BA.%26atitle%3DLiver%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D209%26epage%3D218%26doi%3D10.1172%2FJCI24282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Schuppan, D.</span><span> </span><span class="NLM_article-title">Liver fibrosis: common mechanisms and antifibrotic therapies</span> <span class="citation_source-journal">Clin. Res. Hepatol. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">S51</span><span class="NLM_x">–</span> <span class="NLM_lpage">S59</span><span class="refDoi"> DOI: 10.1016/j.clinre.2015.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2Fj.clinre.2015.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=26189980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVegu77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2015&pages=S51-S59&author=D.+Schuppan&title=Liver+fibrosis%3A+common+mechanisms+and+antifibrotic+therapies&doi=10.1016%2Fj.clinre.2015.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Liver fibrosis: Common mechanisms and antifibrotic therapies</span></div><div class="casAuthors">Schuppan, Detlef</div><div class="citationInfo"><span class="NLM_cas:title">Clinics and Research in Hepatology and Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">Suppl._1</span>),
    <span class="NLM_cas:pages">S51-S59</span>CODEN:
                <span class="NLM_cas:coden">CRHGAQ</span>;
        ISSN:<span class="NLM_cas:issn">2210-7401</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Liver fibrosis and in particular cirrhosis have become major endpoints in clin. trials of patients with chronic liver diseases.  Here, viral hepatitis, alc. and non-alc. steatohepatitis have become the major etiologies.  We have made great progress in our understanding of the mechanisms and the cell biol. of liver fibrosis and have already made the transition from preclin. testing of antifibrotic agents and strategies towards clin. translation.  There continues to be an urgent need for specific antifibrotic therapies, despite the advent of highly potent antiviral agents that can even induce regression of advanced fibrosis.  This review addresses central mechanisms and cells to be targeted, current antifibrotic drug trials, and the state of non-invasive biomarker development that is key to rapid clin. progress and to a personalized treatment of fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlbfqxGvJu87Vg90H21EOLACvtfcHk0liphXvIzsGEww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVegu77M&md5=304d9e38d2f9ace07e18d5cd8682a59a</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2Fj.clinre.2015.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clinre.2015.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DSchuppan%26aufirst%3DD.%26atitle%3DLiver%2520fibrosis%253A%2520common%2520mechanisms%2520and%2520antifibrotic%2520therapies%26jtitle%3DClin.%2520Res.%2520Hepatol.%2520Gastroenterol.%26date%3D2015%26volume%3D39%26spage%3DS51%26epage%3DS59%26doi%3D10.1016%2Fj.clinre.2015.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Genovese, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manresa, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeming, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karsdal, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boor, P.</span><span> </span><span class="NLM_article-title">The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?</span> <span class="citation_source-journal">Fibrog. Tissue Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">4</span><span class="refDoi"> DOI: 10.1186/1755-1536-7-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1186%2F1755-1536-7-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24678881" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjtFyitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=4&author=F.+Genoveseauthor=A.+A.+Manresaauthor=D.+J.+Leemingauthor=M.+A.+Karsdalauthor=P.+Boor&title=The+extracellular+matrix+in+the+kidney%3A+a+source+of+novel+non-invasive+biomarkers+of+kidney+fibrosis%3F&doi=10.1186%2F1755-1536-7-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?</span></div><div class="casAuthors">Genovese, Federica; Manresa, Alba A.; Leeming, Diana Julie; Karsdal, Morten Asser; Boor, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Fibrogenesis & Tissue Repair</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4/1-4/14, 14 pp.</span>CODEN:
                <span class="NLM_cas:coden">FTRIBS</span>;
        ISSN:<span class="NLM_cas:issn">1755-1536</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Interstitial fibrosis is the common endpoint of end-stage chronic kidney disease (CKD) leading to kidney failure.  The clin. course of many renal diseases, and thereby of CKD, is highly variable.  One of the major challenges in deciding which treatment approach is best suited for a patient but also in the development of new treatments is the lack of markers able to identify and stratify patients with stable vs. progressive disease.  At the moment renal biopsy is the only means of diagnosing renal interstitial fibrosis.  Novel biomarkers should improve diagnosis of a disease, est. its prognosis and assess the response to treatment, all in a non-invasive manner.  Existing markers of CKD do not fully and specifically address these requirements and in particular do not specifically reflect renal fibrosis.  The aim of this review is to give an insight of the involvement of the extracellular matrix (ECM) proteins in kidney diseases and as a source of potential novel biomarkers of renal fibrosis.  In particular the use of the protein fingerprint technol., that identifies neo-epitopes of ECM proteins generated by proteolytic cleavage by proteases or other post-translational modifications, might identify such novel biomarkers of renal fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyfy-NeSaIybVg90H21EOLACvtfcHk0liphXvIzsGEww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjtFyitLY%253D&md5=e1ce57b98ffccf936c1b9da94b01b947</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1186%2F1755-1536-7-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1755-1536-7-4%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DF.%26aulast%3DManresa%26aufirst%3DA.%2BA.%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DBoor%26aufirst%3DP.%26atitle%3DThe%2520extracellular%2520matrix%2520in%2520the%2520kidney%253A%2520a%2520source%2520of%2520novel%2520non-invasive%2520biomarkers%2520of%2520kidney%2520fibrosis%253F%26jtitle%3DFibrog.%2520Tissue%2520Repair%26date%3D2014%26volume%3D7%26spage%3D4%26doi%3D10.1186%2F1755-1536-7-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Ho, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laǵares, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tager, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, M.</span><span> </span><span class="NLM_article-title">Fibrosis – a lethal component of systemic sclerosis</span> <span class="citation_source-journal">Nat. Rev. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">402</span><span class="refDoi"> DOI: 10.1038/nrrheum.2014.53</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnrrheum.2014.53" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24752182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmvV2hu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=390-402&author=Y.+Y.+Hoauthor=D.+La%C7%B5aresauthor=A.+M.+Tagerauthor=M.+Kapoor&title=Fibrosis+%E2%80%93+a+lethal+component+of+systemic+sclerosis&doi=10.1038%2Fnrrheum.2014.53"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrosis-a lethal component of systemic sclerosis</span></div><div class="casAuthors">Ho, Yuen Yee; Lagares, David; Tager, Andrew M.; Kapoor, Mohit</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">390-402</span>CODEN:
                <span class="NLM_cas:coden">NRRACB</span>;
        ISSN:<span class="NLM_cas:issn">1759-4790</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Fibrosis is a pathol. process characterized by excessive accumulation of connective tissue components in an organ or tissue.  Fibrosis is produced by deregulated wound healing in response to chronic tissue injury or chronic inflammation, the hallmarks of rheumatic diseases.  Progressive fibrosis, which distorts tissue architecture and results in progressive loss of organ function, is now recognized to be one of the major causes of morbidity and mortality in individuals with one of the most lethal rheumatic disease, systemic sclerosis (SSc).  In this Review, we discuss the pathol. role of fibrosis in SSc.  We discuss the involvement of endothelium and pericyte activation, aberrant immune responses, endoplasmic reticulum stress and chronic tissue injury in the initiation of fibrosis in SSc.  We then discuss fibroblast activation and myofibroblast differentiation that occurs in response to these initiating processes and is responsible for excessive accumulation of extracellular matrix.  Finally, we discuss the chem. and mech. signals that drive fibroblast activation and myofibroblast differentiation, which could serve as targets for new therapies for fibrosis in SSc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3CKGgf3Yn8rVg90H21EOLACvtfcHk0liiP63-hU8D_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmvV2hu7s%253D&md5=1b9a8a7aab0ca5ea4ee2ee310189f86d</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrrheum.2014.53&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrrheum.2014.53%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BY.%26aulast%3DLa%25C7%25B5ares%26aufirst%3DD.%26aulast%3DTager%26aufirst%3DA.%2BM.%26aulast%3DKapoor%26aufirst%3DM.%26atitle%3DFibrosis%2520%25E2%2580%2593%2520a%2520lethal%2520component%2520of%2520systemic%2520sclerosis%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2014%26volume%3D10%26spage%3D390%26epage%3D402%26doi%3D10.1038%2Fnrrheum.2014.53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Maulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">–</span> <span class="NLM_lpage">2082</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1056%2FNEJMoa1402584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24836310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2071-2082&author=L.+Richeldiauthor=R.+M.+du+Boisauthor=G.+Raghuauthor=A.+Azumaauthor=K.+K.+Brownauthor=U.+Costabelauthor=V.+Cottinauthor=K.+R.+Flahertyauthor=D.+M.+Hansellauthor=Y.+Inoueauthor=D.+S.+Kimauthor=M.+Kolbauthor=A.+G.+Nicholsonauthor=P.+W.+Nobleauthor=M.+Selmanauthor=H.+Taniguchiauthor=M.+Brunauthor=F.+Le+Maulfauthor=M.+Girardauthor=S.+Stowasserauthor=R.+Schlenker-Hercegauthor=B.+Disseauthor=H.+R.+Collard&title=Efficacy+and+safety+of+nintedanib+in+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1402584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; du Bois, Roland M.; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, David M.; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moises; Taniguchi, Hiroyuki; Brun, Michele; Le Maulf, Florence; Girard, Mannaig; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Disse, Bernd; Collard, Harold R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2071-2082, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases.  A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.  Methods: We conducted two replicate 52-wk, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St.  George's Respiratory Questionnaire, both assessed over a 52-wk period.  Results: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo.  The adjusted annual rate of change in FVC was -114.7 mL with nintedanib vs. -239.9 mL with placebo (difference, 125.3 mL; 95% confidence interval [CI], 77.7 to 172.8; P < 0.001) in INPULSIS-1 and -113.6 mL with nintedanib vs. -207.3 mL with placebo (difference, 93.7 mL; 95% CI, 44.8 to 142.7; P < 0.001) in INPULSIS-2.  In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P = 0.67); in INPULSIS-2, there was a significant benefit with nintedanib vs. placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).  The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, resp., in INPULSIS-1 and 63.2% and 18.3% in the two groups, resp., in INPULSIS-2.  Conclusions: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently assocd. with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuOhVKeZaSrVg90H21EOLACvtfcHk0liiP63-hU8D_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK&md5=be977cd3b402c7c401f4a3dfaa0f484f</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402584%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DLe%2BMaulf%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520nintedanib%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2071%26epage%3D2082%26doi%3D10.1056%2FNEJMoa1402584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">King, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradford, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro-Bernardini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fagan, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaspole, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glassberg, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hopkins, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kardatzke, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lancaster, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathan, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahn, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sussman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span> </span><span class="NLM_article-title">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2083</span><span class="NLM_x">–</span> <span class="NLM_lpage">2092</span><span class="refDoi"> DOI: 10.1056/NEJMoa1402582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1056%2FNEJMoa1402582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24836312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2083-2092&author=T.+E.+Kingauthor=W.+Z.+Bradfordauthor=S.+Castro-Bernardiniauthor=E.+A.+Faganauthor=I.+Glaspoleauthor=M.+K.+Glassbergauthor=E.+Gorinaauthor=P.+M.+Hopkinsauthor=D.+Kardatzkeauthor=L.+Lancasterauthor=D.+J.+Ledererauthor=S.+D.+Nathanauthor=C.+A.+Pereiraauthor=S.+A.+Sahnauthor=R.+Sussmanauthor=J.+J.+Swigrisauthor=P.+W.+Noble&title=A+phase+3+trial+of+pirfenidone+in+patients+with+idiopathic+pulmonary+fibrosis&doi=10.1056%2FNEJMoa1402582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">King, Talmadge E.; Bradford, Williamson Z.; Castro-Bernardini, Socorro; Fagan, Elizabeth A.; Glaspole, Ian; Glassberg, Marilyn K.; Gorina, Eduard; Hopkins, Peter M.; Kardatzke, David; Lancaster, Lisa; Lederer, David J.; Nathan, Steven D.; Pereira, Carlos A.; Sahn, Steven A.; Sussman, Robert; Swigris, Jeffrey J.; Noble, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2083-2092, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved.  We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients.  Methods: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 wk.  The primary end point was the change in FVC or death at week 52.  Secondary end points were the 6-min walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis.  Results: In the pirfenidone group, as compared with the placebo group, there was a relative redn. of 47.9% in the proportion of patients who had an abs. decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P < 0.001).  Pirfenidone reduced the decline in the 6-min walk distance (P = 0.04) and improved progression-free survival (P < 0.001).  There was no significant between-group difference in dyspnea scores (P = 0.16) or in rates of death from any cause (P = 0.10) or from idiopathic pulmonary fibrosis (P = 0.23).  However, in a prespecified pooled anal. incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P = 0.01) and from idiopathic pulmonary fibrosis (P = 0.006).  Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation.  Conclusions: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.  Treatment was assocd. with an acceptable sideeffect profile and fewer deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBkQ8hqTWxxLVg90H21EOLACvtfcHk0lhCAhqDoIAqkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGktrrJ&md5=17bfe4782c11521d3b7890ae387bbaf6</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402582%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DBradford%26aufirst%3DW.%2BZ.%26aulast%3DCastro-Bernardini%26aufirst%3DS.%26aulast%3DFagan%26aufirst%3DE.%2BA.%26aulast%3DGlaspole%26aufirst%3DI.%26aulast%3DGlassberg%26aufirst%3DM.%2BK.%26aulast%3DGorina%26aufirst%3DE.%26aulast%3DHopkins%26aufirst%3DP.%2BM.%26aulast%3DKardatzke%26aufirst%3DD.%26aulast%3DLancaster%26aufirst%3DL.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DNathan%26aufirst%3DS.%2BD.%26aulast%3DPereira%26aufirst%3DC.%2BA.%26aulast%3DSahn%26aufirst%3DS.%2BA.%26aulast%3DSussman%26aufirst%3DR.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26atitle%3DA%2520phase%25203%2520trial%2520of%2520pirfenidone%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2083%26epage%3D2092%26doi%3D10.1056%2FNEJMoa1402582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kreuter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonella, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijsenbeek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maher, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spagnolo, P.</span><span> </span><span class="NLM_article-title">Pharmacological treatment of idiopathic pulmonary fibrosis: current approaches, unsolved issues, and future perspectives</span> <span class="citation_source-journal">BioMed Res. Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">2015</span><span class="NLM_x">, </span> <span class="NLM_fpage">329481</span><span class="refDoi"> DOI: 10.1155/2015/329481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1155%2F2015%2F329481" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2015&publication_year=2015&pages=329481&author=M.+Kreuterauthor=F.+Bonellaauthor=M.+Wijsenbeekauthor=T.+M.+Maherauthor=P.+Spagnolo&title=Pharmacological+treatment+of+idiopathic+pulmonary+fibrosis%3A+current+approaches%2C+unsolved+issues%2C+and+future+perspectives&doi=10.1155%2F2015%2F329481"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1155%2F2015%2F329481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2015%252F329481%26sid%3Dliteratum%253Aachs%26aulast%3DKreuter%26aufirst%3DM.%26aulast%3DBonella%26aufirst%3DF.%26aulast%3DWijsenbeek%26aufirst%3DM.%26aulast%3DMaher%26aufirst%3DT.%2BM.%26aulast%3DSpagnolo%26aufirst%3DP.%26atitle%3DPharmacological%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520current%2520approaches%252C%2520unsolved%2520issues%252C%2520and%2520future%2520perspectives%26jtitle%3DBioMed%2520Res.%2520Int.%26date%3D2015%26volume%3D2015%26spage%3D329481%26doi%3D10.1155%2F2015%2F329481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Moon, H. – J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finney, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronnebaum, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mure, M.</span><span> </span><span class="NLM_article-title">Human lysyl oxidase-like 2</span> <span class="citation_source-journal">Bioorg. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">231</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1016/j.bioorg.2014.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2Fj.bioorg.2014.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=25146937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht12ntbrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=231-241&author=H.+%E2%80%93+J.+Moonauthor=J.+Finneyauthor=T.+Ronnebaumauthor=M.+Mure&title=Human+lysyl+oxidase-like+2&doi=10.1016%2Fj.bioorg.2014.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Human lysyl oxidase-like 2</span></div><div class="casAuthors">Moon, Hee-Jung; Finney, Joel; Ronnebaum, Trey; Mure, Minae</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">231-241</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Lysyl oxidase like-2 (LOXL2) belongs to the lysyl oxidase (LOX) family, which comprises Cu2+- and lysine tyrosylquinone (LTQ)-dependent amine oxidases.  LOXL2 is proposed to function similarly to LOX in the extracellular matrix (ECM) by promoting crosslinking of collagen and elastin.  LOXL2 has also been proposed to regulate extracellular and intracellular cell signaling pathways.  Dysregulation of LOXL2 has been linked to many diseases, including cancer, pro-oncogenic angiogenesis, fibrosis and heart diseases.  In this review, we will give an overview of the current understandings and hypotheses regarding the mol. functions of LOXL2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocatU98HPEn7Vg90H21EOLACvtfcHk0lgZSz2tum076A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht12ntbrE&md5=b6ded89bd69abcef395afb909f626b0e</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2014.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2014.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DMoon%26aufirst%3DH.%2B%25E2%2580%2593%2BJ.%26aulast%3DFinney%26aufirst%3DJ.%26aulast%3DRonnebaum%26aufirst%3DT.%26aulast%3DMure%26aufirst%3DM.%26atitle%3DHuman%2520lysyl%2520oxidase-like%25202%26jtitle%3DBioorg.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D231%26epage%3D241%26doi%3D10.1016%2Fj.bioorg.2014.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Barry-Hamilton, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spangler, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCauley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyasu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikels, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaysberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghermazien, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velayo, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorgensen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biermann, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaffryar-Eilot, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thai, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neufeld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Vlasselaer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, V.</span><span> </span><span class="NLM_article-title">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1017</span><span class="refDoi"> DOI: 10.1038/nm.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnm.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=20818376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1009-1017&author=V.+Barry-Hamiltonauthor=R.+Spanglerauthor=D.+Marshallauthor=S.+McCauleyauthor=H.+M.+Rodriguezauthor=M.+Oyasuauthor=A.+Mikelsauthor=M.+Vaysbergauthor=H.+Ghermazienauthor=C.+Waiauthor=C.+A.+Garciaauthor=A.+C.+Velayoauthor=B.+Jorgensenauthor=D.+Biermannauthor=D.+Tsaiauthor=J.+Greenauthor=S.+Zaffryar-Eilotauthor=A.+Holzerauthor=S.+Oggauthor=D.+Thaiauthor=G.+Neufeldauthor=P.+Van+Vlasselaerauthor=V.+Smith&title=Allosteric+inhibition+of+lysyl+oxidase-like-2+impedes+the+development+of+a+pathologic+microenvironment&doi=10.1038%2Fnm.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span></div><div class="casAuthors">Barry-Hamilton, Vivian; Spangler, Rhyannon; Marshall, Derek; McCauley, Scott; Rodriguez, Hector M.; Oyasu, Miho; Mikels, Amanda; Vaysberg, Maria; Ghermazien, Haben; Wai, Carol; Garcia, Carlos A.; Velayo, Arleene C.; Jorgensen, Brett; Biermann, Donna; Tsai, Daniel; Green, Jennifer; Zaffryar-Eilot, Shelly; Holzer, Alison; Ogg, Scott; Thai, Dung; Neufeld, Gera; Van Vlasselaer, Peter; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathol. microenvironment of cancer and fibrotic disease.  Our anal. of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-assocd. stroma and limited expression in healthy tissues.  Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models.  Inhibition of LOXL2 resulted in a marked redn. in activated fibroblasts, desmoplasia and endothelial cells, decreased prodn. of growth factors and cytokines and decreased transforming growth factor-β (TGF-β) pathway signaling.  AB0023 outperformed the small-mol. lysyl oxidase inhibitor β-aminopropionitrile.  The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncol. and fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkE52VQCvcZrVg90H21EOLACvtfcHk0lgZSz2tum076A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF&md5=7e69cbf26c2985ad03fbb620538a5f04</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1038%2Fnm.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2208%26sid%3Dliteratum%253Aachs%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DWai%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DTsai%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DOgg%26aufirst%3DS.%26aulast%3DThai%26aufirst%3DD.%26aulast%3DNeufeld%26aufirst%3DG.%26aulast%3DVan%2BVlasselaer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DAllosteric%2520inhibition%2520of%2520lysyl%2520oxidase-like-2%2520impedes%2520the%2520development%2520of%2520a%2520pathologic%2520microenvironment%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1009%26epage%3D1017%26doi%3D10.1038%2Fnm.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Barker, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erler, J. T.</span><span> </span><span class="NLM_article-title">The rationale for targeting the LOX family in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">540</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.1038/nrc3319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnrc3319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=22810810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=540-552&author=H.+E.+Barkerauthor=T.+R.+Coxauthor=J.+T.+Erler&title=The+rationale+for+targeting+the+LOX+family+in+cancer&doi=10.1038%2Fnrc3319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10cR"><div class="casContent"><span class="casTitleNuber">10c</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale for targeting the LOX family in cancer</span></div><div class="casAuthors">Barker, Holly E.; Cox, Thomas R.; Erler, Janine T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-552</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumor microenvironment as pivotal in all aspects of tumor initiation and progression.  Members of the lysyl oxidase (LOX) family of proteins are secreted by tumors and are the subject of much effort to understand their roles in cancer.  In this Review we discuss the roles of members of this family in the remodelling of the tumor microenvironment and their paradoxical roles in tumorigenesis and metastasis.  We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcLr3Y7rPKLVg90H21EOLACvtfcHk0lgNXJHv9pwqoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE&md5=455064ea8d5332b43fa6490a1aaa0c8f</span></div><a href="/servlet/linkout?suffix=cit10c&amp;dbid=16384&amp;doi=10.1038%2Fnrc3319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3319%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DCox%26aufirst%3DT.%2BR.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520rationale%2520for%2520targeting%2520the%2520LOX%2520family%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D540%26epage%3D552%26doi%3D10.1038%2Fnrc3319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ikenaga, N.; Peng, Z.-W.; Vaid, K. A.; Liu, S. B.; Yoshida, S.; Sverdlov, D. Y.; Mikels-Vigdal, A.; Smith, V.; Schuppan, D.; Popov, Y. V.</span><span> </span><span class="NLM_article-title">Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal</span>.  <span class="citation_source-journal">Gut</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1136/gutjnl-2016-312473</span> . Published Online: Jan 10, 2017. <a href="http://dx.doi.org/10.1136/gutjnl-2016-312473" class="extLink">http://dx.doi.org/10.1136/gutjnl-2016-312473</a> (accessed April 3,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1136%2Fgutjnl-2016-312473" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Ikenaga&author=Z.-W.+Peng&author=K.+A.+Vaid&author=S.+B.+Liu&author=S.+Yoshida&author=D.+Y.+Sverdlov&author=A.+Mikels-Vigdal&author=V.+Smith&author=D.+Schuppan&author=Y.+V.+Popov&title=Selective+targeting+of+lysyl+oxidase-like+2+%28LOXL2%29+suppresses+hepatic+fibrosis+progression+and+accelerates+its+reversal&doi=10.1136%2Fgutjnl-2016-312473"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10d&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-312473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-312473%26sid%3Dliteratum%253Aachs%26aulast%3DIkenaga%26aufirst%3DN.%26atitle%3DSelective%2520targeting%2520of%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%2520suppresses%2520hepatic%2520fibrosis%2520progression%2520and%2520accelerates%2520its%2520reversal%26jtitle%3DGut%26doi%3D10.1136%2Fgutjnl-2016-312473%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Chang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonte, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Montolio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deodhar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foot, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarolimek, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timpson, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erler, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, T. R.</span><span> </span><span class="NLM_article-title">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">26066</span><span class="NLM_x">–</span> <span class="NLM_lpage">26078</span><span class="refDoi"> DOI: 10.18632/oncotarget.15257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.18632%2Foncotarget.15257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=28199967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10e&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=26066-26078&author=J.+Changauthor=M.+C.+Lucasauthor=L.+E.+Leonteauthor=M.+Garcia-Montolioauthor=L.+B.+Singhauthor=A.+D.+Findlayauthor=M.+Deodharauthor=J.+S.+Footauthor=W.+Jarolimekauthor=P.+Timpsonauthor=J.+T.+Erlerauthor=T.+R.+Cox&title=Pre-clinical+evaluation+of+small+molecule+LOXL2+inhibitors+in+breast+cancer&doi=10.18632%2Foncotarget.15257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10eR"><div class="casContent"><span class="casTitleNuber">10e</span><div class="casTitle"><span class="NLM_cas:atitle">Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer</span></div><div class="casAuthors">Chang Joan; Leonte Lidia E; Garcia-Montolio Marc; Singh Lukram Babloo; Erler Janine T; Cox Thomas R; Lucas Morghan C; Timpson Paul; Cox Thomas R; Findlay Alison D; Deodhar Mandar; Foot Jonathan S; Jarolimek Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">26066-26078</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors.  Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2 inhibitor in the MDA-MB-231 human model of breast cancer.  We confirmed a functional role for LOXL2 activity in the progression of primary breast cancer.  Inhibition of LOXL2 activity inhibited the growth of primary tumors and reduced primary tumor angiogenesis.  Dual inhibition of LOXL2 and LOX showed a greater effect and also led to a lower overall metastatic burden in the lung and liver.  Our data provides the first evidence to support a role for LOXL2 specific small molecule inhibitors as a potential therapy in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQOpqvFkfAy6suCWE5mhx1RfW6udTcc2eap7AEhUOsWZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3mvFOnsQ%253D%253D&md5=eda7044a327ae1746d7ae3ab2c2386fc</span></div><a href="/servlet/linkout?suffix=cit10e&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.15257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.15257%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BC.%26aulast%3DLeonte%26aufirst%3DL.%2BE.%26aulast%3DGarcia-Montolio%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DL.%2BB.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DTimpson%26aufirst%3DP.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26aulast%3DCox%26aufirst%3DT.%2BR.%26atitle%3DPre-clinical%2520evaluation%2520of%2520small%2520molecule%2520LOXL2%2520inhibitors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D26066%26epage%3D26078%26doi%3D10.18632%2Foncotarget.15257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Peinado, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Carmen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de la Cruz, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olmeda, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Csiszar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, K. S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieto, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Portillo, F.</span><span> </span><span class="NLM_article-title">A molecular role for lysyl oxidase-like 2 enzyme in Snail regulation and tumor progression</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">3446</span><span class="NLM_x">–</span> <span class="NLM_lpage">3458</span><span class="refDoi"> DOI: 10.1038/sj.emboj.7600781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fsj.emboj.7600781" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2005&pages=3446-3458&author=H.+Peinadoauthor=M.+del+Carmenauthor=I.+de+la+Cruzauthor=D.+Olmedaauthor=K.+Csiszarauthor=K.+S.+K.+Fongauthor=S.+Vegaauthor=M.+A.+Nietoauthor=A.+Canoauthor=F.+Portillo&title=A+molecular+role+for+lysyl+oxidase-like+2+enzyme+in+Snail+regulation+and+tumor+progression&doi=10.1038%2Fsj.emboj.7600781"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7600781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7600781%26sid%3Dliteratum%253Aachs%26aulast%3DPeinado%26aufirst%3DH.%26aulast%3Ddel%2BCarmen%26aufirst%3DM.%26aulast%3Dde%2Bla%2BCruz%26aufirst%3DI.%26aulast%3DOlmeda%26aufirst%3DD.%26aulast%3DCsiszar%26aufirst%3DK.%26aulast%3DFong%26aufirst%3DK.%2BS.%2BK.%26aulast%3DVega%26aufirst%3DS.%26aulast%3DNieto%26aufirst%3DM.%2BA.%26aulast%3DCano%26aufirst%3DA.%26aulast%3DPortillo%26aufirst%3DF.%26atitle%3DA%2520molecular%2520role%2520for%2520lysyl%2520oxidase-like%25202%2520enzyme%2520in%2520Snail%2520regulation%2520and%2520tumor%2520progression%26jtitle%3DEMBO%2520J.%26date%3D2005%26volume%3D24%26spage%3D3446%26epage%3D3458%26doi%3D10.1038%2Fsj.emboj.7600781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Herranz, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dave, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millanes-Romero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Reguant, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morey, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Díaz, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lórenz-Fonfría, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gutierrez-Gallego, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jerónimo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iturbide, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Croce, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García de Herreros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peiró, S.</span><span> </span><span class="NLM_article-title">Lysyl oxidase-like-2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3</span> <span class="citation_source-journal">FEBS J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">4263</span><span class="NLM_x">–</span> <span class="NLM_lpage">4273</span><span class="refDoi"> DOI: 10.1111/febs.13922</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1111%2Ffebs.13922" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2016&pages=4263-4273&author=N.+Herranzauthor=N.+Daveauthor=A.+Millanes-Romeroauthor=L.+Pascual-Reguantauthor=L.+Moreyauthor=V.+M.+D%C3%ADazauthor=V.+L%C3%B3renz-Fonfr%C3%ADaauthor=R.+Gutierrez-Gallegoauthor=C.+Jer%C3%B3nimoauthor=A.+Iturbideauthor=L.+Di+Croceauthor=A.+Garc%C3%ADa+de+Herrerosauthor=S.+Peir%C3%B3&title=Lysyl+oxidase-like-2+%28LOXL2%29+oxidizes+trimethylated+lysine+4+in+histone+H3&doi=10.1111%2Ffebs.13922"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1111%2Ffebs.13922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.13922%26sid%3Dliteratum%253Aachs%26aulast%3DHerranz%26aufirst%3DN.%26aulast%3DDave%26aufirst%3DN.%26aulast%3DMillanes-Romero%26aufirst%3DA.%26aulast%3DPascual-Reguant%26aufirst%3DL.%26aulast%3DMorey%26aufirst%3DL.%26aulast%3DD%25C3%25ADaz%26aufirst%3DV.%2BM.%26aulast%3DL%25C3%25B3renz-Fonfr%25C3%25ADa%26aufirst%3DV.%26aulast%3DGutierrez-Gallego%26aufirst%3DR.%26aulast%3DJer%25C3%25B3nimo%26aufirst%3DC.%26aulast%3DIturbide%26aufirst%3DA.%26aulast%3DDi%2BCroce%26aufirst%3DL.%26aulast%3DGarc%25C3%25ADa%2Bde%2BHerreros%26aufirst%3DA.%26aulast%3DPeir%25C3%25B3%26aufirst%3DS.%26atitle%3DLysyl%2520oxidase-like-2%2520%2528LOXL2%2529%2520oxidizes%2520trimethylated%2520lysine%25204%2520in%2520histone%2520H3%26jtitle%3DFEBS%2520J.%26date%3D2016%26volume%3D283%26spage%3D4263%26epage%3D4273%26doi%3D10.1111%2Ffebs.13922" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> See the Gilead website (<a href="http://www.gilead.com/research/pipeline" class="extLink">http://www.gilead.com/research/pipeline</a> and <a href="http://www.gilead.com/news/press-releases" class="extLink">http://www.gilead.com/news/press-releases</a>) accessed Dec 2,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+See+the+Gilead+website+%28http%3A%2F%2Fwww.gilead.com%2Fresearch%2Fpipeline+and+http%3A%2F%2Fwww.gilead.com%2Fnews%2Fpress-releases%29+accessed+Dec+2%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ACollard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lederer, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whelan, T. P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wuyts, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayly, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chien, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, T. G.</span><span> </span><span class="NLM_article-title">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomized, double-blind, controlled, phase 2 trial</span> <span class="citation_source-journal">Lancet Respir. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">22</span><span class="NLM_x">–</span> <span class="NLM_lpage">32</span><span class="refDoi"> DOI: 10.1016/S2213-2600(16)30421-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2FS2213-2600%2816%2930421-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=27939076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=22-32&author=G.+Raghuauthor=K.+K.+Brownauthor=H.+R.+ACollardauthor=V.+Cottinauthor=K.+F.+Gibsonauthor=R.+J.+Kanerauthor=D.+J.+Ledererauthor=F.+J.+Martinezauthor=P.+W.+Nobleauthor=J.+W.+Songauthor=A.+U.+Wellsauthor=T.+P.+M.+Whelanauthor=W.+Wuytsauthor=E.+Moreauauthor=S.+D.+Pattersonauthor=V.+Smithauthor=S.+Baylyauthor=J.+W.+Chienauthor=Q.+Gongauthor=J.+J.+Zhangauthor=T.+G.+O%E2%80%99Riordan&title=Efficacy+of+simtuzumab+versus+placebo+in+patients+with+idiopathic+pulmonary+fibrosis%3A+a+randomized%2C+double-blind%2C+controlled%2C+phase+2+trial&doi=10.1016%2FS2213-2600%2816%2930421-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial</span></div><div class="casAuthors">Raghu, Ganesh; Brown, Kevin K.; Collard, Harold R.; Cottin, Vincent; Gibson, Kevin F.; Kaner, Robert J.; Lederer, David J.; Martinez, Fernando J.; Noble, Paul W.; Song, Jin Woo; Wells, Athol U.; Whelan, Timothy P. M.; Wuyts, Wim; Moreau, Emmanuel; Patterson, Scott D.; Smith, Victoria; Bayly, Selina; Chien, Jason W.; Gong, Qi; Zhang, Jenny J.; O'Riordan, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-32</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lysyl oxidase-like 2 (LOXL2) catalyzes collagen crosslinking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).  The aim of this study was to investigate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF.  In this randomised, double-blind, phase 2 trial, we recruited patients aged 45-85 years with definite IPF diagnosed prior to 3 years of screening from 183 hospitals and respiratory clinics in 14 countries.  Eligible patients, stratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concns., and pirfenidone and nintedanib use, were randomly assigned (1:1) to inject 125 mg/mL simtuzumab or placebo s.c. once a week.  The primary endpoints were progression-free survival, defined as time to all-cause death or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, in patients with sLOXL2 concns. in the 50th percentile or higher, and in patients with sLOXL2 concns. in the 75th percentile or higher.  Treatment duration was event-driven, and interim analyses were planned and conducted after approx. 120 and 200 progression-free survival events, resp., occurred.  We compared treatment groups with the stratified log-rank test.  This study is registered with ClinicalTrials.gov, no. NCT01769196.  Patients with IPF were recruited between Jan 31, 2013, and June 1, 2015.  The intention-to-treat population included 544 randomly assigned patients (272 patients in both groups), and the safety population included 543 randomly assigned patients who received at least one dose of study medication.  The study was terminated when the second interim anal. met the prespecified futility stopping criteria in the intention-to-treat population.  We noted no difference in progression-free survival between simtuzumab and placebo in the intention-to-treat population (median progression free survival times of 12·6 mo and 15·4 mo for simtuzumab and placebo, resp.; stratified HR 1·13, 95% CI 0·88-1·45; p=0·329) and in patients with baseline sLOXL2 in the 50th percentile or higher (median progression-free survival 11·7 mo and 14·3 mo for simtuzumab and placebo, resp.; stratified HR 1·03, 95% CI 0·74-1·43; p=0·851), or in the 75th percentile or higher (median progression-free survival 11·6 mo and 16·9 mo for simtuzumab and placebo, resp.; stratified HR 1·20, 95% CI 0·72-2·00; p=0·475).  The incidence of adverse events and serious adverse events was similar between treatment groups.  The most common adverse events in both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and the most common grade 3 or 4 adverse events were worsening of IPF, dyspnoea, and pneumonia.  Simtuzumab did not improve progression-free survival in a well-defined population of patients with IPF.  Our data do not support the use of simtuzumab for patients with IPF.Gilead Sciences Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogXyb2IAh397Vg90H21EOLACvtfcHk0lhknni-47OOjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK&md5=9ba5c10f1fc48f971010f7ed09fd3b62</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2816%2930421-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252816%252930421-0%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DACollard%26aufirst%3DH.%2BR.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DKaner%26aufirst%3DR.%2BJ.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSong%26aufirst%3DJ.%2BW.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DWhelan%26aufirst%3DT.%2BP.%2BM.%26aulast%3DWuyts%26aufirst%3DW.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPatterson%26aufirst%3DS.%2BD.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DBayly%26aufirst%3DS.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DGong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%2BG.%26atitle%3DEfficacy%2520of%2520simtuzumab%2520versus%2520placebo%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520randomized%252C%2520double-blind%252C%2520controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26spage%3D22%26epage%3D32%26doi%3D10.1016%2FS2213-2600%2816%2930421-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Meissner, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gharib, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sinkus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virtaneva, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sturdevant, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcella, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, Z. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanwar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadigan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masur, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleiner, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kottilil, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovacs, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, C. G.</span><span> </span><span class="NLM_article-title">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span> <span class="citation_source-journal">Liver Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1792</span><span class="refDoi"> DOI: 10.1111/liv.13177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1111%2Fliv.13177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=27232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=1783-1792&author=E.+G.+Meissnerauthor=M.+McLaughlinauthor=L.+Matthewsauthor=A.+M.+Gharibauthor=B.+J.+Woodauthor=E.+Levyauthor=R.+Sinkusauthor=K.+Virtanevaauthor=D.+Sturdevantauthor=C.+Martensauthor=S.+F.+Porcellaauthor=Z.+D.+Goodmanauthor=B.+Kanwarauthor=R.+Myersauthor=M.+Subramanianauthor=C.+Hadiganauthor=H.+Masurauthor=D.+E.+Kleinerauthor=T.+Hellerauthor=S.+Kottililauthor=J.+A.+Kovacsauthor=C.+G.+Morse&title=Simtuzumab+treatment+of+advanced+liver+fibrosis+in+HIV+and+HCV-infected+adults%3A+results+of+a+6-month+open-label+safety+trial&doi=10.1111%2Fliv.13177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12cR"><div class="casContent"><span class="casTitleNuber">12c</span><div class="casTitle"><span class="NLM_cas:atitle">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span></div><div class="casAuthors">Meissner, Eric G.; McLaughlin, Mary; Matthews, Lindsay; Gharib, Ahmed M.; Wood, Bradford J.; Levy, Elliot; Sinkus, Ralph; Virtaneva, Kimmo; Sturdevant, Dan; Martens, Craig; Porcella, Stephen F.; Goodman, Zachary D.; Kanwar, Bittoo; Myers, Robert P.; Subramanian, Mani; Hadigan, Colleen; Masur, Henry; Kleiner, David E.; Heller, Theo; Kottilil, Shyam; Kovacs, Joseph A.; Morse, Caryn G.</div><div class="citationInfo"><span class="NLM_cas:title">Liver International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1783-1792</span>CODEN:
                <span class="NLM_cas:coden">LIINCM</span>;
        ISSN:<span class="NLM_cas:issn">1478-3223</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Chronic liver injury can result in fibrosis that may progress over years to end-stage liver disease.  The most effective anti-fibrotic therapy is treatment of the underlying disease, however when not possible, interventions to reverse or slow fibrosis progression are needed.  Aim : The aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, in subjects with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or HCV-HIV co-infection and advanced liver disease.  Methods : Eighteen subjects with advanced liver fibrosis received simtuzumab 700 mg i.v. every 2 wk for 22 wk.  Transjugular liver biopsies were performed during screening and at the end of treatment to measure hepatic venous pressure gradient (HVPG) and to stage fibrosis.  Results : Treatment was well-tolerated with no discontinuations due to adverse events.  No significant changes were seen in HVPG or liver biopsy fibrosis score after treatment.  Exploratory transcriptional and protein profiling using paired pre- and post-treatment liver biopsy and serum samples suggested up-regulation of TGF-β3 and IL-10 pathways with treatment.  Conclusion : In this open-label, pilot clin. trial, simtuzumab treatment was well-tolerated in HCV- and HIV-infected subjects with advanced liver disease.  Putative modulation of TGF-β3 and IL-10 pathways during simtuzumab treatment merits investigation in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh_oC46Qw8xrVg90H21EOLACvtfcHk0lgY-7RCvt6NBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O&md5=3531ad0273e5e77dd501b2db201794a5</span></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1111%2Fliv.13177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13177%26sid%3Dliteratum%253Aachs%26aulast%3DMeissner%26aufirst%3DE.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DL.%26aulast%3DGharib%26aufirst%3DA.%2BM.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DLevy%26aufirst%3DE.%26aulast%3DSinkus%26aufirst%3DR.%26aulast%3DVirtaneva%26aufirst%3DK.%26aulast%3DSturdevant%26aufirst%3DD.%26aulast%3DMartens%26aufirst%3DC.%26aulast%3DPorcella%26aufirst%3DS.%2BF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DKanwar%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DR.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DHadigan%26aufirst%3DC.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DHeller%26aufirst%3DT.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DJ.%2BA.%26aulast%3DMorse%26aufirst%3DC.%2BG.%26atitle%3DSimtuzumab%2520treatment%2520of%2520advanced%2520liver%2520fibrosis%2520in%2520HIV%2520and%2520HCV-infected%2520adults%253A%2520results%2520of%2520a%25206-month%2520open-label%2520safety%2520trial%26jtitle%3DLiver%2520Int.%26date%3D2016%26volume%3D36%26spage%3D1783%26epage%3D1792%26doi%3D10.1111%2Fliv.13177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pinnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, G. R.</span><span> </span><span class="NLM_article-title">The cross-linking of collagen and elastin: enzymatic conversion of lysine in peptide linkage to α-aminoadipic-δ-semialdehyde (allysine) by an extract from bone</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">708</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span><span class="refDoi"> DOI: 10.1073/pnas.61.2.708</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1073%2Fpnas.61.2.708" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1968&pages=708-716&author=S.+R.+Pinnellauthor=G.+R.+Martin&title=The+cross-linking+of+collagen+and+elastin%3A+enzymatic+conversion+of+lysine+in+peptide+linkage+to+%CE%B1-aminoadipic-%CE%B4-semialdehyde+%28allysine%29+by+an+extract+from+bone&doi=10.1073%2Fpnas.61.2.708"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1073%2Fpnas.61.2.708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.61.2.708%26sid%3Dliteratum%253Aachs%26aulast%3DPinnell%26aufirst%3DS.%2BR.%26aulast%3DMartin%26aufirst%3DG.%2BR.%26atitle%3DThe%2520cross-linking%2520of%2520collagen%2520and%2520elastin%253A%2520enzymatic%2520conversion%2520of%2520lysine%2520in%2520peptide%2520linkage%2520to%2520%25CE%25B1-aminoadipic-%25CE%25B4-semialdehyde%2520%2528allysine%2529%2520by%2520an%2520extract%2520from%2520bone%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1968%26volume%3D61%26spage%3D708%26epage%3D716%26doi%3D10.1073%2Fpnas.61.2.708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tang, S. – S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trackman, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagan, H. M.</span><span> </span><span class="NLM_article-title">Reaction of aortic lysyl oxidase with β-aminopropionitrile</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">258</span><span class="NLM_x">, </span> <span class="NLM_fpage">4331</span><span class="NLM_x">–</span> <span class="NLM_lpage">4338</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1983&pages=4331-4338&author=S.+%E2%80%93+S.+Tangauthor=P.+C.+Trackmanauthor=H.+M.+Kagan&title=Reaction+of+aortic+lysyl+oxidase+with+%CE%B2-aminopropionitrile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2B%25E2%2580%2593%2BS.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26aulast%3DKagan%26aufirst%3DH.%2BM.%26atitle%3DReaction%2520of%2520aortic%2520lysyl%2520oxidase%2520with%2520%25CE%25B2-aminopropionitrile%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1983%26volume%3D258%26spage%3D4331%26epage%3D4338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Pischon, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mäki, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisshaupt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palamakumbura, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">N’Guessan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radlanski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronckers, T. A. L. J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myllyharju, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kielbassa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleber, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernimoulin, J. – P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trackman, P. C.</span><span> </span><span class="NLM_article-title">Lysyl oxidase (<i>Lox</i>) gene deficiency affects osteoblastic phenotype</span> <span class="citation_source-journal">Calcif. Tissue Int.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">119</span><span class="NLM_x">–</span> <span class="NLM_lpage">126</span><span class="refDoi"> DOI: 10.1007/s00223-009-9252-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1007%2Fs00223-009-9252-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=19458888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=119-126&author=N.+Pischonauthor=J.+M.+M%C3%A4kiauthor=P.+Weisshauptauthor=N.+Hengauthor=A.+H.+Palamakumburaauthor=P.+N%E2%80%99Guessanauthor=A.+Dingauthor=R.+Radlanskiauthor=H.+Renzauthor=T.+A.+L.+J.+J.+Bronckersauthor=J.+Myllyharjuauthor=A.+Kielbassaauthor=B.+M.+Kleberauthor=J.+%E2%80%93+P.+Bernimoulinauthor=P.+C.+Trackman&title=Lysyl+oxidase+%28Lox%29+gene+deficiency+affects+osteoblastic+phenotype&doi=10.1007%2Fs00223-009-9252-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase (Lox) Gene Deficiency Affects Osteoblastic Phenotype</span></div><div class="casAuthors">Pischon, N.; Maeki, J. M.; Weisshaupt, P.; Heng, N.; Palamakumbura, A. H.; N'Guessan, P.; Ding, A.; Radlanski, R.; Renz, H.; Bronckers, T. A. L. J. J.; Myllyharju, J.; Kielbassa, A. M.; Kleber, B. M.; Bernimoulin, J.-P.; Trackman, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) catalyzes crosslinking of elastin and collagen, which is essential for the structural integrity and function of bone tissue.  The present study examd. the role of Lox gene deficiency for the osteoblast phenotype in primary calvarial osteoblasts from E18.5 Lox knockout (Lox -/- ) and wild type (wt) (C57BL/6) mice.  Next to Lox gene depletion, mRNA expression of Lox isoforms, LOXL1-4, was significantly downregulated in Lox -/- bone tissue.  A significant decrease of DNA synthesis of Lox -/- osteoblasts compared to wt was found.  Early stages of osteoblastic apoptosis studied by annexin-V binding as well as later stages of DNA fragmentation were not affected.  However, mineral nodule formation and osteoblastic differentiation were markedly decreased, as revealed by significant downregulation of osteoblastic markers, type I collagen, bone sialoprotein, and Runx2/Cbfa1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj0YC3msIvIbVg90H21EOLACvtfcHk0lhMOqwjtCnmsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI&md5=fab4300b8ff8b116247836bdf6aae915</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00223-009-9252-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-009-9252-8%26sid%3Dliteratum%253Aachs%26aulast%3DPischon%26aufirst%3DN.%26aulast%3DM%25C3%25A4ki%26aufirst%3DJ.%2BM.%26aulast%3DWeisshaupt%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DN.%26aulast%3DPalamakumbura%26aufirst%3DA.%2BH.%26aulast%3DN%25E2%2580%2599Guessan%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DA.%26aulast%3DRadlanski%26aufirst%3DR.%26aulast%3DRenz%26aufirst%3DH.%26aulast%3DBronckers%26aufirst%3DT.%2BA.%2BL.%2BJ.%2BJ.%26aulast%3DMyllyharju%26aufirst%3DJ.%26aulast%3DKielbassa%26aufirst%3DA.%26aulast%3DKleber%26aufirst%3DB.%2BM.%26aulast%3DBernimoulin%26aufirst%3DJ.%2B%25E2%2580%2593%2BP.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26atitle%3DLysyl%2520oxidase%2520%2528Lox%2529%2520gene%2520deficiency%2520affects%2520osteoblastic%2520phenotype%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2009%26volume%3D85%26spage%3D119%26epage%3D126%26doi%3D10.1007%2Fs00223-009-9252-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Johnson, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yukl, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klema, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinman, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilmot, C. M.</span><span> </span><span class="NLM_article-title">Structural snapshots from the oxidative half-reaction of a copper amine oxidase: implications for O<sub>2</sub> activation</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">28409</span><span class="NLM_x">–</span> <span class="NLM_lpage">28417</span><span class="refDoi"> DOI: 10.1074/jbc.M113.501791</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1074%2Fjbc.M113.501791" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=23940035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFenu7%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=28409-28417&author=B.+J.+Johnsonauthor=E.+T.+Yuklauthor=V.+J.+Klemaauthor=J.+P.+Klinmanauthor=C.+M.+Wilmot&title=Structural+snapshots+from+the+oxidative+half-reaction+of+a+copper+amine+oxidase%3A+implications+for+O2+activation&doi=10.1074%2Fjbc.M113.501791"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Snapshots from the Oxidative Half-reaction of a Copper Amine Oxidase</span></div><div class="casAuthors">Johnson, Bryan J.; Yukl, Erik T.; Klema, Valerie J.; Klinman, Judith P.; Wilmot, Carrie M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">28409-28417</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The mechanism of mol. oxygen activation is the subject of controversy in the copper amine oxidase family.  At their active sites, copper amine oxidases contain both a mononuclear copper ion and a protein-derived quinone cofactor.  Proposals have been made for the activation of mol. oxygen via both a Cu(II)-aminoquinol catalytic intermediate and a Cu(I)-semiquinone intermediate.  Using protein crystallog. freeze-trapping methods under low oxygen conditions combined with single-crystal microspectrophotometry, we have detd. structures corresponding to the iminoquinone and semiquinone forms of the enzyme.  Methylamine redn. at acidic or neutral pH has revealed protonated and deprotonated forms of the iminoquinone that are accompanied by a bound oxygen species that is likely hydrogen peroxide.  However, methylamine redn. at pH 8.5 has revealed a copper-ligated cofactor proposed to be the semiquinone form.  A copper-ligated orientation, be it the sole identity of the semiquinone or not, blocks the oxygen-binding site, suggesting that accessibility of Cu(I) may be the basis of partitioning O2 activation between the aminoquinol and Cu(I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ8oxH0Fvp8bVg90H21EOLACvtfcHk0lhMOqwjtCnmsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFenu7%252FO&md5=0fac201279b477782e0596f9a4803c07</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.501791&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.501791%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DB.%2BJ.%26aulast%3DYukl%26aufirst%3DE.%2BT.%26aulast%3DKlema%26aufirst%3DV.%2BJ.%26aulast%3DKlinman%26aufirst%3DJ.%2BP.%26aulast%3DWilmot%26aufirst%3DC.%2BM.%26atitle%3DStructural%2520snapshots%2520from%2520the%2520oxidative%2520half-reaction%2520of%2520a%2520copper%2520amine%2520oxidase%253A%2520implications%2520for%2520O2%2520activation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D28409%26epage%3D28417%26doi%3D10.1074%2Fjbc.M113.501791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hutchinson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowbottom, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lonergan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darlington, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prodanovich, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, G.</span><span> </span><span class="NLM_article-title">Small molecule lysyl oxidase-like 2 (LOXL2) inhibitors: the identification of an inhibitor selective for LOXL2 over LOX</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">427</span><span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsFaltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=423-427&author=J.+H.+Hutchinsonauthor=M.+W.+Rowbottomauthor=D.+Lonerganauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=C.+D.+Kingauthor=J.+F.+Evansauthor=G.+Bain&title=Small+molecule+lysyl+oxidase-like+2+%28LOXL2%29+inhibitors%3A+the+identification+of+an+inhibitor+selective+for+LOXL2+over+LOX&doi=10.1021%2Facsmedchemlett.7b00014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Lysyl Oxidase-like 2 (LOXL2) Inhibitors: The Identification of an Inhibitor Selective for LOXL2 over LOX</span></div><div class="casAuthors">Hutchinson, John H.; Rowbottom, Martin W.; Lonergan, David; Darlington, Janice; Prodanovich, Pat; King, Christopher D.; Evans, Jilly F.; Bain, Gretchen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">423-427</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abstr.: Two series of novel LOXL2 enzyme inhibitors are described.  Benzylamines substituted with electron withdrawing groups in the para position and 2-substituted pyridine-4-ylmethanamines.  The most potent compd., (2-chloropyridin-4-yl)methanamine 20 (hLOXL2 IC50 = 126 nM) was shown to be selective for LOXL2 over LOX and three other amine oxidases (MAO-A, MAO-B and SSAO).  Compd. 20 is the first published small mol. inhibitor selective for LOXL2 over LOX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI9k75wz2jKrVg90H21EOLACvtfcHk0lg3-SBRprpjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsFaltLs%253D&md5=64938315fde4a34c52020e4126636acc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00014%26sid%3Dliteratum%253Aachs%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DLonergan%26aufirst%3DD.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DBain%26aufirst%3DG.%26atitle%3DSmall%2520molecule%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%2520inhibitors%253A%2520the%2520identification%2520of%2520an%2520inhibitor%2520selective%2520for%2520LOXL2%2520over%2520LOX%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D423%26epage%3D427%26doi%3D10.1021%2Facsmedchemlett.7b00014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Rowbottom, M. W.; Hutchinson, J. H.; Calderon, I.</span> Fluorinated Lysyl Oxidase-Like 2 Inhibitors and Uses Thereof. Patent Application WO 2016/144703 A1,<span class="NLM_x"> </span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Rowbottom%2C+M.+W.%3B+Hutchinson%2C+J.+H.%3B+Calderon%2C+I.+Fluorinated+Lysyl+Oxidase-Like+2+Inhibitors+and+Uses+Thereof.+Patent+Application+WO+2016%2F144703+A1%2C+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Palamakumbura, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trackman, P. C.</span><span> </span><span class="NLM_article-title">A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">300</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">251</span><span class="refDoi"> DOI: 10.1006/abio.2001.5464</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1006%2Fabio.2001.5464" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=11779117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsFektw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=300&publication_year=2002&pages=245-251&author=A.+H.+Palamakumburaauthor=P.+C.+Trackman&title=A+fluorometric+assay+for+detection+of+lysyl+oxidase+enzyme+activity+in+biological+samples&doi=10.1006%2Fabio.2001.5464"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A fluorometric assay for detection of lysyl oxidase enzyme activity in biological samples</span></div><div class="casAuthors">Palamakumbura, Amitha H.; Trackman, Philip C.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">300</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-251</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Lysyl oxidase (I) catalyzes the final known enzymic step required for collagen and elastin crosslinking in the biosynthesis of normal mature functional insol. extracellular matrixes.  In addn., I has been identified as a possible tumor suppressor.  I activity in biol. samples is traditionally and most reliably assessed by 3H release end-point assays using radiolabeled collagen or elastin substrates involving laborious vacuum distn. of the released tritiated water.  In addn., a less sensitive fluorometric method exists that employs nonpeptidyl amine I substrates and measures H2O2 prodn. with horseradish peroxidase coupled to homovanillate oxidn.  The present study describes a more sensitive fluorescent assay for I activity that utilizes 1,5-diaminopentane as substrate, and released H2O2 is detected using Amplex red in horseradish peroxidase-coupled reactions.  This method allowed the detection of 40 ng I/2 mL assay at 37° and was 7.5-fold more sensitive than the currently available fluorometric assay for enzyme activity.  Using this assay, the amt. of I produced by MC3T3 cell cultures was calcd.  This method eliminated the interference that occurs in some biol. samples and could be successfully used to detect I activity in cell culture expts.  (c) 2002 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorWq09Re0fZrVg90H21EOLACvtfcHk0lg3-SBRprpjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsFektw%253D%253D&md5=4c6438d2929764ab8922b78a4f1765e9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1006%2Fabio.2001.5464&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.2001.5464%26sid%3Dliteratum%253Aachs%26aulast%3DPalamakumbura%26aufirst%3DA.%2BH.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26atitle%3DA%2520fluorometric%2520assay%2520for%2520detection%2520of%2520lysyl%2520oxidase%2520enzyme%2520activity%2520in%2520biological%2520samples%26jtitle%3DAnal.%2520Biochem.%26date%3D2002%26volume%3D300%26spage%3D245%26epage%3D251%26doi%3D10.1006%2Fabio.2001.5464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lipinski, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominy, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feeney, P. J.</span><span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/S0169-409X(96)00423-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2FS0169-409X%2896%2900423-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=3-25&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2896%2900423-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19aR"><div class="casContent"><span class="casTitleNuber">19a</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.; Feeney, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-25</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is >500 and the calcd. Log P (CLogP) is >5.  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon9gEeZ7cboLVg90H21EOLACvtfcHk0lj8NLiGU-NlsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlKlsQ%253D%253D&md5=405f70b0594d428f1275e1d56642cd3a</span></div><a href="/servlet/linkout?suffix=cit19a&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900423-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900423-1%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D3%26epage%3D25%26doi%3D10.1016%2FS0169-409X%2896%2900423-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit19b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Veber, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H. – Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kopple, K. D.</span><span> </span><span class="NLM_article-title">Molecular properties that influence the oral bioavailability of drug candidates</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">2615</span><span class="NLM_x">–</span> <span class="NLM_lpage">2623</span><span class="refDoi"> DOI: 10.1021/jm020017n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020017n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2615-2623&author=D.+F.+Veberauthor=S.+R.+Johnsonauthor=H.+%E2%80%93+Y.+Chengauthor=B.+R.+Smithauthor=K.+W.+Wardauthor=K.+D.+Kopple&title=Molecular+properties+that+influence+the+oral+bioavailability+of+drug+candidates&doi=10.1021%2Fjm020017n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19bR"><div class="casContent"><span class="casTitleNuber">19b</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Properties That Influence the Oral Bioavailability of Drug Candidates</span></div><div class="casAuthors">Veber, Daniel F.; Johnson, Stephen R.; Cheng, Hung-Yuan; Smith, Brian R.; Ward, Keith W.; Kopple, Kenneth D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2615-2623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Oral bioavailability measurements in rats for over 1100 drug candidates studied at Smith-Kline Beecham Pharmaceuticals (now Glaxo Smith-Kline) have allowed us to analyze the relative importance of mol. properties considered to influence that drug property.  Reduced mol. flexibility, as measured by the no. of rotatable bonds, and low polar surface area or total hydrogen bond count (sum of donors and acceptors) are found to be important predictors of good oral bioavailability, independent of mol. wt.  That on av. both the no. of rotatable bonds and polar surface area or hydrogen bond count tend to increase with mol. wt. may in part explain the success of the mol. wt. parameter in predicting oral bioavailability.  The commonly applied mol. wt. cutoff at 500 does not itself significantly sep. compds. with poor oral bioavailability from those with acceptable values in this extensive data set.  Our observations suggest that compds. which meet only the 2 criteria of (1) 10 or fewer rotatable bonds and (2) polar surface area ≤140 Å2 (or 12 or fewer H-bond donors and acceptors) will have a high probability of good oral bioavailability in the rat.  Data sets for the artificial membrane permeation rate and for clearance in the rat were also examd.  Reduced polar surface area correlates better with increased permeation rate than does lipophilicity (C log P), and increased rotatable bond count has a neg. effect on the permeation rate.  A threshold permeation rate is a prerequisite of oral bioavailability.  The rotatable bond count does not correlate with the data examd. here for the in vivo clearance rate in the rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3JtJEkO7yVLVg90H21EOLACvtfcHk0lj8NLiGU-NlsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjsFCmt7g%253D&md5=eaad26ed6a259de82ad65a8834fc397d</span></div><a href="/servlet/linkout?suffix=cit19b&amp;dbid=16384&amp;doi=10.1021%2Fjm020017n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020017n%26sid%3Dliteratum%253Aachs%26aulast%3DVeber%26aufirst%3DD.%2BF.%26aulast%3DJohnson%26aufirst%3DS.%2BR.%26aulast%3DCheng%26aufirst%3DH.%2B%25E2%2580%2593%2BY.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DWard%26aufirst%3DK.%2BW.%26aulast%3DKopple%26aufirst%3DK.%2BD.%26atitle%3DMolecular%2520properties%2520that%2520influence%2520the%2520oral%2520bioavailability%2520of%2520drug%2520candidates%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2615%26epage%3D2623%26doi%3D10.1021%2Fjm020017n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kim, Y. – M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. – C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span> </span><span class="NLM_article-title">The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin</span> <span class="citation_source-journal">Mol. Biol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">145</span><span class="NLM_x">–</span> <span class="NLM_lpage">149</span><span class="refDoi"> DOI: 10.1007/s11033-010-0088-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1007%2Fs11033-010-0088-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=20306300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FgvFWruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=145-149&author=Y.+%E2%80%93+M.+Kimauthor=E.+%E2%80%93+C.+Kimauthor=Y.+Kim&title=The+human+lysyl+oxidase-like+2+protein+functions+as+an+amine+oxidase+toward+collagen+and+elastin&doi=10.1007%2Fs11033-010-0088-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin</span></div><div class="casAuthors">Kim Young-Mi; Kim Eun-Cheol; Kim Youngho</div><div class="citationInfo"><span class="NLM_cas:title">Molecular biology reports</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">145-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The lysyl oxidase-like 2 (LOXL2) protein is a human paralogue of lysyl oxidase (LOX) that functions as an amine oxidase for formation of lysine-derived cross-links found in collagen and elastin.  In addition to the C-terminal domains characteristic to the LOX family members, LOXL2 contains four scavenger receptor cysteine-rich (SRCR) domains in the N-terminus.  In order to assess the amine oxidase activity of LOXL2, we expressed a series of recombinant LOXL2 proteins with deletions in the SRCR domains, using an Escherichia coli expression system.  All of the purified recombinant LOXL2 proteins, with or without the SRCR domains in the N-terminus, showed significant amine oxidase activity toward several different types of collagen and elastin in in vitro amine oxidase assays, indicating deletion of the SRCR domains does not interfere with amine oxidase activity of LOXL2.  Further, amine oxidase activity of LOXL2 was not susceptible to inhibition by β-aminopropionitrile, an irreversible inhibitor of LOX, suggesting a different enzymatic mechanism between these two paralogues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSXYuLX7VGhbzC850By6mxpfW6udTcc2eY1JwgWxwNObLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FgvFWruw%253D%253D&md5=f90539a5efc5af32da720a782572a7e4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs11033-010-0088-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11033-010-0088-0%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%2B%25E2%2580%2593%2BM.%26aulast%3DKim%26aufirst%3DE.%2B%25E2%2580%2593%2BC.%26aulast%3DKim%26aufirst%3DY.%26atitle%3DThe%2520human%2520lysyl%2520oxidase-like%25202%2520protein%2520functions%2520as%2520an%2520amine%2520oxidase%2520toward%2520collagen%2520and%2520elastin%26jtitle%3DMol.%2520Biol.%2520Rep.%26date%3D2011%26volume%3D38%26spage%3D145%26epage%3D149%26doi%3D10.1007%2Fs11033-010-0088-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Duff, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuchar, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dooley, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guss, J. M.</span><span> </span><span class="NLM_article-title">The crystal structure of <i>Pichia pastoris</i> lysyl oxidase</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">15148</span><span class="NLM_x">–</span> <span class="NLM_lpage">15157</span><span class="refDoi"> DOI: 10.1021/bi035338v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi035338v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=15148-15157&author=A.+P.+Duffauthor=A.+E.+Cohenauthor=P.+J.+Ellisauthor=J.+A.+Kucharauthor=D.+B.+Langleyauthor=E.+M.+Shepardauthor=D.+M.+Dooleyauthor=H.+C.+Freemanauthor=J.+M.+Guss&title=The+crystal+structure+of+Pichia+pastoris+lysyl+oxidase&doi=10.1021%2Fbi035338v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fbi035338v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi035338v%26sid%3Dliteratum%253Aachs%26aulast%3DDuff%26aufirst%3DA.%2BP.%26aulast%3DCohen%26aufirst%3DA.%2BE.%26aulast%3DEllis%26aufirst%3DP.%2BJ.%26aulast%3DKuchar%26aufirst%3DJ.%2BA.%26aulast%3DLangley%26aufirst%3DD.%2BB.%26aulast%3DShepard%26aufirst%3DE.%2BM.%26aulast%3DDooley%26aufirst%3DD.%2BM.%26aulast%3DFreeman%26aufirst%3DH.%2BC.%26aulast%3DGuss%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520crystal%2520structure%2520of%2520Pichia%2520pastoris%2520lysyl%2520oxidase%26jtitle%3DBiochemistry%26date%3D2003%26volume%3D42%26spage%3D15148%26epage%3D15157%26doi%3D10.1021%2Fbi035338v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">Calculated using CDD Vault software from Collaborative Drug Discovery, Burlingame, CA.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bohnert, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L. – S.</span><span> </span><span class="NLM_article-title">Plasma protein binding: from discovery to development</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">2953</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span><span class="refDoi"> DOI: 10.1002/jps.23614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1002%2Fjps.23614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=23798314" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2013&pages=2953-2994&author=T.+Bohnertauthor=L.+%E2%80%93+S.+Gan&title=Plasma+protein+binding%3A+from+discovery+to+development&doi=10.1002%2Fjps.23614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Plasma protein binding: From discovery to development</span></div><div class="casAuthors">Bohnert, Tonika; Gan, Liang-Shang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2953-2994</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The importance of plasma protein binding (PPB) in modulating the effective drug concn. at pharmacol. target sites has been the topic of significant discussion and debate amongst drug development groups over the past few decades.  Free drug theory, which states that in absence of energy-dependent processes, after steady state equil. has been attained, free drug concn. in plasma is equal to free drug concn. at the pharmacol. target receptor(s) in tissues, has been used to explain pharmacokinetics/pharmacodynamics relationships in a large no. of cases.  Any sudden increase in free concn. of a drug could potentially cause toxicity and may need dose adjustment.  Free drug concn. is also helpful to est. the effective concn. of drugs that potentially can ppt. metab. (or transporter)-related drug-drug interactions.  Disease models are extensively validated in animals to progress a compd. into development.  Unbound drug concn., and therefore PPB information across species is very informative in establishing safety margins and guiding selection of First in Human (FIH) dose and human efficacious dose.  The scope of this review is to give an overview of reported role of PPB in several therapeutic areas, highlight cases where PPB changes are clin. relevant, and provide drug metab. and pharmacokinetics recommendations in discovery and development settings. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqobJp8eG98XrVg90H21EOLACvtfcHk0lhqeVTPz4AjMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvVymt7c%253D&md5=d676f7490c6e0f09c8acf7cce5183b17</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fjps.23614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23614%26sid%3Dliteratum%253Aachs%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DGan%26aufirst%3DL.%2B%25E2%2580%2593%2BS.%26atitle%3DPlasma%2520protein%2520binding%253A%2520from%2520discovery%2520to%2520development%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D102%26spage%3D2953%26epage%3D2994%26doi%3D10.1002%2Fjps.23614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><div class="note"><p class="first last">Human plasma-protein binding measurements determined by Eurofins Panlabs (Redmond, WA) using the methods noted by</p></div><span class="NLM_contrib-group">Banker, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. A.</span><span> </span><span class="NLM_article-title">Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span><span class="refDoi"> DOI: 10.1002/jps.10332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1002%2Fjps.10332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=12712416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2003&pages=967-974&author=M.+J.+Bankerauthor=T.+H.+Clarkauthor=J.+A.+Williams&title=Development+and+validation+of+a+96-well+equilibrium+dialysis+apparatus+for+measuring+plasma+protein+binding&doi=10.1002%2Fjps.10332"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding</span></div><div class="casAuthors">Banker, Michael J.; Clark, Tracey H.; Williams, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">967-974</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A 96-well equil. dialysis block was designed and constructed that is compatible with most std. 96-well format lab. supplies and instruments.  The unique design of the dialysis app. allows one to dispense and aspirate from either or both the sample and dialyzate sides from the top of the app., which is not possible with systems currently on the market.  This feature permits the investigator to analyze a large no. of samples, time points, or replicates in the same expt.  The novel alignment of the dialysis membrane vertically in the well maximizes the surface-to-vol. ratio, eliminates problems assocd. with trapped air pockets, and allows one to add or remove samples independently or all at once.  Furthermore, the design of the app. allows both the sample and dialyzate sides of the dialysis well to be accessible by robotic systems, so assays can be readily automated.  Teflon construction is used to minimize nonspecific binding of test samples to the app.  The device is reusable, easily assembled, and can be shaken in controlled temp. environments to decrease the time required to reach equil. as well as facilitate dissoln. of test compds.  Plasma protein binding values obtained for 10 diverse compds. using std. dialysis equipment and the 96-well dialysis block validates this method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp9qyX_9tHHrVg90H21EOLACvtfcHk0lhqeVTPz4AjMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjs1ehsrs%253D&md5=0948f0a11373c57be06be9e0d604ad40</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1002%2Fjps.10332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.10332%26sid%3Dliteratum%253Aachs%26aulast%3DBanker%26aufirst%3DM.%2BJ.%26aulast%3DClark%26aufirst%3DT.%2BH.%26aulast%3DWilliams%26aufirst%3DJ.%2BA.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%252096-well%2520equilibrium%2520dialysis%2520apparatus%2520for%2520measuring%2520plasma%2520protein%2520binding%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2003%26volume%3D92%26spage%3D967%26epage%3D974%26doi%3D10.1002%2Fjps.10332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span><span class="refDoi"> DOI: 10.1038/nrd3410</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs&doi=10.1038%2Fnrd3410"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lhqeVTPz4AjMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317%26doi%3D10.1038%2Fnrd3410" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Chien, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindell, K. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyman, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamkewicz, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Riordan, T.</span><span> </span><span class="NLM_article-title">Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1430</span><span class="NLM_x">–</span> <span class="NLM_lpage">1438</span><span class="refDoi"> DOI: 10.1183/09031936.00141013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1183%2F09031936.00141013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=24177001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1430-1438&author=J.+W.+Chienauthor=T.+J.+Richardsauthor=K.+F.+Gibsonauthor=Y.+Zhangauthor=K.+O.+Lindellauthor=L.+Shaoauthor=S.+K.+Lymanauthor=J.+I.+Adamkewiczauthor=V.+Smithauthor=N.+Kaminskiauthor=T.+O%E2%80%99Riordan&title=Serum+lysyl+oxidase-like+2+levels+and+idiopathic+pulmonary+fibrosis+disease+progression&doi=10.1183%2F09031936.00141013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Serum lysyl, oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span></div><div class="casAuthors">Chien, Jason W.; Richards, Thomas J.; Gibson, Kevin F.; Zhang, Yingze; Lindell, Kathleen O.; Shao, Lixin; Lyman, Susan K.; Adamkewicz, Joanne I.; Smith, Victoria; Kaminski, Naftali; O'Riordan, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes crosslinking of collagen in pathol. stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression.  Patients from the ARTEMIS-IPF (n=69) and the Genomic and Proteomic Anal. of Disease Progression in IPF (GAP) (n=104) studies were analyzed.  Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clin. and physiol. surrogates of disease severity, and the assocn. with IPF disease progression was assessed using a classification and regression tree (CART) method.  SLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24-0.05) in both cohorts.  CART-detd. thresholds were similar: ARTEMIS-IPF 800 pg·mL-1 and GAP 700 pg·mL-1.  In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL-1) was assocd. with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65-17.73).  Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL-1) were assocd. with more disease progression events (HR 1.78, 95% CI 1.01-3.11).  Among all GAP subjects, higher sLOXL2 levels were assocd. with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38).  These results suggest that higher sLOXL2 levels are assocd. with increased risk for IPF disease progression.  However, due to multiple limitations, these results require validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8WyURMNVsBLVg90H21EOLACvtfcHk0liJDndV0bstXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I&md5=60faa18c94ef9c37937579571a905faa</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1183%2F09031936.00141013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00141013%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DRichards%26aufirst%3DT.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLindell%26aufirst%3DK.%2BO.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26atitle%3DSerum%2520lysyl%2520oxidase-like%25202%2520levels%2520and%2520idiopathic%2520pulmonary%2520fibrosis%2520disease%2520progression%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1430%26epage%3D1438%26doi%3D10.1183%2F09031936.00141013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bend, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serabjit-Singh, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philpot, R. M.</span><span> </span><span class="NLM_article-title">The pulmonary uptake, accumulation, and metabolism of xenobiotics</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1146/annurev.pa.25.040185.000525</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1146%2Fannurev.pa.25.040185.000525" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1985&pages=97-125&author=J.+R.+Bendauthor=C.+J.+Serabjit-Singhauthor=R.+M.+Philpot&title=The+pulmonary+uptake%2C+accumulation%2C+and+metabolism+of+xenobiotics&doi=10.1146%2Fannurev.pa.25.040185.000525"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1146%2Fannurev.pa.25.040185.000525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.pa.25.040185.000525%26sid%3Dliteratum%253Aachs%26aulast%3DBend%26aufirst%3DJ.%2BR.%26aulast%3DSerabjit-Singh%26aufirst%3DC.%2BJ.%26aulast%3DPhilpot%26aufirst%3DR.%2BM.%26atitle%3DThe%2520pulmonary%2520uptake%252C%2520accumulation%252C%2520and%2520metabolism%2520of%2520xenobiotics%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D1985%26volume%3D25%26spage%3D97%26epage%3D125%26doi%3D10.1146%2Fannurev.pa.25.040185.000525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Boer, F.</span><span> </span><span class="NLM_article-title">Drug handling by the lungs</span> <span class="citation_source-journal">Br. J. Anaesth.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">91</span><span class="NLM_x">, </span> <span class="NLM_fpage">50</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1093/bja/aeg117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1093%2Fbja%2Faeg117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=12821565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltVSqtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2003&pages=50-60&author=F.+Boer&title=Drug+handling+by+the+lungs&doi=10.1093%2Fbja%2Faeg117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27bR"><div class="casContent"><span class="casTitleNuber">27b</span><div class="casTitle"><span class="NLM_cas:atitle">Drug handling by the lungs</span></div><div class="casAuthors">Boer, F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Anaesthesia</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-60</span>CODEN:
                <span class="NLM_cas:coden">BJANAD</span>;
        ISSN:<span class="NLM_cas:issn">0007-0912</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review describes how the pharmacokinetic function of the lungs can be studied, which anesthetics are taken up by the lungs, how the pharmacokinetic function of the lungs is affected and how this can be related to systemic pharmacokinetics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmTAtvDIYUWbVg90H21EOLACvtfcHk0liJDndV0bstXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltVSqtL8%253D&md5=8a320e8652870164ff6e96656f9af79e</span></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1093%2Fbja%2Faeg117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbja%252Faeg117%26sid%3Dliteratum%253Aachs%26aulast%3DBoer%26aufirst%3DF.%26atitle%3DDrug%2520handling%2520by%2520the%2520lungs%26jtitle%3DBr.%2520J.%2520Anaesth.%26date%3D2003%26volume%3D91%26spage%3D50%26epage%3D60%26doi%3D10.1093%2Fbja%2Faeg117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="note"><p class="first last">For example, compound <b>28</b> had a measured p<i>K</i><sub>a</sub> = 7.8. Data were generated on a Sirius GLpKa instrument with a D-PAS attachment. Measurements were made at 25 °C in aqueous solution by UV. The titration media were of ionic-strength adjusted (ISA) with aqueous 0.15 M KCl. The data were refined using Refinement Pro software v2.2.3.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Hübner, R. – H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gitter, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Mokhtari, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathiak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Both, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolte, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freitag-Wolf, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bewig, B.</span><span> </span><span class="NLM_article-title">Standardized quantification of pulmonary fibrosis in histological samples</span> <span class="citation_source-journal">BioTechniques</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">507</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.2144/000112729</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.2144%2F000112729" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=18476815" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslymtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2008&pages=507-517&author=R.+%E2%80%93+H.+H%C3%BCbnerauthor=W.+Gitterauthor=N.+E.+El+Mokhtariauthor=M.+Mathiakauthor=M.+Bothauthor=H.+Bolteauthor=S.+Freitag-Wolfauthor=B.+Bewig&title=Standardized+quantification+of+pulmonary+fibrosis+in+histological+samples&doi=10.2144%2F000112729"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Standardized quantification of pulmonary fibrosis in histological samples</span></div><div class="casAuthors">Huebner, Ralf-Harto; Gitter, Wolfram; El Mokhtari, Nour Eddine; Mathiak, Micaela; Both, Marcus; Bolte, Hendrik; Freitag-Wolf, Sandra; Bewig, Burkhard</div><div class="citationInfo"><span class="NLM_cas:title">BioTechniques</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">507-511,514-517</span>CODEN:
                <span class="NLM_cas:coden">BTNQDO</span>;
        ISSN:<span class="NLM_cas:issn">0736-6205</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">The Ashcroft scale for the evaluation of bleomycin-induced lung fibrosis is the anal. of stained histol. samples by visual assessment.  Based on the knowledge that this procedure is not standardized in animals and results are highly variable, the authors hypothesized that modification of this method may improve quantification of lung fibrosis in small animals.  To prove the hypothesis, the authors evaluated pulmonary fibrosis in Lewis rats induced by a single intratracheal injection of 0.3 mg/kg body wt. bleomycin (n = 13) compared with the same amt. of saline in a control group (n = 4).  The authors modified the Ashcroft scale by precised defining the assignment of grades from 0 to 8 for the increasing extent of fibrosis in lung histol. samples.  Thirty-two observers were randomly assigned to evaluate 108 photographs of slides using either the Ashcroft scale or the modified scale.  Consistent with the authors' hypothesis, there was a significant redn. in the variability of std. deviations with the modified scale compared with the Ashcroft scale (mean of variability 0.25 vs. 0.62, P < 0.0001).  Applying the κ index, the Ashcroft scale showed only a fair to moderate agreement (0.23-0.59) between the observers and a low intra-observer agreement (0.51-0.74) in contrast to the modified scale, which demonstrated a moderate to good agreement between the observers (0.65-0.93, P < 0.0001) and a high intra-observer agreement (0.87-0.91, P < 0.05).  To test the modified scale in vivo, the authors compared both scales with the results of computed tomog. (CT) of the lungs obtained from the same mice.  In agreement, the modified scale demonstrated a better correlation to CT scans (R = 0.58) compared with the Ashcroft scale (R = 0.33).  In summary, quantification of lung fibrosis in histol. lung sections using the modified scale is reliable and reproducible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyLtTZGYVlSLVg90H21EOLACvtfcHk0lg40OEj-B0Btw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslymtLk%253D&md5=171841380870b8c990a4a17e07a7e858</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2144%2F000112729&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2144%252F000112729%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25BCbner%26aufirst%3DR.%2B%25E2%2580%2593%2BH.%26aulast%3DGitter%26aufirst%3DW.%26aulast%3DEl%2BMokhtari%26aufirst%3DN.%2BE.%26aulast%3DMathiak%26aufirst%3DM.%26aulast%3DBoth%26aufirst%3DM.%26aulast%3DBolte%26aufirst%3DH.%26aulast%3DFreitag-Wolf%26aufirst%3DS.%26aulast%3DBewig%26aufirst%3DB.%26atitle%3DStandardized%2520quantification%2520of%2520pulmonary%2520fibrosis%2520in%2520histological%2520samples%26jtitle%3DBioTechniques%26date%3D2008%26volume%3D44%26spage%3D507%26epage%3D517%26doi%3D10.2144%2F000112729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="note"><p class="first last">ExpressProfile screen carried out by Eurofins Cerep Panlabs (Redmond, WA).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lg40OEj-B0Btw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Foot, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yow, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schilter, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deodhar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, C. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarolimek, W.</span><span> </span><span class="NLM_article-title">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">347</span><span class="NLM_x">, </span> <span class="NLM_fpage">365</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1124/jpet.113.207613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1124%2Fjpet.113.207613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=23943052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=365-374&author=J.+S.+Footauthor=T.+T.+Yowauthor=H.+Schilterauthor=A.+Busonauthor=M.+Deodharauthor=A.+D.+Findlayauthor=L.+Guoauthor=I.+A.+McDonaldauthor=C.+I.+Turnerauthor=W.+Zhouauthor=W.+Jarolimek&title=PXS-4681A%2C+a+potent+and+selective+mechanism-based+inhibitor+of+SSAO%2FVAP-1+with+anti-inflammatory+effects+in+vivo&doi=10.1124%2Fjpet.113.207613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span></div><div class="casAuthors">Foot, Jonathan S.; Yow, Tin T.; Schilter, Heidi; Buson, Alberto; Deodhar, Mandar; Findlay, Alison D.; Guo, Lily; McDonald, Ian A.; Turner, Craig I.; Zhou, Wenbin; Jarolimek, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">365-374</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), is a member of the copper-dependent amine oxidase family that is assocd. with various forms of inflammation and fibrosis.  To investigate the therapeutic potential of SSAO/VAP-1 inhibition, potent and selective inhibitors with drug-like properties are required.  PXS-4681A [(Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)benzenesulfonamide hydrochloride] is a mechanism-based inhibitor of enzyme function with a pharmacokinetic and pharmacodynamic profile that ensures complete, long-lasting inhibition of the enzyme after a single low dose in vivo.  PXS-4681A irreversibly inhibits the enzyme with an apparent Ki of 37 nM and a kinact of 0.26 min-1 with no obsd. turnover in vitro.  It is highly selective for SSAO/VAP-1 when profiled against related amine oxidases, ion channels, and seven-transmembrane domain receptors, and is superior to previously reported inhibitors.  In mouse models of lung inflammation and localized inflammation, dosing of this mol. at 2 mg/kg attenuates neutrophil migration, tumor necrosis factor-α, and interleukin-6 levels.  These results demonstrate the drug-like properties of PXS-4681A and its potential use in the treatment of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUjl7gonLQrVg90H21EOLACvtfcHk0lg40OEj-B0Btw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L&md5=d3c24925c4b717c9405d46be9a82f2d9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207613%26sid%3Dliteratum%253Aachs%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DBuson%26aufirst%3DA.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DPXS-4681A%252C%2520a%2520potent%2520and%2520selective%2520mechanism-based%2520inhibitor%2520of%2520SSAO%252FVAP-1%2520with%2520anti-inflammatory%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D365%26epage%3D374%26doi%3D10.1124%2Fjpet.113.207613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Walters, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kleeberger, S. R.</span><span> </span><span class="NLM_article-title">Mouse models of bleomycin-induced pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Protoc. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">5.46.1</span><span class="NLM_x">–</span> <span class="NLM_lpage">5.46.17</span><span class="refDoi"> DOI: 10.1002/0471141755.ph0546s40</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1002%2F0471141755.ph0546s40" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2008&pages=5.46.1-5.46.17&author=D.+M.+Waltersauthor=S.+R.+Kleeberger&title=Mouse+models+of+bleomycin-induced+pulmonary+fibrosis&doi=10.1002%2F0471141755.ph0546s40"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2F0471141755.ph0546s40&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F0471141755.ph0546s40%26sid%3Dliteratum%253Aachs%26aulast%3DWalters%26aufirst%3DD.%2BM.%26aulast%3DKleeberger%26aufirst%3DS.%2BR.%26atitle%3DMouse%2520models%2520of%2520bleomycin-induced%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Protoc.%2520Pharmacol.%26date%3D2008%26volume%3D40%26spage%3D5.46.1%26epage%3D5.46.17%26doi%3D10.1002%2F0471141755.ph0546s40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Maron, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, B. N.</span><span> </span><span class="NLM_article-title">Revised methods for the <i>Salmonella</i> mutagenicity test</span> <span class="citation_source-journal">Mutat. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">215</span><span class="refDoi"> DOI: 10.1016/0165-1161(83)90010-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=10.1016%2F0165-1161%2883%2990010-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=6341825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;key=1%3ACAS%3A528%3ADyaL3sXhvFarsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=1983&pages=173-215&author=D.+M.+Maronauthor=B.+N.+Ames&title=Revised+methods+for+the+Salmonella+mutagenicity+test&doi=10.1016%2F0165-1161%2883%2990010-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Revised methods for the Salmonella mutagenicity test</span></div><div class="casAuthors">Maron, Dorothy M.; Ames, Bruce N.</div><div class="citationInfo"><span class="NLM_cas:title">Mutation Research, Environmental Mutagenesis and Related Subjects </span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">173-215</span>CODEN:
                <span class="NLM_cas:coden">MEMSE8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A revision of methods for detecting carcinogens and mutagens with the Salmonella mutagenicity test (A. et al., 1975b) is described.  Two new tester strains, a frameshift strain (TA 97) and a strain carrying an ochre mutation on a multicopy plasmid (TA 102), are added to the std. tester set.  TA 97 replaces TA 1537.  TA 1535 and 1538 are removed from the recommended set, but can be retained at the option of the investigator.  TA 98 and 100 are retained.  Other special purpose strains are discussed and minor changes in procedure, (principally in the growth, storage, and preservation of the tester strains) are presented.  Two substitutions are made in diagnostic mutagens to eliminate MNNG and 9-aminoacridine.  Some test modifications are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzIjKbxaVZYrVg90H21EOLACvtfcHk0lg_Yu4Rvk36Dg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhvFarsb4%253D&md5=415285947b98c9ddbbd79bbe000c9dca</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0165-1161%2883%2990010-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-1161%252883%252990010-9%26sid%3Dliteratum%253Aachs%26aulast%3DMaron%26aufirst%3DD.%2BM.%26aulast%3DAmes%26aufirst%3DB.%2BN.%26atitle%3DRevised%2520methods%2520for%2520the%2520Salmonella%2520mutagenicity%2520test%26jtitle%3DMutat.%2520Res.%26date%3D1983%26volume%3D113%26spage%3D173%26epage%3D215%26doi%3D10.1016%2F0165-1161%2883%2990010-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i82"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00345">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32338"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00345">10.1021/acs.jmedchem.7b00345</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Screening data for compound <b>43</b>; amine oxidase activity in CCM from hLOXL2/CHO and hLOX/HEK stable cell lines versus parent CHO and HEK cells; amine oxidase activity from LOXL2/CHO and LOX/HEK CCM collected in the presence or absence of BSA; Michaelis–Menten kinetics and compound <b>1</b> inhibition of hLOXL2 and hLOX using CCM as the enzyme source; concentration–response curves of compound <b>43</b>; photomicrographs for representative histological lung sections (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_001.pdf">jm7b00345_si_001.pdf (1.02 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00345/suppl_file/jm7b00345_si_002.csv">jm7b00345_si_002.csv (4.84 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-10%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00345%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00345" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994f3e4b8c3dbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
